P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
6.230e-10 | -21.20 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 42 | 16828 | 49 |
ABLIM1,MACF1,PCDH9,ITPR2,LSAMP,RORA,GPM6A,GPC5,SFXN5,NKAIN3,COL5A3,NFIA,TRPS1,PTPRZ1,PITPNC1,ZNF98,FBXL7,SOX5,TNIK,ATP13A4,FGFR3,NCKAP5,RFX4,LRIG1,ACSS1,NTM,ZBTB20,SLC1A3,NRXN1,PARD3B,CADM1,NPAS3,ERBB4,SLC1A2,AHCYL2,QKI,CTNND2,MAML2,RYR3,SLC4A4,NHSL1,PREX2 |
1.266e-09 | -20.49 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 41 | 16828 | 49 |
TNIK,SOX5,HIF3A,FBXL7,PITPNC1,ZNF98,TRPS1,PTPRZ1,CDH20,SFXN5,GPC5,RORA,GPM6A,ABLIM1,MACF1,PCDH9,ITPR2,LSAMP,PREX2,SLC4A4,NHSL1,MAML2,RYR3,SLC1A2,QKI,CTNND2,ERBB4,CADM1,PARD3B,NRXN1,ATP1A2,DTNA,ZBTB20,NTM,LRIG1,ACSS1,RFX4,CST3,NCKAP5,ATP13A4,FGFR3 |
1.647e-09 | -20.22 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 28 | 16828 | 49 |
GPM6A,RORA,LSAMP,ITPR2,PCDH9,NKAIN3,SFXN5,GPC5,PTPRZ1,CDH20,TNIK,SOX5,FBXL7,NCKAP5,FGFR3,ATP13A4,SLC1A3,ZBTB20,CTNND2,QKI,AHCYL2,SLC1A2,NPAS3,ERBB4,CADM1,PREX2,MAML2,RYR3 |
3.796e-09 | -19.39 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 25 | 16828 | 49 |
GPM6A,RORA,PCDH9,LSAMP,ITPR2,NKAIN3,SFXN5,GPC5,PTPRZ1,CDH20,TNIK,SOX5,FBXL7,NCKAP5,ATP13A4,SLC1A3,ZBTB20,CTNND2,AHCYL2,QKI,ERBB4,CADM1,PREX2,RYR3,MAML2 |
3.883e-09 | -19.37 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 23 | 16828 | 49 |
LRIG1,GPC5,NKAIN3,SLC1A3,ATP13A4,NCKAP5,PCDH9,LSAMP,ITPR2,GPM6A,RFX4,MAML2,RYR3,FBXL7,NHSL1,SOX5,PREX2,CADM1,NPAS3,ERBB4,SLC1A2,AHCYL2,CTNND2 |
3.883e-09 | -19.37 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 23 | 16828 | 49 |
GPM6A,ITPR2,LSAMP,PCDH9,NKAIN3,GPC5,FBXL7,SOX5,RFX4,ATP13A4,NCKAP5,SLC1A3,LRIG1,NPAS3,ERBB4,AHCYL2,CTNND2,SLC1A2,CADM1,PREX2,MAML2,RYR3,NHSL1 |
1.790e-08 | -17.84 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 20 | 16828 | 49 |
GPM6A,PCDH9,LSAMP,ITPR2,ATP13A4,FGFR3,SLC1A3,DTNA,SFXN5,ACSS1,GPC5,CTNND2,TRPS1,ERBB4,CADM1,PARD3B,TNIK,SOX5,RYR3,MAML2 |
1.793e-08 | -17.84 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 19 | 16828 | 49 |
NKAIN3,SLC1A3,COL5A3,ACSS1,GPC5,RORA,NCKAP5,PCDH9,LSAMP,ITPR2,PREX2,RYR3,MAML2,FBXL7,SOX5,ERBB4,CTNND2,QKI,CADM1 |
1.793e-08 | -17.84 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 19 | 16828 | 49 |
ERBB4,CTNND2,QKI,CADM1,PREX2,FBXL7,RYR3,MAML2,SOX5,RORA,ITPR2,LSAMP,PCDH9,NCKAP5,NKAIN3,COL5A3,SLC1A3,GPC5,ACSS1 |
2.157e-08 | -17.65 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 14 | 16828 | 49 |
LSAMP,NCKAP5,PCDH9,COL5A3,ATP1A2,NKAIN3,GPC5,SLC1A2,ERBB4,PREX2,SOX5,FBXL7,RYR3,MAML2 |
2.342e-08 | -17.57 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 14 | 16828 | 49 |
GPC5,ITPR2,PCDH9,ABLIM1,RYR3,MAML2,NRXN1,PARD3B,CADM1,PTPRZ1,ERBB4,NPAS3,QKI,CTNND2 |
4.276e-08 | -16.97 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 29 | 16828 | 49 |
GPM6A,RORA,ITPR2,LSAMP,PCDH9,NKAIN3,COL5A3,GPC5,PTPRZ1,NFIA,ZNF98,TNIK,FBXL7,HIF3A,SOX5,ATP13A4,NCKAP5,ZBTB20,SLC1A3,NTM,ERBB4,CTNND2,SLC1A2,NRXN1,CADM1,PREX2,RYR3,MAML2,SLC4A4 |
4.276e-08 | -16.97 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 29 | 16828 | 49 |
RORA,GPM6A,PCDH9,ITPR2,LSAMP,NKAIN3,COL5A3,GPC5,NFIA,PTPRZ1,ZNF98,TNIK,FBXL7,HIF3A,SOX5,ATP13A4,NCKAP5,ZBTB20,SLC1A3,NTM,ERBB4,SLC1A2,CTNND2,NRXN1,CADM1,PREX2,MAML2,RYR3,SLC4A4 |
4.446e-08 | -16.93 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 25 | 16828 | 49 |
LSAMP,ITPR2,PCDH9,NCKAP5,ATP13A4,RFX4,GPM6A,SFXN5,GPC5,LRIG1,SLC1A3,NKAIN3,CADM1,PARD3B,CTNND2,ZNF98,SLC1A2,ERBB4,TRPS1,HIF3A,SOX5,FBXL7,RYR3,MAML2,PREX2 |
5.023e-08 | -16.81 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 44 | 16828 | 49 |
FBXL7,HIF3A,TNIK,CDH20,NFIA,PTPRZ1,PITPNC1,PCDH9,MACF1,ITPR2,LSAMP,GPM6A,RYR3,NHSL1,SLC4A4,CADM1,LRIG1,NTM,ZBTB20,SLC1A3,DTNA,SOX5,TRPS1,GPC5,SFXN5,NKAIN3,COL5A3,ABLIM1,RORA,MAML2,PREX2,PARD3B,NRXN1,ERBB4,NPAS3,SLC1A2,CTNND2,QKI,AHCYL2,ATP13A4,FGFR3,NCKAP5,MSI2,RFX4 |
5.110e-08 | -16.79 | mouth | COSMIC cancer mutations | mouth | 9004 | 44 | 16828 | 49 |
CDH20,PITPNC1,ZNF98,PTPRZ1,HIF3A,FBXL7,TNIK,MACF1,PCDH9,LSAMP,ITPR2,GPM6A,CADM1,SLC4A4,NHSL1,RYR3,NTM,LRIG1,SLC1A3,DTNA,ATP1A2,ZBTB20,TRPS1,SOX5,ABLIM1,RORA,SFXN5,GPC5,COL5A3,PARD3B,NRXN1,SLC1A2,CTNND2,QKI,ERBB4,NPAS3,MAML2,PREX2,NCKAP5,ATP13A4,FGFR3,RFX4,CST3,ACSS1 |
5.958e-08 | -16.64 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 30 | 16828 | 49 |
DTNA,ATP1A2,SLC1A3,ACSS1,FGFR3,ATP13A4,NCKAP5,PREX2,RYR3,MAML2,ERBB4,AHCYL2,CTNND2,QKI,SLC1A2,CADM1,NKAIN3,GPC5,RORA,GPM6A,LSAMP,ITPR2,PCDH9,MACF1,TNIK,FBXL7,SOX5,TRPS1,ZNF98,CDH20 |
8.769e-08 | -16.25 | nervous system development | biological process | GO:0007399 | 2185 | 21 | 18204 | 50 |
GPM6A,PTPRZ1,ATP1A2,CTNNA2,SLC1A2,CTNND2,NRXN1,PCDH9,ERBB4,RORA,RFX4,PREX2,NTM,SLC1A3,MSI2,SOX5,TNIK,QKI,LSAMP,LRIG1,NFIA |
9.120e-08 | -16.21 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 11 | 16828 | 49 |
RYR3,MAML2,ERBB4,CTNND2,CADM1,GPC5,SFXN5,GPM6A,ATP13A4,PCDH9,LSAMP |
1.027e-07 | -16.09 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 24 | 16828 | 49 |
PREX2,RYR3,MAML2,ERBB4,CTNND2,SLC1A2,PARD3B,CADM1,SLC1A3,LRIG1,RFX4,NCKAP5,FBXL7,SOX5,HIF3A,TRPS1,ZNF98,NKAIN3,GPC5,SFXN5,GPM6A,ITPR2,LSAMP,PCDH9 |
2.603e-07 | -15.16 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 12 | 16828 | 49 |
NRXN1,PARD3B,CADM1,ERBB4,NPAS3,PTPRZ1,CTNND2,MAML2,RYR3,ABLIM1,PCDH9,ITPR2 |
2.608e-07 | -15.16 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 27 | 16828 | 49 |
ACSS1,ATP1A2,NCKAP5,ATP13A4,FGFR3,RYR3,MAML2,PREX2,CADM1,SLC1A2,QKI,AHCYL2,CTNND2,ERBB4,GPC5,NKAIN3,MACF1,PCDH9,ITPR2,LSAMP,GPM6A,RORA,SOX5,FBXL7,TNIK,CDH20,ZNF98 |
2.646e-07 | -15.15 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 12 | 16828 | 49 |
ITPR2,ABLIM1,PCDH9,NRXN1,PARD3B,CADM1,ERBB4,PTPRZ1,NPAS3,CTNND2,RYR3,MAML2 |
2.732e-07 | -15.11 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 21 | 16828 | 49 |
PREX2,MAML2,RYR3,FBXL7,SOX5,PTPRZ1,ERBB4,SLC1A2,CTNND2,CDH20,CADM1,NKAIN3,SLC1A3,COL5A3,GPC5,GPM6A,FGFR3,NCKAP5,PCDH9,LSAMP,ITPR2 |
2.894e-07 | -15.06 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 11 | 16828 | 49 |
RYR3,SOX5,CTNND2,AHCYL2,NKAIN3,GPC5,SFXN5,GPM6A,NCKAP5,PCDH9,LSAMP |
3.797e-07 | -14.78 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 23 | 16828 | 49 |
DTNA,ATP1A2,RFX4,NCKAP5,FGFR3,ATP13A4,PREX2,SLC4A4,NHSL1,RYR3,CTNND2,QKI,SLC1A2,NPAS3,PARD3B,SFXN5,GPC5,MACF1,PCDH9,ZNF98,PITPNC1,PTPRZ1,NFIA |
4.013e-07 | -14.73 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 14 | 19454 | 49 |
MSI2,SLC4A4,SLC1A3,AHCYL2,PTPRZ1,LSAMP,TRPS1,QKI,ATP1A2,ABLIM1,MACF1,NHSL1,GPM6A,MAML2 |
5.309e-07 | -14.45 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 29 | 16828 | 49 |
GPM6A,PTGDS,ITPR2,PCDH9,MACF1,COL5A3,PTPRZ1,NFIA,TRPS1,CDH20,TNIK,FBXL7,HIF3A,SOX5,RFX4,FGFR3,ATP13A4,NCKAP5,ZBTB20,ACSS1,LRIG1,NTM,CTNND2,PARD3B,CADM1,PREX2,RYR3,SLC4A4,NHSL1 |
6.811e-07 | -14.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 15 | 16828 | 49 |
COL5A3,ATP1A2,NKAIN3,LSAMP,NCKAP5,FGFR3,TNIK,PREX2,SOX5,FBXL7,RYR3,SLC1A2,NPAS3,ERBB4,NFIA |
6.811e-07 | -14.20 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 15 | 16828 | 49 |
SLC1A2,NFIA,NPAS3,ERBB4,SOX5,RYR3,FBXL7,TNIK,PREX2,NCKAP5,LSAMP,FGFR3,ATP1A2,COL5A3,NKAIN3 |
8.806e-07 | -13.94 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 19 | 16828 | 49 |
GPM6A,RORA,ITPR2,PCDH9,MACF1,NCKAP5,FGFR3,COL5A3,ZBTB20,AHCYL2,ERBB4,NPAS3,NRXN1,PARD3B,TNIK,SOX5,SLC4A4,RYR3,MAML2 |
8.947e-07 | -13.93 | larynx | COSMIC cancer mutations | larynx | 1948 | 19 | 16828 | 49 |
NPAS3,ERBB4,AHCYL2,PARD3B,NRXN1,TNIK,MAML2,RYR3,SLC4A4,SOX5,RORA,GPM6A,FGFR3,NCKAP5,MACF1,PCDH9,ITPR2,ZBTB20,COL5A3 |
1.129e-06 | -13.69 | system development | biological process | GO:0048731 | 3533 | 25 | 18204 | 50 |
LSAMP,QKI,NFIA,SLC1A3,SOX5,MSI2,CADM1,CTNND2,GPM6A,ATP1A2,LRIG1,TNIK,NTM,RFX4,PREX2,ERBB4,RORA,PCDH9,TRPS1,SLC1A2,NRXN1,HIF3A,PTPRZ1,CTNNA2,FGFR3 |
1.170e-06 | -13.66 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 20 | 16828 | 49 |
PREX2,MAML2,RYR3,FBXL7,SOX5,PTPRZ1,ERBB4,SLC1A2,CTNND2,CDH20,CADM1,NKAIN3,SLC1A3,COL5A3,GPC5,GPM6A,NCKAP5,PCDH9,ITPR2,LSAMP |
1.170e-06 | -13.66 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 20 | 16828 | 49 |
GPC5,SLC1A3,COL5A3,NKAIN3,PCDH9,NCKAP5,ITPR2,LSAMP,GPM6A,SOX5,RYR3,MAML2,FBXL7,PREX2,CADM1,CDH20,SLC1A2,CTNND2,PTPRZ1,ERBB4 |
1.677e-06 | -13.30 | bone | COSMIC cancer mutations | bone | 8157 | 40 | 16828 | 49 |
COL5A3,NKAIN3,SFXN5,GPC5,RORA,GPM6A,ITPR2,LSAMP,ABLIM1,PCDH9,MACF1,PTGDS,TNIK,HIF3A,SOX5,ZNF98,PTPRZ1,TRPS1,DTNA,SLC1A3,ATP1A2,ZBTB20,ACSS1,LRIG1,CST3,NCKAP5,FGFR3,ATP13A4,PREX2,SLC4A4,MAML2,RYR3,QKI,CTNND2,AHCYL2,NPAS3,ERBB4,CADM1,NRXN1,PARD3B |
2.341e-06 | -12.96 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 27 | 16828 | 49 |
RFX4,NCKAP5,FGFR3,ATP1A2,ACSS1,SLC1A2,CTNND2,NPAS3,ERBB4,PARD3B,PREX2,SLC4A4,NHSL1,RYR3,MAML2,GPM6A,PCDH9,MACF1,COL5A3,PITPNC1,ZNF98,NFIA,TRPS1,PTPRZ1,TNIK,HIF3A,FBXL7 |
2.521e-06 | -12.89 | multicellular organism development | biological process | GO:0007275 | 3957 | 26 | 18204 | 50 |
NRXN1,SLC1A2,CTNNA2,FGFR3,HIF3A,PTPRZ1,RORA,ERBB4,TRPS1,PCDH9,NTM,PREX2,RFX4,LRIG1,TNIK,CTNND2,GPM6A,ATP1A2,CADM1,CDH20,MSI2,SOX5,SLC1A3,NFIA,LSAMP,QKI |
3.516e-06 | -12.56 | tibia | COSMIC cancer mutations | tibia | 836 | 12 | 16828 | 49 |
FGFR3,LSAMP,MACF1,NCKAP5,ABLIM1,GPM6A,ACSS1,NKAIN3,CTNND2,QKI,PREX2,TNIK |
3.596e-06 | -12.54 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 37 | 16828 | 49 |
PCDH9,MACF1,ITPR2,LSAMP,RORA,SFXN5,COL5A3,CDH20,PITPNC1,ZNF98,NFIA,TRPS1,PTPRZ1,SOX5,FBXL7,NCKAP5,ATP13A4,FGFR3,RFX4,CST3,NTM,LRIG1,ACSS1,ATP1A2,ZBTB20,PARD3B,NRXN1,SLC1A2,CTNND2,QKI,ERBB4,NPAS3,SLC4A4,NHSL1,RYR3,MAML2,PREX2 |
3.596e-06 | -12.54 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 37 | 16828 | 49 |
PITPNC1,ZNF98,TRPS1,NFIA,PTPRZ1,CDH20,SOX5,FBXL7,RORA,MACF1,PCDH9,ITPR2,LSAMP,COL5A3,SFXN5,SLC1A2,QKI,CTNND2,ERBB4,NPAS3,PARD3B,NRXN1,PREX2,NHSL1,SLC4A4,RYR3,MAML2,RFX4,CST3,NCKAP5,ATP13A4,FGFR3,ATP1A2,ZBTB20,NTM,ACSS1,LRIG1 |
4.679e-06 | -12.27 | cell junction | cellular component | GO:0030054 | 2224 | 18 | 19108 | 49 |
PARD3B,QKI,CDH20,ATP1A2,PTPRZ1,CTNNA2,CTNND2,GPM6A,DTNA,CADM1,ERBB4,NFIA,NRXN1,TNIK,SLC1A3,PCDH9,FGFR3,SLC1A2 |
6.215e-06 | -11.99 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 49 | 16828 | 49 |
RYR3,SLC4A4,NHSL1,CADM1,ZBTB20,DTNA,SLC1A3,ATP1A2,LRIG1,NTM,TNIK,FBXL7,HIF3A,NFIA,PTPRZ1,PITPNC1,ZNF98,CDH20,GPM6A,PCDH9,MACF1,ITPR2,LSAMP,PREX2,MAML2,ERBB4,NPAS3,SLC1A2,QKI,AHCYL2,CTNND2,NRXN1,PARD3B,ACSS1,CST3,MSI2,RFX4,ATP13A4,FGFR3,NCKAP5,SOX5,TRPS1,NKAIN3,COL5A3,GPC5,SFXN5,RORA,PTGDS,ABLIM1 |
7.624e-06 | -11.78 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 15 | 16828 | 49 |
PREX2,NHSL1,SLC4A4,NFIA,PITPNC1,SLC1A2,CTNND2,ZNF98,QKI,ATP1A2,SFXN5,RFX4,ATP13A4,FGFR3,NCKAP5 |
7.624e-06 | -11.78 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 15 | 16828 | 49 |
NFIA,SLC1A2,PITPNC1,ZNF98,QKI,CTNND2,SLC4A4,NHSL1,PREX2,ATP13A4,FGFR3,NCKAP5,RFX4,SFXN5,ATP1A2 |
7.657e-06 | -11.78 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 26 | 16828 | 49 |
PARD3B,SLC1A2,CTNND2,NPAS3,ERBB4,SLC4A4,MAML2,RYR3,PREX2,NCKAP5,FGFR3,RFX4,ACSS1,ATP1A2,PITPNC1,ZNF98,NFIA,TRPS1,PTPRZ1,HIF3A,FBXL7,TNIK,MACF1,PCDH9,GPM6A,COL5A3 |
7.694e-06 | -11.78 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 26 | 16828 | 49 |
PARD3B,CTNND2,SLC1A2,ERBB4,NPAS3,SLC4A4,RYR3,MAML2,PREX2,NCKAP5,FGFR3,RFX4,ACSS1,ATP1A2,ZNF98,PITPNC1,PTPRZ1,NFIA,TRPS1,HIF3A,FBXL7,TNIK,PCDH9,MACF1,GPM6A,COL5A3 |
9.205e-06 | -11.60 | neurogenesis | biological process | GO:0022008 | 1334 | 14 | 18204 | 50 |
NRXN1,CTNND2,CTNNA2,PTPRZ1,GPM6A,RORA,ERBB4,SOX5,SLC1A3,NTM,PREX2,NFIA,QKI,TNIK |
9.407e-06 | -11.57 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 5 | 16828 | 49 |
CTNND2,GPM6A,NKAIN3,NCKAP5,LSAMP |
1.006e-05 | -11.51 | plasma membrane | cellular component | GO:0005886 | 5538 | 29 | 19108 | 49 |
PREX2,ATP1A2,CDH20,LRIG1,CST3,TNIK,SLC1A3,MACF1,GPC5,ERBB4,CADM1,NKAIN3,SLC4A4,CTNNA2,PTPRZ1,ITPR2,ATP13A4,PARD3B,SLC1A2,FGFR3,NTM,HIF3A,PCDH9,NRXN1,GPM6A,DTNA,LSAMP,CTNND2,RYR3 |
1.014e-05 | -11.50 | generation of neurons | biological process | GO:0048699 | 1158 | 13 | 18204 | 50 |
RORA,ERBB4,CTNNA2,GPM6A,PTPRZ1,NRXN1,CTNND2,TNIK,NFIA,PREX2,SOX5,SLC1A3,NTM |
1.294e-05 | -11.26 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 18 | 18204 | 50 |
QKI,NFIA,LRIG1,TNIK,SLC1A3,ABLIM1,SOX5,PREX2,ERBB4,RORA,CDH20,CTNND2,NRXN1,HIF3A,GPM6A,PTPRZ1,CTNNA2,FGFR3 |
1.332e-05 | -11.23 | scalp | COSMIC cancer mutations | scalp | 2110 | 18 | 16828 | 49 |
SOX5,SLC4A4,PREX2,NRXN1,CADM1,PTPRZ1,ERBB4,NFIA,TRPS1,GPC5,NTM,COL5A3,ATP1A2,FGFR3,ATP13A4,LSAMP,MACF1,RORA |
1.437e-05 | -11.15 | cell morphogenesis | biological process | GO:0000902 | 687 | 10 | 18204 | 50 |
SLC1A3,CTNND2,NRXN1,GPM6A,PTPRZ1,CTNNA2,PREX2,NFIA,CDH20,TNIK |
1.661e-05 | -11.01 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 3 | 19454 | 49 |
CTNND2,NRXN1,CST3 |
1.707e-05 | -10.98 | cell periphery | cellular component | GO:0071944 | 6020 | 30 | 19108 | 49 |
CTNNA2,PTPRZ1,ITPR2,PARD3B,ATP13A4,HIF3A,PCDH9,SLC1A2,FGFR3,NTM,NRXN1,CTNND2,LSAMP,DTNA,GPM6A,RYR3,PREX2,ATP1A2,CDH20,TNIK,MACF1,SLC1A3,LRIG1,CST3,CADM1,GPC5,ERBB4,COL5A3,SLC4A4,NKAIN3 |
2.407e-05 | -10.63 | humerus | COSMIC cancer mutations | humerus | 546 | 9 | 16828 | 49 |
NKAIN3,GPC5,HIF3A,SOX5,SFXN5,GPM6A,AHCYL2,PARD3B,NCKAP5 |
2.465e-05 | -10.61 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 7 | 16828 | 49 |
GPC5,SFXN5,SOX5,NKAIN3,NCKAP5,GPM6A,AHCYL2 |
2.586e-05 | -10.56 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 37 | 16828 | 49 |
GPM6A,RORA,PCDH9,ABLIM1,MACF1,LSAMP,ITPR2,COL5A3,NKAIN3,SFXN5,GPC5,ZNF98,TRPS1,PTPRZ1,CDH20,TNIK,SOX5,FBXL7,RFX4,NCKAP5,ATP13A4,FGFR3,SLC1A3,ATP1A2,ACSS1,LRIG1,SLC1A2,CTNND2,AHCYL2,QKI,ERBB4,CADM1,PREX2,NHSL1,SLC4A4,MAML2,RYR3 |
2.682e-05 | -10.53 | neuron differentiation | biological process | GO:0030182 | 1081 | 12 | 18204 | 50 |
CTNNA2,PREX2,GPM6A,PTPRZ1,NRXN1,SLC1A3,CTNND2,NTM,TNIK,NFIA,RORA,ERBB4 |
2.973e-05 | -10.42 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 47 | 16828 | 49 |
RORA,ABLIM1,COL5A3,NKAIN3,SFXN5,GPC5,TRPS1,SOX5,RFX4,MSI2,NCKAP5,ATP13A4,FGFR3,ACSS1,SLC1A2,CTNND2,AHCYL2,QKI,NPAS3,ERBB4,NRXN1,PARD3B,PREX2,MAML2,GPM6A,PCDH9,MACF1,LSAMP,ITPR2,PITPNC1,ZNF98,NFIA,PTPRZ1,CDH20,TNIK,HIF3A,FBXL7,SLC1A3,ATP1A2,DTNA,ZBTB20,NTM,LRIG1,CADM1,NHSL1,SLC4A4,RYR3 |
4.464e-05 | -10.02 | anatomical structure development | biological process | GO:0048856 | 5207 | 28 | 18204 | 50 |
PREX2,RFX4,ABLIM1,NTM,TNIK,LRIG1,FGFR3,CTNNA2,PTPRZ1,HIF3A,NRXN1,SLC1A2,TRPS1,PCDH9,RORA,ERBB4,MSI2,SOX5,SLC1A3,NFIA,QKI,LSAMP,GPM6A,ATP1A2,COL5A3,CTNND2,CADM1,CDH20 |
4.501e-05 | -10.01 | multicellular organismal process | biological process | GO:0032501 | 6177 | 31 | 18204 | 50 |
PCDH9,TRPS1,PTGDS,ERBB4,RORA,HIF3A,PTPRZ1,CTNNA2,FGFR3,SLC1A2,NRXN1,TNIK,SLC4A4,RYR3,LRIG1,RFX4,PREX2,NTM,ABLIM1,DTNA,CDH20,CADM1,ATP1A2,GPM6A,CTNND2,LSAMP,QKI,NFIA,SLC1A3,MSI2,SOX5 |
4.627e-05 | -9.98 | Ig_3 | pfam domains | PF13927 | 141 | 5 | 17795 | 50 |
LRIG1,CADM1,LSAMP,FGFR3,NTM |
4.917e-05 | -9.92 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 2 | 10285 | 30 |
SLC1A3,SLC1A2 |
4.917e-05 | -9.92 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
6.571e-05 | -9.63 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
6.571e-05 | -9.63 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
7.355e-05 | -9.52 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
7.355e-05 | -9.52 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
7.513e-05 | -9.50 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 3 | 18204 | 50 |
ATP1A2,SLC1A3,SLC1A2 |
7.769e-05 | -9.46 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 49 |
NTM,LSAMP,GPM6A |
8.981e-05 | -9.32 | developmental process | biological process | GO:0032502 | 5716 | 29 | 18204 | 50 |
TNIK,LRIG1,RFX4,PREX2,NTM,ABLIM1,PCDH9,TRPS1,ERBB4,RORA,HIF3A,PTPRZ1,CTNNA2,FGFR3,SLC1A2,NRXN1,LSAMP,QKI,NFIA,NHSL1,SLC1A3,SOX5,MSI2,CADM1,CDH20,GPM6A,ATP1A2,CTNND2,COL5A3 |
9.059e-05 | -9.31 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 4 | 18204 | 50 |
ATP1A2,SLC1A3,SLC4A4,SLC1A2 |
9.059e-05 | -9.31 | vascular transport | biological process | GO:0010232 | 86 | 4 | 18204 | 50 |
ATP1A2,SLC4A4,SLC1A3,SLC1A2 |
1.004e-04 | -9.21 | response to auditory stimulus | biological process | GO:0010996 | 33 | 3 | 18204 | 50 |
SLC1A3,NRXN1,ATP1A2 |
1.045e-04 | -9.17 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 10 | 19454 | 49 |
GPM6A,ABLIM1,CTNND2,SLC1A2,ATP1A2,SLC1A3,TNIK,NTM,LSAMP,CTNNA2 |
1.064e-04 | -9.15 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 2 | 18521 | 50 |
ITPR2,RYR3 |
1.064e-04 | -9.15 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.064e-04 | -9.15 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.064e-04 | -9.15 | RIH_dom | interpro domains | IPR000699 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.064e-04 | -9.15 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 2 | 18521 | 50 |
ITPR2,RYR3 |
1.101e-04 | -9.11 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.101e-04 | -9.11 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
1.152e-04 | -9.07 | RYDR_ITPR | pfam domains | PF01365 | 6 | 2 | 17795 | 50 |
RYR3,ITPR2 |
1.152e-04 | -9.07 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 2 | 17795 | 50 |
ITPR2,RYR3 |
1.152e-04 | -9.07 | RIH_assoc | pfam domains | PF08454 | 6 | 2 | 17795 | 50 |
RYR3,ITPR2 |
1.162e-04 | -9.06 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 9 | 18094 | 47 |
RYR3,GPM6A,ITPR2,SLC1A2,SLC4A4,SFXN5,SLC1A3,ATP13A4,ATP1A2 |
1.186e-04 | -9.04 | Salivary secretion | KEGG pathways | ko04970 | 90 | 4 | 7161 | 21 |
CST3,ATP1A2,ITPR2,RYR3 |
1.186e-04 | -9.04 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 4 | 7161 | 21 |
RYR3,ITPR2,ATP1A2,CST3 |
1.255e-04 | -8.98 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 14 | 16828 | 49 |
SLC4A4,SOX5,TRPS1,PTPRZ1,NRXN1,CADM1,ATP1A2,COL5A3,GPC5,RORA,ATP13A4,FGFR3,MACF1,LSAMP |
1.284e-04 | -8.96 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 2 | 14470 | 43 |
RYR3,ITPR2 |
1.338e-04 | -8.92 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 7 | 18094 | 47 |
SLC1A3,ATP1A2,SLC1A2,SLC4A4,ITPR2,GPM6A,RYR3 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.487e-04 | -8.81 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.582e-04 | -8.75 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 5 | 19454 | 49 |
ABLIM1,NRXN1,CADM1,DTNA,PARD3B |
1.585e-04 | -8.75 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 6 | 19454 | 49 |
TNIK,DTNA,NHSL1,CTNNA2,MACF1,ABLIM1 |
1.610e-04 | -8.73 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 50 |
SLC1A3,SLC1A2 |
1.662e-04 | -8.70 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 3 | 18204 | 50 |
RYR3,SLC1A2,SLC1A3 |
1.695e-04 | -8.68 | beta-catenin binding | molecular function | GO:0008013 | 107 | 4 | 18094 | 47 |
CTNND2,RORA,CDH20,CTNNA2 |
1.762e-04 | -8.64 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 34 | 16828 | 49 |
COL5A3,NKAIN3,SFXN5,GPC5,GPM6A,RORA,ITPR2,LSAMP,ABLIM1,PCDH9,MACF1,SOX5,FBXL7,ZNF98,CDH20,ATP1A2,SLC1A3,ACSS1,LRIG1,RFX4,NCKAP5,FGFR3,ATP13A4,PREX2,NHSL1,SLC4A4,RYR3,MAML2,AHCYL2,CTNND2,QKI,SLC1A2,ERBB4,CADM1 |
1.794e-04 | -8.63 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 43 |
SLC1A3,SLC1A2 |
1.955e-04 | -8.54 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 8 | 18094 | 47 |
RYR3,GPM6A,SLC1A3,ATP1A2,ATP13A4,ITPR2,SLC4A4,SLC1A2 |
2.037e-04 | -8.50 | cell adhesion | biological process | GO:0007155 | 942 | 10 | 18204 | 50 |
NRXN1,NTM,COL5A3,PARD3B,CTNND2,CTNNA2,LSAMP,CDH20,CADM1,PCDH9 |
2.071e-04 | -8.48 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 42 | 16828 | 49 |
RFX4,ATP13A4,FGFR3,NCKAP5,ZBTB20,SLC1A3,DTNA,ATP1A2,LRIG1,NTM,NPAS3,ERBB4,SLC1A2,CTNND2,AHCYL2,NRXN1,PARD3B,CADM1,PREX2,RYR3,SLC4A4,GPM6A,RORA,MACF1,ABLIM1,PCDH9,LSAMP,ITPR2,NKAIN3,COL5A3,GPC5,SFXN5,NFIA,TRPS1,PTPRZ1,PITPNC1,ZNF98,CDH20,TNIK,FBXL7,HIF3A,SOX5 |
2.071e-04 | -8.48 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 42 | 16828 | 49 |
PREX2,RYR3,SLC4A4,NPAS3,ERBB4,SLC1A2,CTNND2,AHCYL2,NRXN1,PARD3B,CADM1,ZBTB20,DTNA,SLC1A3,ATP1A2,LRIG1,NTM,RFX4,ATP13A4,FGFR3,NCKAP5,TNIK,FBXL7,SOX5,HIF3A,NFIA,TRPS1,PTPRZ1,PITPNC1,ZNF98,CDH20,NKAIN3,COL5A3,GPC5,SFXN5,GPM6A,RORA,MACF1,ABLIM1,PCDH9,ITPR2,LSAMP |
2.212e-04 | -8.42 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 49 |
LSAMP,NTM |
2.212e-04 | -8.42 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 49 |
LSAMP,NTM |
2.300e-04 | -8.38 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 45 | 16828 | 49 |
CDH20,NFIA,PTPRZ1,PITPNC1,ZNF98,FBXL7,HIF3A,TNIK,MACF1,PCDH9,LSAMP,ITPR2,GPM6A,CADM1,RYR3,NHSL1,SLC4A4,LRIG1,NTM,ZBTB20,SLC1A3,DTNA,ATP1A2,TRPS1,SOX5,ABLIM1,RORA,GPC5,SFXN5,COL5A3,PARD3B,NRXN1,ERBB4,NPAS3,SLC1A2,CTNND2,QKI,MAML2,PREX2,ATP13A4,FGFR3,NCKAP5,CST3,RFX4,ACSS1 |
2.328e-04 | -8.37 | cervix | COSMIC cancer mutations | cervix | 11793 | 45 | 16828 | 49 |
CST3,RFX4,FGFR3,ATP13A4,NCKAP5,ACSS1,ERBB4,NPAS3,CTNND2,QKI,SLC1A2,PARD3B,NRXN1,PREX2,MAML2,RORA,ABLIM1,COL5A3,GPC5,SFXN5,TRPS1,SOX5,ZBTB20,SLC1A3,DTNA,ATP1A2,LRIG1,NTM,CADM1,RYR3,SLC4A4,NHSL1,GPM6A,ITPR2,LSAMP,MACF1,PCDH9,PTPRZ1,NFIA,ZNF98,PITPNC1,CDH20,TNIK,FBXL7,HIF3A |
2.329e-04 | -8.37 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 18 |
SLC1A3,SLC1A2 |
2.383e-04 | -8.34 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 29 | 16828 | 49 |
CST3,NCKAP5,ATP13A4,ATP1A2,SLC1A3,DTNA,NTM,LRIG1,CTNND2,AHCYL2,NPAS3,ERBB4,PARD3B,SLC4A4,RYR3,MAML2,GPM6A,MACF1,ITPR2,LSAMP,COL5A3,NKAIN3,GPC5,ZNF98,TRPS1,PTPRZ1,CDH20,SOX5,FBXL7 |
2.383e-04 | -8.34 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 29 | 16828 | 49 |
CST3,NCKAP5,ATP13A4,DTNA,ATP1A2,SLC1A3,NTM,LRIG1,CTNND2,AHCYL2,NPAS3,ERBB4,PARD3B,SLC4A4,MAML2,RYR3,GPM6A,MACF1,LSAMP,ITPR2,COL5A3,NKAIN3,GPC5,ZNF98,TRPS1,PTPRZ1,CDH20,SOX5,FBXL7 |
2.409e-04 | -8.33 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 42 |
SLC1A3,SLC1A2 |
2.409e-04 | -8.33 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 42 |
SLC1A2,SLC1A3 |
2.464e-04 | -8.31 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 4 | 10285 | 30 |
SLC4A4,SLC1A2,AHCYL2,SLC1A3 |
2.655e-04 | -8.23 | synapse | cellular component | GO:0045202 | 1473 | 12 | 19108 | 49 |
CTNND2,GPM6A,DTNA,SLC1A3,TNIK,SLC1A2,CADM1,ERBB4,NRXN1,ATP1A2,QKI,PTPRZ1 |
2.909e-04 | -8.14 | nodular | COSMIC cancer mutations | nodular | 1515 | 13 | 16828 | 49 |
ATP1A2,ABLIM1,MACF1,ATP13A4,FGFR3,SLC4A4,HIF3A,PREX2,CDH20,CTNND2,NPAS3,ERBB4,PTPRZ1 |
3.003e-04 | -8.11 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 9 | 18204 | 50 |
ITPR2,RYR3,SLC4A4,ATP13A4,ATP1A2,GPM6A,SFXN5,SLC1A2,SLC1A3 |
3.121e-04 | -8.07 | cell-cell junction | cellular component | GO:0005911 | 513 | 7 | 19108 | 49 |
CTNNA2,PCDH9,CADM1,ATP1A2,CTNND2,CDH20,PARD3B |
3.155e-04 | -8.06 | plasma membrane region | cellular component | GO:0098590 | 1278 | 11 | 19108 | 49 |
GPM6A,ATP1A2,PARD3B,SLC4A4,SLC1A2,SLC1A3,MACF1,TNIK,ERBB4,NRXN1,CADM1 |
3.155e-04 | -8.06 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 34 | 16828 | 49 |
FGFR3,ATP13A4,NCKAP5,CST3,LRIG1,ACSS1,ZBTB20,DTNA,SLC1A3,ATP1A2,NRXN1,PARD3B,CADM1,ERBB4,NPAS3,QKI,CTNND2,RYR3,MAML2,SLC4A4,PREX2,PTGDS,ITPR2,MACF1,ABLIM1,RORA,NKAIN3,COL5A3,PTPRZ1,TRPS1,ZNF98,SOX5,HIF3A,TNIK |
3.165e-04 | -8.06 | central nervous system development | biological process | GO:0007417 | 995 | 10 | 18204 | 50 |
RORA,QKI,ERBB4,PCDH9,MSI2,SLC1A2,CTNNA2,ATP1A2,RFX4,PTPRZ1 |
3.170e-04 | -8.06 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 2 | 18521 | 50 |
RYR3,ITPR2 |
3.170e-04 | -8.06 | MIR_motif | interpro domains | IPR016093 | 10 | 2 | 18521 | 50 |
ITPR2,RYR3 |
3.234e-04 | -8.04 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 31 | 16828 | 49 |
HIF3A,SOX5,FBXL7,PITPNC1,TRPS1,CDH20,COL5A3,SFXN5,GPC5,GPM6A,RORA,MACF1,ABLIM1,PREX2,SLC4A4,NHSL1,RYR3,MAML2,SLC1A2,CTNND2,QKI,ERBB4,NPAS3,PARD3B,SLC1A3,ZBTB20,NTM,ACSS1,RFX4,NCKAP5,FGFR3 |
3.281e-04 | -8.02 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
3.346e-04 | -8.00 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 4 | 16828 | 49 |
PREX2,SLC1A2,RYR3,SOX5 |
3.424e-04 | -7.98 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 7 | 18204 | 50 |
PTPRZ1,GPM6A,CTNNA2,PREX2,CTNND2,NRXN1,TNIK |
3.432e-04 | -7.98 | MIR | pfam domains | PF02815 | 10 | 2 | 17795 | 50 |
RYR3,ITPR2 |
3.642e-04 | -7.92 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 7 | 18204 | 50 |
PTPRZ1,GPM6A,CTNNA2,PREX2,CTNND2,NRXN1,TNIK |
3.648e-04 | -7.92 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 2 | 10285 | 30 |
AHCYL2,SLC4A4 |
3.870e-04 | -7.86 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 7 | 18204 | 50 |
PTPRZ1,GPM6A,CTNNA2,PREX2,CTNND2,NRXN1,TNIK |
3.975e-04 | -7.83 | NAKATPASE | prints domains | PR00121 | 9 | 2 | 5227 | 18 |
ATP13A4,ATP1A2 |
4.003e-04 | -7.82 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
4.003e-04 | -7.82 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
4.404e-04 | -7.73 | Ig_I-set | interpro domains | IPR013098 | 132 | 4 | 18521 | 50 |
NTM,LSAMP,LRIG1,FGFR3 |
4.439e-04 | -7.72 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 10 | 16828 | 49 |
NCKAP5,PCDH9,LSAMP,ITPR2,RORA,CTNND2,ZNF98,GPC5,SOX5,NKAIN3 |
4.529e-04 | -7.70 | Ig_sub2 | interpro domains | IPR003598 | 239 | 5 | 18521 | 50 |
LSAMP,LRIG1,NTM,FGFR3,CADM1 |
4.593e-04 | -7.69 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 43 | 16828 | 49 |
RFX4,MSI2,NCKAP5,FGFR3,ATP13A4,DTNA,ATP1A2,SLC1A3,NTM,ACSS1,LRIG1,AHCYL2,QKI,CTNND2,SLC1A2,ERBB4,NPAS3,CADM1,PARD3B,NRXN1,PREX2,SLC4A4,NHSL1,MAML2,RYR3,RORA,LSAMP,ITPR2,PCDH9,ABLIM1,MACF1,COL5A3,NKAIN3,SFXN5,GPC5,ZNF98,PTPRZ1,NFIA,CDH20,TNIK,HIF3A,SOX5,FBXL7 |
4.781e-04 | -7.65 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 23 | 16828 | 49 |
CDH20,TRPS1,ITPR2,ABLIM1,PCDH9,MACF1,RORA,GPC5,COL5A3,PARD3B,ERBB4,CTNND2,QKI,AHCYL2,SLC1A2,SLC4A4,PREX2,FGFR3,ATP13A4,RFX4,LRIG1,ACSS1,ATP1A2 |
4.795e-04 | -7.64 | auditory behavior | biological process | GO:0031223 | 12 | 2 | 18204 | 50 |
NRXN1,SLC1A3 |
4.874e-04 | -7.63 | neuron development | biological process | GO:0048666 | 859 | 9 | 18204 | 50 |
PREX2,CTNNA2,GPM6A,PTPRZ1,NRXN1,CTNND2,SLC1A3,NTM,TNIK |
4.895e-04 | -7.62 | trunk | COSMIC cancer mutations | trunk | 3554 | 21 | 16828 | 49 |
ATP1A2,SLC1A3,LSAMP,PCDH9,NCKAP5,ABLIM1,MACF1,FGFR3,ATP13A4,HIF3A,SOX5,MAML2,RYR3,PREX2,NRXN1,CDH20,CTNND2,NPAS3,PTPRZ1,ERBB4,TRPS1 |
5.115e-04 | -7.58 | I-set | pfam domains | PF07679 | 132 | 4 | 17795 | 50 |
NTM,FGFR3,LSAMP,LRIG1 |
5.128e-04 | -7.58 | MIR | prosite domains | PS50919 | 10 | 2 | 12186 | 42 |
ITPR2,RYR3 |
5.247e-04 | -7.55 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 23 | 16828 | 49 |
COL5A3,GPC5,MACF1,PCDH9,ITPR2,LSAMP,TNIK,SOX5,HIF3A,NFIA,TRPS1,PTPRZ1,DTNA,ATP1A2,ACSS1,LRIG1,ATP13A4,FGFR3,RYR3,CTNND2,ERBB4,CADM1,NRXN1 |
5.566e-04 | -7.49 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 42 | 16828 | 49 |
NCKAP5,ATP13A4,FGFR3,CST3,MSI2,NTM,ACSS1,LRIG1,ATP1A2,DTNA,SLC1A3,ZBTB20,CADM1,PARD3B,NRXN1,SLC1A2,CTNND2,AHCYL2,QKI,ERBB4,NPAS3,SLC4A4,NHSL1,MAML2,RYR3,PREX2,MACF1,PCDH9,ITPR2,LSAMP,PTGDS,RORA,SFXN5,GPC5,COL5A3,CDH20,ZNF98,TRPS1,PTPRZ1,SOX5,FBXL7,TNIK |
5.593e-04 | -7.49 | Ion homeostasis | REACTOME pathways | R-HSA-5578775 | 56 | 3 | 10285 | 30 |
ATP1A2,RYR3,ITPR2 |
5.625e-04 | -7.48 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 7 | 18094 | 47 |
CTNNA2,CADM1,MACF1,CDH20,NRXN1,CTNND2,PTPRZ1 |
5.787e-04 | -7.45 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 11 | 16828 | 49 |
TNIK,SOX5,CTNND2,ZNF98,NKAIN3,GPC5,RORA,NCKAP5,PCDH9,LSAMP,ITPR2 |
5.865e-04 | -7.44 | neurotransmitter transport | biological process | GO:0006836 | 140 | 4 | 18204 | 50 |
ATP1A2,NRXN1,SLC1A2,SLC1A3 |
5.891e-04 | -7.44 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
6.143e-04 | -7.40 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 18 | 16828 | 49 |
ITPR2,PCDH9,MACF1,FGFR3,COL5A3,NKAIN3,LRIG1,CTNND2,ZNF98,PITPNC1,ERBB4,PTPRZ1,TRPS1,TNIK,PREX2,NHSL1,SLC4A4,RYR3 |
6.143e-04 | -7.40 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 18 | 16828 | 49 |
FGFR3,PCDH9,MACF1,ITPR2,NKAIN3,COL5A3,LRIG1,TRPS1,ERBB4,PTPRZ1,PITPNC1,ZNF98,CTNND2,TNIK,PREX2,RYR3,NHSL1,SLC4A4 |
6.144e-04 | -7.39 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 33 | 16828 | 49 |
PCDH9,ABLIM1,MACF1,ITPR2,LSAMP,RORA,GPM6A,GPC5,SFXN5,NKAIN3,COL5A3,CDH20,PTPRZ1,FBXL7,SOX5,TNIK,ATP13A4,NCKAP5,RFX4,ACSS1,LRIG1,SLC1A3,PARD3B,CADM1,ERBB4,SLC1A2,AHCYL2,QKI,CTNND2,RYR3,MAML2,NHSL1,PREX2 |
6.228e-04 | -7.38 | MIR | smart domains | SM00472 | 10 | 2 | 9717 | 37 |
RYR3,ITPR2 |
6.366e-04 | -7.36 | Neurexin-like | interpro domains | IPR003585 | 14 | 2 | 18521 | 50 |
CADM1,NRXN1 |
6.588e-04 | -7.33 | mechanosensory behavior | biological process | GO:0007638 | 14 | 2 | 18204 | 50 |
NRXN1,SLC1A3 |
6.588e-04 | -7.33 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 2 | 18204 | 50 |
SLC4A4,ATP1A2 |
6.866e-04 | -7.28 | adult behavior | biological process | GO:0030534 | 146 | 4 | 18204 | 50 |
ATP1A2,PREX2,SLC1A2,NRXN1 |
7.003e-04 | -7.26 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 5 | 18094 | 47 |
ATP1A2,SLC1A3,ATP13A4,SLC4A4,SLC1A2 |
7.220e-04 | -7.23 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 3 | 18204 | 50 |
CTNNA2,PREX2,CTNND2 |
7.454e-04 | -7.20 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 47 |
ATP1A2,SLC1A3,SLC1A2,SLC4A4 |
7.502e-04 | -7.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 5 | 16828 | 49 |
NFIA,NPAS3,ERBB4,PCDH9,GPC5 |
7.502e-04 | -7.20 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 5 | 16828 | 49 |
GPC5,PCDH9,NFIA,ERBB4,NPAS3 |
7.583e-04 | -7.18 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 7 | 18094 | 47 |
SLC1A3,ATP1A2,ITPR2,SLC1A2,SLC4A4,RYR3,GPM6A |
8.065e-04 | -7.12 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 41 | 16828 | 49 |
SFXN5,GPC5,COL5A3,NKAIN3,LSAMP,ITPR2,MACF1,PCDH9,ABLIM1,RORA,SOX5,HIF3A,FBXL7,TNIK,CDH20,ZNF98,PTPRZ1,NFIA,NTM,ACSS1,LRIG1,SLC1A3,ATP1A2,NCKAP5,ATP13A4,RFX4,MSI2,SLC4A4,NHSL1,RYR3,MAML2,PREX2,CADM1,PARD3B,NRXN1,AHCYL2,QKI,CTNND2,SLC1A2,NPAS3,ERBB4 |
8.065e-04 | -7.12 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 41 | 16828 | 49 |
CDH20,ZNF98,PTPRZ1,NFIA,HIF3A,SOX5,FBXL7,TNIK,ITPR2,LSAMP,MACF1,PCDH9,ABLIM1,RORA,SFXN5,GPC5,COL5A3,NKAIN3,CADM1,PARD3B,NRXN1,CTNND2,QKI,AHCYL2,SLC1A2,ERBB4,NPAS3,SLC4A4,NHSL1,RYR3,MAML2,PREX2,NCKAP5,ATP13A4,RFX4,MSI2,NTM,ACSS1,LRIG1,ATP1A2,SLC1A3 |
8.086e-04 | -7.12 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 2 | 26134 | 50 |
LSAMP,ZBTB20 |
8.975e-04 | -7.02 | presynaptic membrane | cellular component | GO:0042734 | 168 | 4 | 19108 | 49 |
ERBB4,NRXN1,GPM6A,SLC1A2 |
9.218e-04 | -6.99 | transporter activity | molecular function | GO:0005215 | 1211 | 10 | 18094 | 47 |
ATP13A4,SLC1A3,ATP1A2,SFXN5,ITPR2,SLC4A4,SLC1A2,PITPNC1,RYR3,GPM6A |
9.531e-04 | -6.96 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 9 | 16828 | 49 |
ABLIM1,NCKAP5,ITPR2,FGFR3,PTGDS,PTPRZ1,NPAS3,LRIG1,ATP1A2 |
9.636e-04 | -6.94 | Htt (huntingtin) | protein interactions | 15194 | 77 | 3 | 19454 | 49 |
GPM6A,LSAMP,NTM |
9.763e-04 | -6.93 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 5 | 16828 | 49 |
SOX5,FGFR3,RYR3,SLC1A2,PREX2 |
9.840e-04 | -6.92 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
9.840e-04 | -6.92 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 2 | 18094 | 47 |
ITPR2,RYR3 |
9.998e-04 | -6.91 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 11 | 16828 | 49 |
HIF3A,PREX2,CDH20,NPAS3,PTPRZ1,ERBB4,CTNND2,ATP1A2,ATP13A4,ABLIM1,MACF1 |
1.028e-03 | -6.88 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 28 | 16828 | 49 |
NKAIN3,COL5A3,GPC5,GPM6A,RORA,ITPR2,LSAMP,PCDH9,MACF1,FBXL7,SOX5,PTPRZ1,TRPS1,NFIA,CDH20,SLC1A3,FGFR3,NCKAP5,PREX2,RYR3,MAML2,NHSL1,ERBB4,NPAS3,CTNND2,SLC1A2,PARD3B,CADM1 |
1.048e-03 | -6.86 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 9 | 16828 | 49 |
LRIG1,ATP1A2,ABLIM1,NCKAP5,ITPR2,FGFR3,PTGDS,NPAS3,PTPRZ1 |
1.063e-03 | -6.85 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.068e-03 | -6.84 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 5 | 19454 | 49 |
ABLIM1,MACF1,AHCYL2,DTNA,TNIK |
1.069e-03 | -6.84 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 30 | 16828 | 49 |
COL5A3,SFXN5,GPC5,GPM6A,ITPR2,PCDH9,ABLIM1,MACF1,TNIK,HIF3A,SOX5,FBXL7,PITPNC1,PTPRZ1,TRPS1,ATP1A2,ZBTB20,NCKAP5,FGFR3,ATP13A4,PREX2,SLC4A4,RYR3,MAML2,CTNND2,NPAS3,ERBB4,CADM1,PARD3B,NRXN1 |
1.112e-03 | -6.80 | monoatomic ion transport | biological process | GO:0006811 | 964 | 9 | 18204 | 50 |
SLC4A4,ATP13A4,RYR3,ITPR2,SLC1A2,SLC1A3,SFXN5,GPM6A,ATP1A2 |
1.150e-03 | -6.77 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
1.156e-03 | -6.76 | GSC (goosecoid homeobox) | protein interactions | 145258 | 82 | 3 | 19454 | 49 |
NFIA,TRPS1,SOX5 |
1.173e-03 | -6.75 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 3 | 18094 | 47 |
SLC1A3,SLC1A2,SLC4A4 |
1.186e-03 | -6.74 | PAS_fold | interpro domains | IPR013767 | 19 | 2 | 18521 | 50 |
NPAS3,HIF3A |
1.209e-03 | -6.72 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 42 | 16828 | 49 |
CDH20,ZNF98,PTPRZ1,TRPS1,SOX5,FBXL7,TNIK,ITPR2,LSAMP,MACF1,PCDH9,PTGDS,RORA,SFXN5,GPC5,COL5A3,CADM1,NRXN1,PARD3B,CTNND2,AHCYL2,QKI,SLC1A2,ERBB4,NPAS3,NHSL1,SLC4A4,RYR3,MAML2,PREX2,NCKAP5,FGFR3,ATP13A4,MSI2,CST3,NTM,ACSS1,LRIG1,SLC1A3,ATP1A2,DTNA,ZBTB20 |
1.247e-03 | -6.69 | 4.1m | smart domains | SM00294 | 14 | 2 | 9717 | 37 |
NRXN1,CADM1 |
1.252e-03 | -6.68 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-peripheral_T_cell_lymphoma_unspecified | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-peripheral_T_cell_lymphoma_unspecified | 162 | 4 | 16828 | 49 |
RYR3,MACF1,NCKAP5,ITPR2 |
1.283e-03 | -6.66 | PAS | pfam domains | PF00989 | 19 | 2 | 17795 | 50 |
HIF3A,NPAS3 |
1.284e-03 | -6.66 | arm | COSMIC cancer mutations | arm | 1331 | 11 | 16828 | 49 |
PARD3B,TRPS1,NPAS3,ERBB4,SLC4A4,MACF1,FGFR3,NTM,ATP1A2,COL5A3,ZBTB20 |
1.289e-03 | -6.65 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 6 | 18204 | 50 |
SLC1A3,CTNND2,NRXN1,PTPRZ1,CTNNA2,PREX2 |
1.295e-03 | -6.65 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 23 | 16828 | 49 |
ACSS1,SLC1A3,DTNA,ATP1A2,ABLIM1,MACF1,PCDH9,NCKAP5,FGFR3,RFX4,GPM6A,SOX5,HIF3A,NHSL1,RYR3,PREX2,CADM1,ZNF98,QKI,CTNND2,ERBB4,PTPRZ1,TRPS1 |
1.295e-03 | -6.65 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 23 | 16828 | 49 |
ABLIM1,MACF1,PCDH9,GPM6A,SOX5,HIF3A,ZNF98,TRPS1,PTPRZ1,ACSS1,SLC1A3,DTNA,ATP1A2,NCKAP5,FGFR3,RFX4,NHSL1,RYR3,PREX2,CADM1,CTNND2,QKI,ERBB4 |
1.361e-03 | -6.60 | adherens junction | cellular component | GO:0005912 | 188 | 4 | 19108 | 49 |
CTNNA2,CTNND2,CDH20,PARD3B |
1.361e-03 | -6.60 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.400e-03 | -6.57 | peripheral_T_cell_lymphoma_unspecified | COSMIC cancer mutations | peripheral_T_cell_lymphoma_unspecified | 167 | 4 | 16828 | 49 |
RYR3,ITPR2,MACF1,NCKAP5 |
1.502e-03 | -6.50 | positive regulation of purine nucleotide catabolic process | biological process | GO:0033123 | 21 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
1.502e-03 | -6.50 | positive regulation of nucleotide catabolic process | biological process | GO:0030813 | 21 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.502e-03 | -6.50 | positive regulation of glycolytic process | biological process | GO:0045821 | 21 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
1.517e-03 | -6.49 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 14 | 16828 | 49 |
PTPRZ1,ERBB4,TRPS1,PREX2,MSI2,RORA,GPM6A,LSAMP,ITPR2,MACF1,PCDH9,ABLIM1,FGFR3,GPC5 |
1.520e-03 | -6.49 | Rbm38 (RNA binding motif protein 38) | protein interactions | 56190 | 23 | 2 | 19454 | 49 |
MSI2,QKI |
1.614e-03 | -6.43 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
1.632e-03 | -6.42 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 6 | 18204 | 50 |
ATP1A2,SLC1A3,SLC1A2,ITPR2,RORA,RYR3 |
1.637e-03 | -6.41 | Cation_ATPase_N | smart domains | SM00831 | 16 | 2 | 9717 | 37 |
ATP13A4,ATP1A2 |
1.649e-03 | -6.41 | intracellular sodium ion homeostasis | biological process | GO:0006883 | 22 | 2 | 18204 | 50 |
ATP1A2,SLC1A3 |
1.664e-03 | -6.40 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 7 | 18204 | 50 |
ATP1A2,GPM6A,SLC1A3,ITPR2,ATP13A4,SLC4A4,RYR3 |
1.688e-03 | -6.38 | forearm | COSMIC cancer mutations | forearm | 81 | 3 | 16828 | 49 |
FGFR3,PREX2,ERBB4 |
1.740e-03 | -6.35 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 11 | 16828 | 49 |
RYR3,PARD3B,ERBB4,CTNND2,ATP1A2,ATP13A4,FGFR3,PCDH9,NCKAP5,MACF1,ITPR2 |
1.751e-03 | -6.35 | neuron projection | cellular component | GO:0043005 | 1331 | 10 | 19108 | 49 |
CADM1,AHCYL2,SLC1A3,CTNNA2,PCDH9,SLC1A2,CTNND2,DTNA,GPM6A,ATP1A2 |
1.757e-03 | -6.34 | P-type transmembrane transporter activity | molecular function | GO:0140358 | 24 | 2 | 18094 | 47 |
ATP13A4,ATP1A2 |
1.757e-03 | -6.34 | P-type ion transporter activity | molecular function | GO:0015662 | 24 | 2 | 18094 | 47 |
ATP13A4,ATP1A2 |
1.913e-03 | -6.26 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 50 |
RYR3 |
1.913e-03 | -6.26 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 50 |
TNIK |
1.920e-03 | -6.26 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 28 | 16828 | 49 |
GPM6A,ITPR2,MACF1,PCDH9,ABLIM1,COL5A3,SFXN5,GPC5,PTPRZ1,NFIA,TRPS1,CDH20,HIF3A,RFX4,FGFR3,ATP13A4,DTNA,ATP1A2,SLC1A3,ZBTB20,LRIG1,ACSS1,ERBB4,CADM1,PARD3B,NRXN1,PREX2,SLC4A4 |
1.928e-03 | -6.25 | anchoring junction | cellular component | GO:0070161 | 902 | 8 | 19108 | 49 |
CADM1,CTNNA2,PCDH9,FGFR3,PARD3B,CDH20,CTNND2,ATP1A2 |
1.931e-03 | -6.25 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 28 | 16828 | 49 |
GPM6A,ABLIM1,MACF1,PCDH9,ITPR2,COL5A3,GPC5,SFXN5,NFIA,TRPS1,PTPRZ1,CDH20,HIF3A,RFX4,ATP13A4,FGFR3,ZBTB20,ATP1A2,SLC1A3,DTNA,ACSS1,LRIG1,ERBB4,PARD3B,NRXN1,CADM1,PREX2,SLC4A4 |
1.940e-03 | -6.25 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 7 | 19454 | 49 |
SLC1A3,MSI2,TNIK,ERBB4,MACF1,DTNA,ABLIM1 |
1.957e-03 | -6.24 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 4 | 16828 | 49 |
NCKAP5,PCDH9,RYR3,GPC5 |
1.959e-03 | -6.24 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 9 | 18094 | 47 |
ITPR2,SLC4A4,SLC1A2,SLC1A3,ATP1A2,ATP13A4,SFXN5,RYR3,GPM6A |
1.978e-03 | -6.23 | IGc2 | smart domains | SM00408 | 239 | 5 | 9717 | 37 |
FGFR3,LRIG1,LSAMP,CADM1,NTM |
1.997e-03 | -6.22 | Proximal tubule bicarbonate reclamation | KEGG pathways | ko04964 | 23 | 2 | 7161 | 21 |
ATP1A2,SLC4A4 |
1.997e-03 | -6.22 | Proximal tubule bicarbonate reclamation | KEGG pathways | hsa04964 | 23 | 2 | 7161 | 21 |
ATP1A2,SLC4A4 |
2.018e-03 | -6.21 | back | COSMIC cancer mutations | back | 310 | 5 | 16828 | 49 |
FGFR3,ATP1A2,PREX2,ERBB4,TNIK |
2.021e-03 | -6.20 | skin-face-malignant_melanoma-lentigo_maligna | COSMIC cancer mutations | skin-face-malignant_melanoma-lentigo_maligna | 23 | 2 | 16828 | 49 |
FGFR3,PREX2 |
2.048e-03 | -6.19 | NCK1 (NCK adaptor protein 1) | protein interactions | 4690 | 214 | 4 | 19454 | 49 |
NCKAP5,NHSL1,ERBB4,TNIK |
2.095e-03 | -6.17 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 49 |
ABLIM1,DTNA |
2.095e-03 | -6.17 | MBNL2 (muscleblind like splicing regulator 2) | protein interactions | 10150 | 27 | 2 | 19454 | 49 |
QKI,MSI2 |
2.130e-03 | -6.15 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
2.146e-03 | -6.14 | synapse organization | biological process | GO:0050808 | 333 | 5 | 18204 | 50 |
GPM6A,ERBB4,CTNND2,NFIA,NRXN1 |
2.152e-03 | -6.14 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 49 |
DTNA,CTNNA2,CDH20 |
2.181e-03 | -6.13 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
2.196e-03 | -6.12 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 17 | 16828 | 49 |
COL5A3,ZBTB20,ACSS1,GPC5,GPM6A,NCKAP5,MACF1,PCDH9,FGFR3,HIF3A,SOX5,RYR3,CTNND2,PTPRZ1,NPAS3,ERBB4,CDH20 |
2.253e-03 | -6.10 | LRRC7 (leucine rich repeat containing 7) | protein interactions | 57554 | 28 | 2 | 19454 | 49 |
CTNND2,ERBB4 |
2.287e-03 | -6.08 | NS-malignant_melanoma | COSMIC cancer mutations | NS-malignant_melanoma | 3420 | 19 | 16828 | 49 |
GPC5,LRIG1,COL5A3,ATP1A2,ITPR2,PCDH9,MACF1,NCKAP5,FGFR3,ATP13A4,RFX4,PREX2,CADM1,NRXN1,ZNF98,CTNND2,PITPNC1,ERBB4,PTPRZ1 |
2.299e-03 | -6.08 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 7 | 18094 | 47 |
GPM6A,RYR3,SLC1A3,ATP1A2,SLC1A2,SLC4A4,ITPR2 |
2.304e-03 | -6.07 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
2.414e-03 | -6.03 | hairy_cell_leukaemia | COSMIC cancer mutations | hairy_cell_leukaemia | 1440 | 11 | 16828 | 49 |
CDH20,NRXN1,FGFR3,MACF1,NCKAP5,PTPRZ1,RFX4,CTNND2,RYR3,PREX2,COL5A3 |
2.414e-03 | -6.03 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | 1440 | 11 | 16828 | 49 |
RYR3,PREX2,CDH20,NRXN1,PTPRZ1,CTNND2,COL5A3,FGFR3,MACF1,NCKAP5,RFX4 |
2.417e-03 | -6.03 | MAPRE3 (microtubule associated protein RP/EB family member 3) | protein interactions | 22924 | 224 | 4 | 19454 | 49 |
GPM6A,ABLIM1,MACF1,NCKAP5 |
2.435e-03 | -6.02 | face | COSMIC cancer mutations | face | 2139 | 14 | 16828 | 49 |
ERBB4,PTPRZ1,TRPS1,PREX2,ITPR2,LSAMP,MACF1,ABLIM1,PCDH9,FGFR3,RORA,MSI2,GPM6A,GPC5 |
2.478e-03 | -6.00 | Calcium-transporting ATPase, transmembrane domain | gene3d domains | 1.20.1110.10 | 25 | 2 | 14470 | 43 |
ATP13A4,ATP1A2 |
2.504e-03 | -5.99 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 16 | 16828 | 49 |
CTNND2,TRPS1,ERBB4,PTPRZ1,CDH20,NRXN1,PREX2,SOX5,RYR3,MAML2,NCKAP5,PCDH9,LSAMP,ATP13A4,SLC1A3,ATP1A2 |
2.519e-03 | -5.98 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 49 |
PITPNC1 |
2.519e-03 | -5.98 | Sh2b1 (SH2B adaptor protein 1) | protein interactions | 20399 | 1 | 1 | 19454 | 49 |
FGFR3 |
2.519e-03 | -5.98 | fgf3.L (fibroblast growth factor 3 L homeolog) | protein interactions | 373669 | 1 | 1 | 19454 | 49 |
FGFR3 |
2.519e-03 | -5.98 | Sytl1 (synaptotagmin-like 1) | protein interactions | 269589 | 1 | 1 | 19454 | 49 |
NRXN1 |
2.530e-03 | -5.98 | Pancreatic secretion | KEGG pathways | ko04972 | 95 | 3 | 7161 | 21 |
ATP1A2,ITPR2,SLC4A4 |
2.530e-03 | -5.98 | Pancreatic secretion | KEGG pathways | hsa04972 | 95 | 3 | 7161 | 21 |
ATP1A2,ITPR2,SLC4A4 |
2.546e-03 | -5.97 | EN1 (engrailed homeobox 1) | protein interactions | 2019 | 108 | 3 | 19454 | 49 |
NFIA,AHCYL2,TRPS1 |
2.546e-03 | -5.97 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 3 | 19454 | 49 |
RYR3,MSI2,ERBB4 |
2.564e-03 | -5.97 | ligand-gated calcium channel activity | molecular function | GO:0099604 | 29 | 2 | 18094 | 47 |
RYR3,ITPR2 |
2.564e-03 | -5.97 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
2.577e-03 | -5.96 | upper_back | COSMIC cancer mutations | upper_back | 328 | 5 | 16828 | 49 |
MACF1,GPC5,PARD3B,FGFR3,ERBB4 |
2.579e-03 | -5.96 | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 649 | 7 | 16828 | 49 |
QKI,TNIK,PREX2,ABLIM1,MACF1,FGFR3,ACSS1 |
2.598e-03 | -5.95 | internal N(7)-methylguanine-containing RNA reader activity | molecular function | GO:0160089 | 1 | 1 | 18094 | 47 |
QKI |
2.614e-03 | -5.95 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 50 |
SLC1A3,SLC1A2,RYR3 |
2.670e-03 | -5.93 | positive regulation of oligodendrocyte differentiation | biological process | GO:0048714 | 28 | 2 | 18204 | 50 |
QKI,PTPRZ1 |
2.671e-03 | -5.93 | human chr20p11.21 | chromosome location | human chr20p11.21 | 40 | 2 | 26134 | 50 |
CST3,ACSS1 |
2.700e-03 | -5.91 | STAR_dimer | interpro domains | IPR032377 | 1 | 1 | 18521 | 50 |
QKI |
2.700e-03 | -5.91 | Rex2_DEP_1 | interpro domains | IPR037367 | 1 | 1 | 18521 | 50 |
PREX2 |
2.700e-03 | -5.91 | Quaking_NLS | interpro domains | IPR032367 | 1 | 1 | 18521 | 50 |
QKI |
2.700e-03 | -5.91 | MAML2_TAD | interpro domains | IPR048452 | 1 | 1 | 18521 | 50 |
MAML2 |
2.700e-03 | -5.91 | TRPS1 | interpro domains | IPR028440 | 1 | 1 | 18521 | 50 |
TRPS1 |
2.701e-03 | -5.91 | neuron projection development | biological process | GO:0031175 | 693 | 7 | 18204 | 50 |
GPM6A,PTPRZ1,PREX2,CTNNA2,CTNND2,NRXN1,TNIK |
2.709e-03 | -5.91 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 49 |
TNIK,FBXL7,HIF3A,PTPRZ1,NFIA,ZNF98,PITPNC1,CDH20,GPM6A,ITPR2,LSAMP,PCDH9,MACF1,RYR3,SLC4A4,NHSL1,CADM1,ZBTB20,DTNA,SLC1A3,ATP1A2,LRIG1,NTM,SOX5,TRPS1,NKAIN3,COL5A3,GPC5,SFXN5,RORA,PTGDS,ABLIM1,PREX2,MAML2,ERBB4,NPAS3,CTNND2,AHCYL2,QKI,SLC1A2,PARD3B,NRXN1,ACSS1,CST3,RFX4,FGFR3,ATP13A4,NCKAP5 |
2.747e-03 | -5.90 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 50 |
ATP1A2 |
2.747e-03 | -5.90 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 50 |
ATP1A2 |
2.747e-03 | -5.90 | negative regulation of collagen catabolic process | biological process | GO:0010711 | 1 | 1 | 18204 | 50 |
CST3 |
2.747e-03 | -5.90 | negative regulation of elastin catabolic process | biological process | GO:0060311 | 1 | 1 | 18204 | 50 |
CST3 |
2.758e-03 | -5.89 | SH2D1B (SH2 domain containing 1B) | protein interactions | 117157 | 31 | 2 | 19454 | 49 |
ERBB4,ABLIM1 |
2.758e-03 | -5.89 | SH2B1 (SH2B adaptor protein 1) | protein interactions | 25970 | 31 | 2 | 19454 | 49 |
FGFR3,ERBB4 |
2.783e-03 | -5.88 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 7 | 10285 | 30 |
SLC1A3,ATP1A2,ATP13A4,RYR3,AHCYL2,SLC1A2,SLC4A4 |
2.809e-03 | -5.87 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 49 |
CADM1,RYR3,NHSL1,SLC4A4,LRIG1,NTM,ZBTB20,SLC1A3,DTNA,ATP1A2,CDH20,PTPRZ1,NFIA,ZNF98,PITPNC1,FBXL7,HIF3A,TNIK,LSAMP,ITPR2,PCDH9,MACF1,GPM6A,NRXN1,PARD3B,ERBB4,NPAS3,CTNND2,QKI,AHCYL2,SLC1A2,MAML2,PREX2,FGFR3,ATP13A4,NCKAP5,CST3,RFX4,ACSS1,TRPS1,SOX5,PTGDS,ABLIM1,RORA,GPC5,SFXN5,NKAIN3,COL5A3 |
2.810e-03 | -5.87 | FGFR3_TM | pfam domains | PF21165 | 1 | 1 | 17795 | 50 |
FGFR3 |
2.810e-03 | -5.87 | STAR_dimer | pfam domains | PF16544 | 1 | 1 | 17795 | 50 |
QKI |
2.810e-03 | -5.87 | MAML2_TAD | pfam domains | PF20804 | 1 | 1 | 17795 | 50 |
MAML2 |
2.810e-03 | -5.87 | Quaking_NLS | pfam domains | PF16551 | 1 | 1 | 17795 | 50 |
QKI |
2.823e-03 | -5.87 | TBR1 (T-box brain transcription factor 1) | protein interactions | 10716 | 112 | 3 | 19454 | 49 |
SOX5,TRPS1,NFIA |
2.857e-03 | -5.86 | cell body | cellular component | GO:0044297 | 556 | 6 | 19108 | 49 |
SLC1A2,SLC1A3,NRXN1,ATP1A2,GPM6A,CTNND2 |
2.857e-03 | -5.86 | catenin complex | cellular component | GO:0016342 | 31 | 2 | 19108 | 49 |
CDH20,CTNNA2 |
2.917e-03 | -5.84 | t(4;14) translocations of FGFR3 | REACTOME pathways | R-HSA-2033515 | 1 | 1 | 10285 | 30 |
FGFR3 |
2.927e-03 | -5.83 | intracellularly ligand-gated monoatomic ion channel activity | molecular function | GO:0005217 | 31 | 2 | 18094 | 47 |
RYR3,ITPR2 |
2.937e-03 | -5.83 | NXPH2 (neurexophilin 2) | protein interactions | 11249 | 32 | 2 | 19454 | 49 |
NRXN1,PCDH9 |
2.968e-03 | -5.82 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 3 | 19454 | 49 |
ZBTB20,MACF1,PCDH9 |
2.972e-03 | -5.82 | - | gene3d domains | 1.20.5.4010 | 1 | 1 | 14470 | 43 |
QKI |
2.972e-03 | -5.82 | - | gene3d domains | 6.10.250.880 | 1 | 1 | 14470 | 43 |
ERBB4 |
2.972e-03 | -5.82 | - | gene3d domains | 6.10.250.1740 | 1 | 1 | 14470 | 43 |
FGFR3 |
3.002e-03 | -5.81 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 3 | 18204 | 50 |
NFIA,SOX5,RORA |
3.009e-03 | -5.81 | GJA1 (gap junction protein alpha 1) | protein interactions | 2697 | 572 | 6 | 19454 | 49 |
PCDH9,MACF1,ITPR2,ERBB4,TNIK,DTNA |
3.028e-03 | -5.80 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 10 | 16828 | 49 |
GPM6A,TRPS1,CTNND2,ATP13A4,FGFR3,ABLIM1,MACF1,TNIK,RYR3,NTM |
3.028e-03 | -5.80 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 10 | 16828 | 49 |
FGFR3,ATP13A4,ABLIM1,MACF1,GPM6A,TRPS1,CTNND2,RYR3,NTM,TNIK |
3.062e-03 | -5.79 | L-glutamate import | biological process | GO:0051938 | 30 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
3.131e-03 | -5.77 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 19 | 16828 | 49 |
SLC4A4,RYR3,FBXL7,PREX2,TNIK,PARD3B,PITPNC1,CTNND2,ERBB4,NPAS3,PTPRZ1,GPC5,SLC1A3,DTNA,MACF1,PCDH9,NCKAP5,LSAMP,MSI2 |
3.131e-03 | -5.77 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 19 | 16828 | 49 |
FBXL7,RYR3,SLC4A4,PREX2,TNIK,PARD3B,NPAS3,ERBB4,PTPRZ1,CTNND2,PITPNC1,GPC5,SLC1A3,DTNA,LSAMP,MACF1,PCDH9,NCKAP5,MSI2 |
3.219e-03 | -5.74 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 4 | 16828 | 49 |
NTM,SLC4A4,ATP13A4,COL5A3 |
3.234e-03 | -5.73 | cell junction organization | biological process | GO:0034330 | 532 | 6 | 18204 | 50 |
GPM6A,CDH20,CTNND2,ERBB4,NRXN1,NFIA |
3.404e-03 | -5.68 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 9 | 18204 | 50 |
ITPR2,ERBB4,RYR3,NFIA,ATP1A2,FGFR3,SLC1A2,SLC1A3,SOX5 |
3.415e-03 | -5.68 | E1-E2_ATPase | pfam domains | PF00122 | 31 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
3.430e-03 | -5.68 | lentigo_maligna | COSMIC cancer mutations | lentigo_maligna | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.430e-03 | -5.68 | skin-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-malignant_melanoma-acral_lentiginous | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.445e-03 | -5.67 | brain development | biological process | GO:0007420 | 724 | 7 | 18204 | 50 |
CTNNA2,RFX4,ATP1A2,PCDH9,RORA,SLC1A2,ERBB4 |
3.473e-03 | -5.66 | calcium channel activity | molecular function | GO:0005262 | 117 | 3 | 18094 | 47 |
ITPR2,RYR3,GPM6A |
3.473e-03 | -5.66 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 3 | 18094 | 47 |
SLC1A3,SLC1A2,SLC4A4 |
3.479e-03 | -5.66 | positive regulation of ATP metabolic process | biological process | GO:1903580 | 32 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
3.479e-03 | -5.66 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
3.624e-03 | -5.62 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 8 | 16828 | 49 |
NFIA,ERBB4,FGFR3,PCDH9,PREX2,ACSS1,LRIG1,HIF3A |
3.637e-03 | -5.62 | Cation_ATPase | pfam domains | PF13246 | 32 | 2 | 17795 | 50 |
ATP1A2,ATP13A4 |
3.674e-03 | -5.61 | cell-cell adhesion | biological process | GO:0098609 | 546 | 6 | 18204 | 50 |
NRXN1,CTNND2,CDH20,CADM1,CTNNA2,PCDH9 |
3.692e-03 | -5.60 | dendrite development | biological process | GO:0016358 | 113 | 3 | 18204 | 50 |
CTNNA2,PREX2,CTNND2 |
3.721e-03 | -5.59 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
3.758e-03 | -5.58 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 9 | 18204 | 50 |
TNIK,RFX4,PTPRZ1,GPM6A,CTNNA2,PREX2,CTNND2,NRXN1,ABLIM1 |
3.792e-03 | -5.57 | PAS-like_dom_sf | interpro domains | IPR035965 | 34 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.792e-03 | -5.57 | PAS | interpro domains | IPR000014 | 34 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.808e-03 | -5.57 | DELLA | smart domains | SM01129 | 1 | 1 | 9717 | 37 |
MACF1 |
3.879e-03 | -5.55 | fatty acid biosynthetic process | biological process | GO:0006633 | 115 | 3 | 18204 | 50 |
QKI,ACSS1,PTGDS |
3.897e-03 | -5.55 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 10 | 16828 | 49 |
ZBTB20,COL5A3,ATP1A2,SLC4A4,NTM,ERBB4,NPAS3,TRPS1,PARD3B,MACF1 |
3.913e-03 | -5.54 | TRNAU1AP (tRNA selenocysteine 1 associated protein 1) | protein interactions | 54952 | 37 | 2 | 19454 | 49 |
ZBTB20,QKI |
3.913e-03 | -5.54 | HPCA (hippocalcin) | protein interactions | 3208 | 37 | 2 | 19454 | 49 |
CST3,GPM6A |
3.913e-03 | -5.54 | MAGI2 (membrane associated guanylate kinase, WW and PDZ domain containing 2) | protein interactions | 9863 | 37 | 2 | 19454 | 49 |
CTNND2,ERBB4 |
3.932e-03 | -5.54 | Diseases of signal transduction | REACTOME pathways | R-HSA-5663202 | 369 | 5 | 10285 | 30 |
MAML2,FGFR3,MACF1,ERBB4,QKI |
4.005e-03 | -5.52 | PAS | smart domains | SM00091 | 25 | 2 | 9717 | 37 |
HIF3A,NPAS3 |
4.010e-03 | -5.52 | TRIM67 (tripartite motif containing 67) | protein interactions | 440730 | 4804 | 21 | 19454 | 49 |
ATP1A2,CTNND2,DTNA,QKI,PTPRZ1,ITPR2,LSAMP,MSI2,CST3,AHCYL2,SLC1A3,SLC4A4,LRIG1,PITPNC1,GPM6A,ACSS1,CADM1,MACF1,CTNNA2,NTM,TNIK |
4.021e-03 | -5.52 | EPB41L4A (erythrocyte membrane protein band 4.1 like 4A) | protein interactions | 64097 | 127 | 3 | 19454 | 49 |
ABLIM1,MACF1,DTNA |
4.021e-03 | -5.52 | PAX9 (paired box 9) | protein interactions | 5083 | 127 | 3 | 19454 | 49 |
QKI,NFIA,TRPS1 |
4.102e-03 | -5.50 | Ig_sub | interpro domains | IPR003599 | 394 | 5 | 18521 | 50 |
FGFR3,CADM1,LRIG1,LSAMP,NTM |
4.111e-03 | -5.49 | ATF7IP (activating transcription factor 7 interacting protein) | protein interactions | 55729 | 128 | 3 | 19454 | 49 |
MACF1,CADM1,SOX5 |
4.123e-03 | -5.49 | Pcbp1 (poly(rC) binding protein 1) | protein interactions | 23983 | 38 | 2 | 19454 | 49 |
MSI2,QKI |
4.158e-03 | -5.48 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 6 | 19454 | 49 |
DTNA,AHCYL2,TNIK,FGFR3,ABLIM1,NHSL1 |
4.169e-03 | -5.48 | synapse assembly | biological process | GO:0007416 | 118 | 3 | 18204 | 50 |
GPM6A,ERBB4,NRXN1 |
4.193e-03 | -5.47 | transcription cis-regulatory region binding | molecular function | GO:0000976 | 1485 | 10 | 18094 | 47 |
RORA,SOX5,ERBB4,ZBTB20,ZNF98,RFX4,NPAS3,NFIA,TRPS1,HIF3A |
4.201e-03 | -5.47 | Lima1 (LIM domain and actin binding 1) | protein interactions | 65970 | 129 | 3 | 19454 | 49 |
ZBTB20,ABLIM1,ITPR2 |
4.234e-03 | -5.46 | transcription regulatory region nucleic acid binding | molecular function | GO:0001067 | 1487 | 10 | 18094 | 47 |
ZBTB20,ZNF98,RFX4,NFIA,NPAS3,TRPS1,HIF3A,RORA,SOX5,ERBB4 |
4.240e-03 | -5.46 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 3 | 7161 | 21 |
SLC1A2,SLC1A3,ITPR2 |
4.240e-03 | -5.46 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 3 | 7161 | 21 |
SLC1A2,SLC1A3,ITPR2 |
4.244e-03 | -5.46 | ATPase_P-typ_P_site | interpro domains | IPR018303 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_transduc_dom_A_sf | interpro domains | IPR008250 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | P_typ_ATPase_HD_dom | interpro domains | IPR044492 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | P_typ_ATPase | interpro domains | IPR001757 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | ATPase_P-typ_cyto_dom_N | interpro domains | IPR023299 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.257e-03 | -5.46 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 10 | 18204 | 50 |
PTGDS,ITPR2,NFIA,ERBB4,RYR3,FGFR3,ATP1A2,SOX5,SLC1A3,SLC1A2 |
4.289e-03 | -5.45 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 9 | 16828 | 49 |
NTM,SLC4A4,COL5A3,PREX2,MACF1,ATP13A4,FGFR3,CTNND2,ERBB4 |
4.335e-03 | -5.44 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 40 | 16828 | 49 |
SFXN5,GPC5,COL5A3,NKAIN3,PCDH9,ABLIM1,MACF1,ITPR2,LSAMP,RORA,GPM6A,SOX5,FBXL7,TNIK,CDH20,ZNF98,TRPS1,PTPRZ1,LRIG1,ACSS1,DTNA,ATP1A2,SLC1A3,ZBTB20,NCKAP5,ATP13A4,FGFR3,RFX4,NHSL1,RYR3,MAML2,PREX2,CADM1,NRXN1,SLC1A2,AHCYL2,QKI,CTNND2,ERBB4,NPAS3 |
4.370e-03 | -5.43 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 50 |
ATP1A2,DTNA,RYR3 |
4.391e-03 | -5.43 | central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_I | 34 | 2 | 16828 | 49 |
FGFR3,QKI |
4.470e-03 | -5.41 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 9 | 16828 | 49 |
ERBB4,QKI,SLC1A2,ATP13A4,CDH20,NCKAP5,GPC5,RYR3,SOX5 |
4.478e-03 | -5.41 | ATPase_P-typ_TM_dom_sf | interpro domains | IPR023298 | 37 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.574e-03 | -5.39 | RHOB (ras homolog family member B) | protein interactions | 388 | 832 | 7 | 19454 | 49 |
SLC1A3,AHCYL2,TNIK,PARD3B,MACF1,DTNA,ABLIM1 |
4.631e-03 | -5.38 | positive regulation of purine nucleotide metabolic process | biological process | GO:1900544 | 37 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
4.631e-03 | -5.38 | positive regulation of nucleotide metabolic process | biological process | GO:0045981 | 37 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
4.632e-03 | -5.37 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 44 | 16828 | 49 |
SLC1A3,ATP1A2,ZBTB20,NTM,LRIG1,CADM1,NHSL1,RYR3,GPM6A,MACF1,PCDH9,ITPR2,LSAMP,PITPNC1,ZNF98,NFIA,PTPRZ1,CDH20,TNIK,HIF3A,FBXL7,RFX4,NCKAP5,ATP13A4,FGFR3,ACSS1,SLC1A2,QKI,CTNND2,AHCYL2,NPAS3,ERBB4,PARD3B,NRXN1,PREX2,MAML2,RORA,ABLIM1,COL5A3,NKAIN3,SFXN5,GPC5,TRPS1,SOX5 |
4.668e-03 | -5.37 | bone-fibula-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-fibula-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 377 | 5 | 16828 | 49 |
COL5A3,MACF1,NCKAP5,FGFR3,NRXN1 |
4.691e-03 | -5.36 | monoatomic cation transport | biological process | GO:0006812 | 766 | 7 | 18204 | 50 |
SLC1A3,ATP1A2,GPM6A,RYR3,SLC4A4,ATP13A4,ITPR2 |
4.745e-03 | -5.35 | PAS | prosite domains | PS50112 | 30 | 2 | 12186 | 42 |
NPAS3,HIF3A |
4.770e-03 | -5.35 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 3 | 19454 | 49 |
ABLIM1,ITPR2,TRPS1 |
4.770e-03 | -5.35 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 3 | 19454 | 49 |
DTNA,ABLIM1,ERBB4 |
4.783e-03 | -5.34 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 38 | 16828 | 49 |
GPM6A,RORA,ITPR2,PCDH9,ABLIM1,MACF1,COL5A3,NKAIN3,GPC5,PITPNC1,PTPRZ1,TRPS1,NFIA,CDH20,TNIK,HIF3A,SOX5,FBXL7,RFX4,CST3,MSI2,FGFR3,ATP13A4,DTNA,ATP1A2,NTM,LRIG1,CTNND2,QKI,AHCYL2,ERBB4,NPAS3,NRXN1,PARD3B,PREX2,SLC4A4,MAML2,RYR3 |
4.840e-03 | -5.33 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 38 | 16828 | 49 |
ITPR2,ABLIM1,PCDH9,MACF1,RORA,GPM6A,GPC5,NKAIN3,COL5A3,CDH20,PTPRZ1,TRPS1,NFIA,PITPNC1,FBXL7,SOX5,HIF3A,TNIK,FGFR3,ATP13A4,MSI2,CST3,RFX4,LRIG1,NTM,ATP1A2,DTNA,NRXN1,PARD3B,ERBB4,NPAS3,AHCYL2,CTNND2,QKI,RYR3,MAML2,SLC4A4,PREX2 |
4.880e-03 | -5.32 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
4.912e-03 | -5.32 | central_nervous_system-thalamus-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-thalamus-glioma-astrocytoma_Grade_I | 36 | 2 | 16828 | 49 |
FGFR3,QKI |
4.915e-03 | -5.32 | cell projection organization | biological process | GO:0030030 | 1200 | 9 | 18204 | 50 |
RFX4,GPM6A,PTPRZ1,PREX2,CTNNA2,CTNND2,ABLIM1,NRXN1,TNIK |
4.963e-03 | -5.31 | head development | biological process | GO:0060322 | 774 | 7 | 18204 | 50 |
SLC1A2,CTNNA2,ATP1A2,RFX4,RORA,ERBB4,PCDH9 |
4.969e-03 | -5.30 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 6 | 18204 | 50 |
RYR3,SLC1A3,ATP13A4,SLC4A4,ZBTB20,ATP1A2 |
5.031e-03 | -5.29 | cdh11.S (cadherin 11 S homeolog) | protein interactions | 100337621 | 2 | 1 | 19454 | 49 |
ERBB4 |
5.070e-03 | -5.28 | NFIB (nuclear factor I B) | protein interactions | 4781 | 138 | 3 | 19454 | 49 |
NFIA,SOX5,TRPS1 |
5.093e-03 | -5.28 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 4 | 18094 | 47 |
SLC4A4,SLC1A2,SFXN5,SLC1A3 |
5.097e-03 | -5.28 | Calcium-transporting ATPase, cytoplasmic transduction domain A | gene3d domains | 2.70.150.10 | 36 | 2 | 14470 | 43 |
ATP13A4,ATP1A2 |
5.097e-03 | -5.28 | Calcium-transporting ATPase, cytoplasmic domain N | gene3d domains | 3.40.1110.10 | 36 | 2 | 14470 | 43 |
ATP13A4,ATP1A2 |
5.109e-03 | -5.28 | forebrain development | biological process | GO:0030900 | 408 | 5 | 18204 | 50 |
ERBB4,SLC1A2,PCDH9,ATP1A2,RFX4 |
5.134e-03 | -5.27 | olfactory lobe development | biological process | GO:0021988 | 39 | 2 | 18204 | 50 |
ATP1A2,ERBB4 |
5.134e-03 | -5.27 | sodium ion homeostasis | biological process | GO:0055078 | 39 | 2 | 18204 | 50 |
ATP1A2,SLC1A3 |
5.135e-03 | -5.27 | prostate | COSMIC cancer mutations | prostate | 13883 | 47 | 16828 | 49 |
TRPS1,SOX5,ABLIM1,RORA,SFXN5,GPC5,COL5A3,NKAIN3,NRXN1,PARD3B,SLC1A2,CTNND2,AHCYL2,QKI,NPAS3,ERBB4,MAML2,PREX2,NCKAP5,ATP13A4,FGFR3,RFX4,MSI2,ACSS1,CDH20,PITPNC1,ZNF98,NFIA,PTPRZ1,HIF3A,FBXL7,TNIK,MACF1,PCDH9,ITPR2,LSAMP,GPM6A,CADM1,SLC4A4,NHSL1,RYR3,NTM,LRIG1,DTNA,ATP1A2,SLC1A3,ZBTB20 |
5.154e-03 | -5.27 | spindle | COSMIC cancer mutations | spindle | 386 | 5 | 16828 | 49 |
CTNND2,PREX2,MACF1,PCDH9,FGFR3 |
5.184e-03 | -5.26 | central_nervous_system-third_ventricle-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-third_ventricle-glioma-astrocytoma_Grade_I | 37 | 2 | 16828 | 49 |
FGFR3,QKI |
5.210e-03 | -5.26 | fibula | COSMIC cancer mutations | fibula | 387 | 5 | 16828 | 49 |
COL5A3,NRXN1,FGFR3,NCKAP5,MACF1 |
5.251e-03 | -5.25 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 3 | 16828 | 49 |
CDH20,FGFR3,DTNA |
5.290e-03 | -5.24 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 3 | 18094 | 47 |
RYR3,ITPR2,GPM6A |
5.302e-03 | -5.24 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 6 | 16828 | 49 |
RYR3,FBXL7,SLC4A4,TRPS1,ERBB4,CTNND2 |
5.322e-03 | -5.24 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
5.356e-03 | -5.23 | lung-middle_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-middle_lobe-carcinoma-adenocarcinoma | 1368 | 10 | 16828 | 49 |
PCDH9,MACF1,NCKAP5,ITPR2,ATP13A4,PARD3B,CTNND2,ERBB4,RYR3,ATP1A2 |
5.373e-03 | -5.23 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 11 | 18204 | 50 |
QKI,SOX5,ERBB4,RORA,CADM1,MACF1,SFXN5,NRXN1,ZBTB20,PTPRZ1,ATP1A2 |
5.382e-03 | -5.22 | SNTB2 (syntrophin beta 2) | protein interactions | 6645 | 141 | 3 | 19454 | 49 |
DTNA,ERBB4,FGFR3 |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.392e-03 | -5.22 | Nckap5l | interpro domains | IPR026163 | 2 | 1 | 18521 | 50 |
NCKAP5 |
5.392e-03 | -5.22 | Alpha_CARP_receptor-type | interpro domains | IPR041887 | 2 | 1 | 18521 | 50 |
PTPRZ1 |
5.392e-03 | -5.22 | NCKAP5_C | interpro domains | IPR032769 | 2 | 1 | 18521 | 50 |
NCKAP5 |
5.392e-03 | -5.22 | Ac_CoA_lig | interpro domains | IPR011904 | 2 | 1 | 18521 | 50 |
ACSS1 |
5.392e-03 | -5.22 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 50 |
MSI2 |
5.392e-03 | -5.22 | Par3/HAL_N | interpro domains | IPR021922 | 2 | 1 | 18521 | 50 |
PARD3B |
5.394e-03 | -5.22 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 6 | 16828 | 49 |
RYR3,FBXL7,SLC4A4,TRPS1,ERBB4,CTNND2 |
5.440e-03 | -5.21 | sarcoplasmic reticulum membrane | cellular component | GO:0033017 | 43 | 2 | 19108 | 49 |
RYR3,ITPR2 |
5.461e-03 | -5.21 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_I | 38 | 2 | 16828 | 49 |
QKI,FGFR3 |
5.486e-03 | -5.21 | propionate biosynthetic process | biological process | GO:0019542 | 2 | 1 | 18204 | 50 |
ACSS1 |
5.486e-03 | -5.21 | myofibroblast contraction | biological process | GO:1990764 | 2 | 1 | 18204 | 50 |
QKI |
5.486e-03 | -5.21 | negative regulation of 3'-UTR-mediated mRNA stabilization | biological process | GO:1905869 | 2 | 1 | 18204 | 50 |
QKI |
5.486e-03 | -5.21 | establishment of planar polarity involved in nephron morphogenesis | biological process | GO:0072046 | 2 | 1 | 18204 | 50 |
ERBB4 |
5.486e-03 | -5.21 | fibroblast growth factor receptor apoptotic signaling pathway | biological process | GO:1902178 | 2 | 1 | 18204 | 50 |
FGFR3 |
5.486e-03 | -5.21 | regulation of elastin catabolic process | biological process | GO:0060310 | 2 | 1 | 18204 | 50 |
CST3 |
5.486e-03 | -5.21 | negative regulation of ERBB4 signaling pathway | biological process | GO:0120154 | 2 | 1 | 18204 | 50 |
CADM1 |
5.486e-03 | -5.21 | negative regulation of blood vessel remodeling | biological process | GO:0060313 | 2 | 1 | 18204 | 50 |
CST3 |
5.486e-03 | -5.21 | acetyl-CoA biosynthetic process from acetate | biological process | GO:0019427 | 2 | 1 | 18204 | 50 |
ACSS1 |
5.486e-03 | -5.21 | acetate biosynthetic process | biological process | GO:0019413 | 2 | 1 | 18204 | 50 |
ACSS1 |
5.601e-03 | -5.18 | sequence-specific double-stranded DNA binding | molecular function | GO:1990837 | 1547 | 10 | 18094 | 47 |
NPAS3,NFIA,RFX4,ZNF98,ZBTB20,HIF3A,TRPS1,ERBB4,RORA,SOX5 |
5.612e-03 | -5.18 | Par3_HAL_N_term | pfam domains | PF12053 | 2 | 1 | 17795 | 50 |
PARD3B |
5.612e-03 | -5.18 | NCKAP5 | pfam domains | PF15246 | 2 | 1 | 17795 | 50 |
NCKAP5 |
5.625e-03 | -5.18 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 7 | 16828 | 49 |
TRPS1,CTNND2,ITPR2,SLC1A3,DTNA,ACSS1,SOX5 |
5.697e-03 | -5.17 | amino acid transport | biological process | GO:0006865 | 132 | 3 | 18204 | 50 |
SFXN5,SLC1A3,SLC1A2 |
5.706e-03 | -5.17 | Calml3 (calmodulin-like 3) | protein interactions | 70405 | 144 | 3 | 19454 | 49 |
ABLIM1,ZBTB20,MACF1 |
5.718e-03 | -5.16 | active transmembrane transporter activity | molecular function | GO:0022804 | 444 | 5 | 18094 | 47 |
ATP1A2,ATP13A4,SLC1A3,SLC1A2,SLC4A4 |
5.767e-03 | -5.16 | sarcolemma | cellular component | GO:0042383 | 142 | 3 | 19108 | 49 |
RYR3,DTNA,ATP1A2 |
5.775e-03 | -5.15 | hand | COSMIC cancer mutations | hand | 566 | 6 | 16828 | 49 |
HIF3A,SLC4A4,FGFR3,COL5A3,PREX2,ERBB4 |
5.817e-03 | -5.15 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 3 | 18204 | 50 |
RYR3,ITPR2,ATP1A2 |
5.929e-03 | -5.13 | postsynapse | cellular component | GO:0098794 | 646 | 6 | 19108 | 49 |
TNIK,CTNND2,ATP1A2,GPM6A,CADM1,ERBB4 |
5.935e-03 | -5.13 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 43 |
CTNNA2 |
5.935e-03 | -5.13 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 43 |
RYR3 |
5.944e-03 | -5.13 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 11 | 16828 | 49 |
FGFR3,MACF1,ABLIM1,RORA,DTNA,CDH20,PARD3B,PTPRZ1,CTNND2,QKI,PREX2 |
5.944e-03 | -5.13 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 11 | 16828 | 49 |
RORA,PTPRZ1,CTNND2,QKI,CDH20,PARD3B,FGFR3,ABLIM1,MACF1,PREX2,DTNA |
6.035e-03 | -5.11 | Ig-like_dom | interpro domains | IPR007110 | 432 | 5 | 18521 | 50 |
FGFR3,CADM1,LRIG1,LSAMP,NTM |
6.153e-03 | -5.09 | cell projection | cellular component | GO:0042995 | 2398 | 13 | 19108 | 49 |
ATP1A2,ABLIM1,AHCYL2,CTNNA2,CTNND2,GPM6A,DTNA,PCDH9,MACF1,SLC1A3,SLC1A2,CADM1,NRXN1 |
6.161e-03 | -5.09 | cell development | biological process | GO:0048468 | 2236 | 13 | 18204 | 50 |
NRXN1,CTNND2,CTNNA2,GPM6A,PTPRZ1,RORA,ERBB4,MSI2,SLC1A3,NTM,PREX2,QKI,TNIK |
6.231e-03 | -5.08 | CATATPASE | prints domains | PR00119 | 35 | 2 | 5227 | 18 |
ATP1A2,ATP13A4 |
6.237e-03 | -5.08 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 5 | 18204 | 50 |
SLC4A4,ATP13A4,SLC1A3,RYR3,ATP1A2 |
6.250e-03 | -5.08 | ZNRF2 (zinc and ring finger 2) | protein interactions | 223082 | 47 | 2 | 19454 | 49 |
NCKAP5,ATP1A2 |
6.250e-03 | -5.08 | LRIG3 (leucine rich repeats and immunoglobulin like domains 3) | protein interactions | 121227 | 47 | 2 | 19454 | 49 |
LRIG1,ERBB4 |
6.250e-03 | -5.08 | CNTN1 (contactin 1) | protein interactions | 1272 | 47 | 2 | 19454 | 49 |
GPM6A,PTPRZ1 |
6.263e-03 | -5.07 | PAS domain | gene3d domains | 3.30.450.20 | 40 | 2 | 14470 | 43 |
HIF3A,NPAS3 |
6.270e-03 | -5.07 | GSE1 (Gse1 coiled-coil protein) | protein interactions | 23199 | 149 | 3 | 19454 | 49 |
SOX5,TNIK,NFIA |
6.272e-03 | -5.07 | cell differentiation | biological process | GO:0030154 | 3645 | 18 | 18204 | 50 |
CADM1,ERBB4,RORA,PTPRZ1,GPM6A,FGFR3,CTNNA2,CTNND2,NRXN1,TNIK,QKI,NFIA,NHSL1,PREX2,NTM,SLC1A3,MSI2,SOX5 |
6.288e-03 | -5.07 | basal plasma membrane | cellular component | GO:0009925 | 288 | 4 | 19108 | 49 |
ERBB4,SLC4A4,CADM1,SLC1A3 |
6.328e-03 | -5.06 | cellular developmental process | biological process | GO:0048869 | 3648 | 18 | 18204 | 50 |
NFIA,QKI,TNIK,SOX5,MSI2,NTM,SLC1A3,PREX2,NHSL1,RORA,ERBB4,CADM1,NRXN1,CTNND2,FGFR3,CTNNA2,PTPRZ1,GPM6A |
6.428e-03 | -5.05 | skin-hand-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-hand-carcinoma-squamous_cell_carcinoma | 407 | 5 | 16828 | 49 |
ERBB4,COL5A3,FGFR3,HIF3A,SLC4A4 |
6.429e-03 | -5.05 | extremity | COSMIC cancer mutations | extremity | 1876 | 12 | 16828 | 49 |
FBXL7,RYR3,PREX2,CDH20,PITPNC1,PTPRZ1,ERBB4,ACSS1,COL5A3,PCDH9,FGFR3,ATP13A4 |
6.454e-03 | -5.04 | leg | COSMIC cancer mutations | leg | 969 | 8 | 16828 | 49 |
FGFR3,ATP13A4,PTPRZ1,HIF3A,SLC4A4,NTM,ZBTB20,COL5A3 |
6.466e-03 | -5.04 | carboxylic acid biosynthetic process | biological process | GO:0046394 | 271 | 4 | 18204 | 50 |
SLC1A3,QKI,PTGDS,ACSS1 |
6.576e-03 | -5.02 | SP7 (Sp7 transcription factor) | protein interactions | 121340 | 297 | 4 | 19454 | 49 |
SOX5,TRPS1,NFIA,QKI |
6.597e-03 | -5.02 | upper_arm | COSMIC cancer mutations | upper_arm | 582 | 6 | 16828 | 49 |
ITPR2,FGFR3,PARD3B,ERBB4,SLC4A4,PREX2 |
6.634e-03 | -5.02 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 4 | 18204 | 50 |
SLC1A2,SLC1A3,SLC4A4,ATP1A2 |
6.676e-03 | -5.01 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 6 | 18204 | 50 |
SLC4A4,RYR3,ITPR2,SLC1A3,ATP1A2,GPM6A |
6.684e-03 | -5.01 | symporter activity | molecular function | GO:0015293 | 148 | 3 | 18094 | 47 |
SLC1A3,SLC4A4,SLC1A2 |
6.719e-03 | -5.00 | organic acid biosynthetic process | biological process | GO:0016053 | 274 | 4 | 18204 | 50 |
ACSS1,PTGDS,SLC1A3,QKI |
6.728e-03 | -5.00 | behavior | biological process | GO:0007610 | 619 | 6 | 18204 | 50 |
PREX2,PTPRZ1,ATP1A2,NRXN1,SLC1A2,SLC1A3 |
6.745e-03 | -5.00 | SOX6 (SRY-box transcription factor 6) | protein interactions | 55553 | 153 | 3 | 19454 | 49 |
NFIA,TRPS1,SOX5 |
6.760e-03 | -5.00 | peritoneum-appendix-other-pseudomyxoma_peritonei | COSMIC cancer mutations | peritoneum-appendix-other-pseudomyxoma_peritonei | 585 | 6 | 16828 | 49 |
COL5A3,TRPS1,NCKAP5,MACF1,FBXL7,FGFR3 |
6.760e-03 | -5.00 | pseudomyxoma_peritonei | COSMIC cancer mutations | pseudomyxoma_peritonei | 585 | 6 | 16828 | 49 |
NCKAP5,MACF1,FBXL7,FGFR3,COL5A3,TRPS1 |
6.783e-03 | -4.99 | ATPASE_E1_E2 | prosite domains | PS00154 | 36 | 2 | 12186 | 42 |
ATP13A4,ATP1A2 |
6.788e-03 | -4.99 | acidic amino acid transport | biological process | GO:0015800 | 45 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
6.798e-03 | -4.99 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 5 | 18204 | 50 |
ATP1A2,SLC1A3,SLC4A4,ATP13A4,RYR3 |
6.815e-03 | -4.99 | appendix | COSMIC cancer mutations | appendix | 586 | 6 | 16828 | 49 |
COL5A3,FBXL7,TRPS1,NCKAP5,MACF1,FGFR3 |
6.870e-03 | -4.98 | peritoneum | COSMIC cancer mutations | peritoneum | 587 | 6 | 16828 | 49 |
TRPS1,FGFR3,NCKAP5,MACF1,COL5A3,FBXL7 |
6.875e-03 | -4.98 | transmembrane transport | biological process | GO:0055085 | 1264 | 9 | 18204 | 50 |
ATP1A2,GPM6A,SFXN5,SLC1A3,SLC1A2,ITPR2,RYR3,ATP13A4,SLC4A4 |
6.890e-03 | -4.98 | telencephalon development | biological process | GO:0021537 | 276 | 4 | 18204 | 50 |
ATP1A2,RFX4,ERBB4,SLC1A2 |
6.969e-03 | -4.97 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 50 |
SLC4A4,SLC1A3,SLC1A2 |
7.084e-03 | -4.95 | positive regulation of glial cell differentiation | biological process | GO:0045687 | 46 | 2 | 18204 | 50 |
PTPRZ1,QKI |
7.084e-03 | -4.95 | regulation of oligodendrocyte differentiation | biological process | GO:0048713 | 46 | 2 | 18204 | 50 |
PTPRZ1,QKI |
7.130e-03 | -4.94 | CARM1 (coactivator associated arginine methyltransferase 1) | protein interactions | 10498 | 304 | 4 | 19454 | 49 |
NCKAP5,RORA,QKI,DTNA |
7.312e-03 | -4.92 | metal ion transport | biological process | GO:0030001 | 630 | 6 | 18204 | 50 |
ITPR2,SLC4A4,RYR3,GPM6A,ATP1A2,SLC1A3 |
7.325e-03 | -4.92 | Ndc80 (NDC80 kinetochore complex component) | protein interactions | 67052 | 51 | 2 | 19454 | 49 |
MACF1,NHSL1 |
7.349e-03 | -4.91 | DNA-binding transcription factor activity, RNA polymerase II-specific | molecular function | GO:0000981 | 1355 | 9 | 18094 | 47 |
ZNF98,ZBTB20,NPAS3,NFIA,RFX4,TRPS1,HIF3A,SOX5,RORA |
7.493e-03 | -4.89 | cell surface | cellular component | GO:0009986 | 896 | 7 | 19108 | 49 |
NRXN1,GPC5,SLC1A2,FGFR3,SLC1A3,SLC4A4,ATP1A2 |
7.538e-03 | -4.89 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 49 |
NTM |
7.538e-03 | -4.89 | TULP1 (TUB like protein 1) | protein interactions | 7287 | 3 | 1 | 19454 | 49 |
NRXN1 |
7.538e-03 | -4.89 | Hk2 (hexokinase 2) | protein interactions | 25059 | 3 | 1 | 19454 | 49 |
PTGDS |
7.538e-03 | -4.89 | BCO1 (beta-carotene oxygenase 1) | protein interactions | 53630 | 3 | 1 | 19454 | 49 |
ABLIM1 |
7.538e-03 | -4.89 | IL34 (interleukin 34) | protein interactions | 146433 | 3 | 1 | 19454 | 49 |
PTPRZ1 |
7.538e-03 | -4.89 | NRG3 (neuregulin 3) | protein interactions | 10718 | 3 | 1 | 19454 | 49 |
ERBB4 |
7.592e-03 | -4.88 | third_ventricle | COSMIC cancer mutations | third_ventricle | 45 | 2 | 16828 | 49 |
FGFR3,QKI |
7.605e-03 | -4.88 | SNAP91 (synaptosome associated protein 91) | protein interactions | 9892 | 52 | 2 | 19454 | 49 |
ERBB4,GPM6A |
7.626e-03 | -4.88 | SOX5 (SRY-box transcription factor 5) | protein interactions | 6660 | 160 | 3 | 19454 | 49 |
TRPS1,SOX5,NFIA |
7.631e-03 | -4.88 | human chr8q23.3 | chromosome location | human chr8q23.3 | 4 | 1 | 26134 | 50 |
TRPS1 |
7.700e-03 | -4.87 | cell junction assembly | biological process | GO:0034329 | 285 | 4 | 18204 | 50 |
ERBB4,NRXN1,GPM6A,CDH20 |
7.700e-03 | -4.87 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 3 | 16828 | 49 |
QKI,FGFR3,GPC5 |
7.702e-03 | -4.87 | animal organ development | biological process | GO:0048513 | 2846 | 15 | 18204 | 50 |
SLC1A2,COL5A3,CTNNA2,FGFR3,GPM6A,ATP1A2,RORA,ERBB4,CADM1,PCDH9,ABLIM1,SOX5,RFX4,NFIA,LRIG1 |
7.761e-03 | -4.86 | C20 prostanoid biosynthesis | BIOCYC pathways | HUMAN_PWY66-374 | 7 | 1 | 902 | 1 |
PTGDS |
7.761e-03 | -4.86 | C20 prostanoid biosynthesis | BIOCYC pathways | META_PWY66-374 | 7 | 1 | 902 | 1 |
PTGDS |
7.773e-03 | -4.86 | epidermal growth factor receptor activity | molecular function | GO:0005006 | 3 | 1 | 18094 | 47 |
ERBB4 |
7.773e-03 | -4.86 | neuregulin receptor activity | molecular function | GO:0038131 | 3 | 1 | 18094 | 47 |
ERBB4 |
7.773e-03 | -4.86 | prostaglandin-D synthase activity | molecular function | GO:0004667 | 3 | 1 | 18094 | 47 |
PTGDS |
7.773e-03 | -4.86 | adenosylhomocysteinase activity | molecular function | GO:0004013 | 3 | 1 | 18094 | 47 |
AHCYL2 |
7.773e-03 | -4.86 | hydrolase activity, acting on carbon-sulfur bonds | molecular function | GO:0046508 | 3 | 1 | 18094 | 47 |
AHCYL2 |
7.773e-03 | -4.86 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 47 |
SLC1A2 |
7.773e-03 | -4.86 | inositol 1,4,5-trisphosphate-gated calcium channel activity | molecular function | GO:0005220 | 3 | 1 | 18094 | 47 |
ITPR2 |
7.800e-03 | -4.85 | abdomen | COSMIC cancer mutations | abdomen | 603 | 6 | 16828 | 49 |
CTNND2,PREX2,ERBB4,ITPR2,LRIG1,FGFR3 |
7.832e-03 | -4.85 | response to organic cyclic compound | biological process | GO:0014070 | 843 | 7 | 18204 | 50 |
SLC1A2,SLC1A3,ATP1A2,RORA,RYR3,PTGDS,ITPR2 |
7.847e-03 | -4.85 | basal part of cell | cellular component | GO:0045178 | 307 | 4 | 19108 | 49 |
SLC1A3,ERBB4,CADM1,SLC4A4 |
7.891e-03 | -4.84 | FOXF2 (forkhead box F2) | protein interactions | 2295 | 53 | 2 | 19454 | 49 |
AHCYL2,ZBTB20 |
7.952e-03 | -4.83 | neuromuscular process | biological process | GO:0050905 | 149 | 3 | 18204 | 50 |
SLC1A3,NRXN1,CTNNA2 |
7.964e-03 | -4.83 | Cardiac conduction | REACTOME pathways | R-HSA-5576891 | 142 | 3 | 10285 | 30 |
ITPR2,RYR3,ATP1A2 |
8.078e-03 | -4.82 | MAML1-3 | interpro domains | IPR046369 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | Mastermind-like_N | interpro domains | IPR019082 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | S-Ado-L-homoCys_hydrolase_CS | interpro domains | IPR020082 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | InsP3_rcpt | interpro domains | IPR000493 | 3 | 1 | 18521 | 50 |
ITPR2 |
8.078e-03 | -4.82 | ROR_rcpt | interpro domains | IPR003079 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Adenosylhomocysteinase-like | interpro domains | IPR000043 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | HIF_alpha-like | interpro domains | IPR021537 | 3 | 1 | 18521 | 50 |
HIF3A |
8.078e-03 | -4.82 | NR_DBD_ROR | interpro domains | IPR044101 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | Ado_hCys_hydrolase_NAD-bd | interpro domains | IPR015878 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 50 |
CTNNA2 |
8.078e-03 | -4.82 | MAML_N_sf | interpro domains | IPR046370 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Adenosylhomocyst_ase-like_sf | interpro domains | IPR042172 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | TM_ErbB1 | interpro domains | IPR049328 | 3 | 1 | 18521 | 50 |
ERBB4 |
8.078e-03 | -4.82 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 50 |
RYR3 |
8.124e-03 | -4.81 | neuronal cell body | cellular component | GO:0043025 | 489 | 5 | 19108 | 49 |
NRXN1,ATP1A2,GPM6A,SLC1A3,CTNND2 |
8.157e-03 | -4.81 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 18 | 16828 | 49 |
TNIK,PREX2,NHSL1,SLC4A4,SOX5,MAML2,RYR3,CTNND2,PTPRZ1,ATP1A2,COL5A3,ZBTB20,LRIG1,GPC5,GPM6A,MACF1,PCDH9,ABLIM1 |
8.181e-03 | -4.81 | SYNM (synemin) | protein interactions | 23336 | 54 | 2 | 19454 | 49 |
ERBB4,DTNA |
8.206e-03 | -4.80 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 18 | 16828 | 49 |
CTNND2,PTPRZ1,TNIK,PREX2,SOX5,SLC4A4,NHSL1,MAML2,RYR3,GPM6A,PCDH9,ABLIM1,MACF1,COL5A3,ATP1A2,ZBTB20,GPC5,LRIG1 |
8.218e-03 | -4.80 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 50 |
ATP1A2 |
8.218e-03 | -4.80 | acetate metabolic process | biological process | GO:0006083 | 3 | 1 | 18204 | 50 |
ACSS1 |
8.218e-03 | -4.80 | central nervous system morphogenesis | biological process | GO:0021551 | 3 | 1 | 18204 | 50 |
ERBB4 |
8.218e-03 | -4.80 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 50 |
CTNNA2 |
8.218e-03 | -4.80 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 50 |
SLC1A2 |
8.218e-03 | -4.80 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 50 |
SLC1A2 |
8.218e-03 | -4.80 | neuroligin clustering involved in postsynaptic membrane assembly | biological process | GO:0097118 | 3 | 1 | 18204 | 50 |
NRXN1 |
8.218e-03 | -4.80 | susceptibility to natural killer cell mediated cytotoxicity | biological process | GO:0042271 | 3 | 1 | 18204 | 50 |
CADM1 |
8.296e-03 | -4.79 | EGR2 (early growth response 2) | protein interactions | 1959 | 165 | 3 | 19454 | 49 |
SOX5,TRPS1,NFIA |
8.310e-03 | -4.79 | HNRNPL (heterogeneous nuclear ribonucleoprotein L) | protein interactions | 3191 | 1958 | 11 | 19454 | 49 |
FGFR3,TRPS1,MACF1,NFIA,AHCYL2,PARD3B,MSI2,ABLIM1,ZBTB20,QKI,DTNA |
8.327e-03 | -4.79 | cell surface receptor signaling pathway via JAK-STAT | biological process | GO:0007259 | 50 | 2 | 18204 | 50 |
FGFR3,ERBB4 |
8.365e-03 | -4.78 | ATPase-coupled monoatomic cation transmembrane transporter activity | molecular function | GO:0019829 | 53 | 2 | 18094 | 47 |
ATP13A4,ATP1A2 |
8.406e-03 | -4.78 | HIF-1 | pfam domains | PF11413 | 3 | 1 | 17795 | 50 |
HIF3A |
8.406e-03 | -4.78 | TM_ErbB1 | pfam domains | PF21314 | 3 | 1 | 17795 | 50 |
ERBB4 |
8.406e-03 | -4.78 | AdoHcyase | pfam domains | PF05221 | 3 | 1 | 17795 | 50 |
AHCYL2 |
8.406e-03 | -4.78 | AdoHcyase_NAD | pfam domains | PF00670 | 3 | 1 | 17795 | 50 |
AHCYL2 |
8.406e-03 | -4.78 | MamL-1 | pfam domains | PF09596 | 3 | 1 | 17795 | 50 |
MAML2 |
8.406e-03 | -4.78 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | SR_plectin_7 | pfam domains | PF21097 | 3 | 1 | 17795 | 50 |
MACF1 |
8.406e-03 | -4.78 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 50 |
GPM6A |
8.444e-03 | -4.77 | RNA polymerase II transcription regulatory region sequence-specific DNA binding | molecular function | GO:0000977 | 1385 | 9 | 18094 | 47 |
RORA,SOX5,TRPS1,HIF3A,ZNF98,ZBTB20,NFIA,NPAS3,RFX4 |
8.494e-03 | -4.77 | double-stranded DNA binding | molecular function | GO:0003690 | 1643 | 10 | 18094 | 47 |
SOX5,RORA,ERBB4,TRPS1,HIF3A,ZBTB20,ZNF98,NPAS3,RFX4,NFIA |
8.546e-03 | -4.76 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 13 | 16828 | 49 |
SLC4A4,SOX5,PREX2,TNIK,PARD3B,CADM1,TRPS1,NFIA,PTPRZ1,ERBB4,DTNA,ATP1A2,FGFR3 |
8.651e-03 | -4.75 | neuromuscular process controlling balance | biological process | GO:0050885 | 51 | 2 | 18204 | 50 |
NRXN1,SLC1A3 |
8.702e-03 | -4.74 | calcium-mediated signaling | biological process | GO:0019722 | 154 | 3 | 18204 | 50 |
RYR3,ITPR2,ATP1A2 |
8.711e-03 | -4.74 | lentigo | COSMIC cancer mutations | lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-face-lentigo | COSMIC cancer mutations | skin-face-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-lentigo | COSMIC cancer mutations | skin-leg-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-forearm-lentigo | COSMIC cancer mutations | skin-forearm-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-lentigo | COSMIC cancer mutations | skin-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-trunk-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-lentigo | COSMIC cancer mutations | skin-trunk-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-hand-lentigo | COSMIC cancer mutations | skin-hand-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-leg-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | urinary_tract-bladder-papilloma | COSMIC cancer mutations | urinary_tract-bladder-papilloma | 3 | 1 | 16828 | 49 |
FGFR3 |
8.736e-03 | -4.74 | Amyotrophic lateral sclerosis (ALS) | WikiPathways | WP2447 | 38 | 2 | 5310 | 20 |
CST3,SLC1A2 |
8.761e-03 | -4.74 | postsynaptic density | cellular component | GO:0014069 | 317 | 4 | 19108 | 49 |
CTNND2,TNIK,ERBB4,CADM1 |
8.771e-03 | -4.74 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 4 | 18204 | 50 |
QKI,MACF1,NRXN1,PTPRZ1 |
8.816e-03 | -4.73 | sequence-specific DNA binding | molecular function | GO:0043565 | 1652 | 10 | 18094 | 47 |
ERBB4,RORA,SOX5,ZNF98,ZBTB20,RFX4,NPAS3,NFIA,TRPS1,HIF3A |
8.836e-03 | -4.73 | skin-back-malignant_melanoma | COSMIC cancer mutations | skin-back-malignant_melanoma | 280 | 4 | 16828 | 49 |
ATP1A2,ERBB4,TNIK,PREX2 |
8.889e-03 | -4.72 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 43 |
CTNNA2 |
8.889e-03 | -4.72 | - | gene3d domains | 6.10.250.970 | 3 | 1 | 14470 | 43 |
MAML2 |
8.889e-03 | -4.72 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 43 |
RYR3 |
8.889e-03 | -4.72 | Adenosylhomocysteinase-like | gene3d domains | 3.40.50.1480 | 3 | 1 | 14470 | 43 |
AHCYL2 |
8.972e-03 | -4.71 | chest | COSMIC cancer mutations | chest | 147 | 3 | 16828 | 49 |
PREX2,ERBB4,FGFR3 |
8.982e-03 | -4.71 | regulation of purine nucleotide catabolic process | biological process | GO:0033121 | 52 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
8.982e-03 | -4.71 | regulation of nucleotide catabolic process | biological process | GO:0030811 | 52 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
8.982e-03 | -4.71 | regulation of glycolytic process | biological process | GO:0006110 | 52 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
9.081e-03 | -4.70 | NXPH3 (neurexophilin 3) | protein interactions | 11248 | 57 | 2 | 19454 | 49 |
CTNNA2,NRXN1 |
9.185e-03 | -4.69 | SLC-mediated transmembrane transport | REACTOME pathways | R-HSA-425407 | 287 | 4 | 10285 | 30 |
AHCYL2,SLC1A2,SLC1A3,SLC4A4 |
9.273e-03 | -4.68 | NR3C1 (nuclear receptor subfamily 3 group C member 1) | protein interactions | 2908 | 950 | 7 | 19454 | 49 |
ZBTB20,CADM1,CTNND2,TRPS1,ATP13A4,NFIA,SLC1A3 |
9.318e-03 | -4.68 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
9.318e-03 | -4.68 | regulation of chondrocyte differentiation | biological process | GO:0032330 | 53 | 2 | 18204 | 50 |
SOX5,TRPS1 |
9.428e-03 | -4.66 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 10 | 16828 | 49 |
PREX2,DTNA,RYR3,GPC5,PTPRZ1,NPAS3,FGFR3,PARD3B,MACF1,PCDH9 |
9.492e-03 | -4.66 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 50 |
SLC1A2,SLC1A3,SLC4A4 |
9.541e-03 | -4.65 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 5 | 18521 | 50 |
LRIG1,LSAMP,NTM,FGFR3,CADM1 |
9.597e-03 | -4.65 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 30 |
SLC1A3,SLC1A2 |
9.616e-03 | -4.64 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 48 | 16828 | 49 |
RORA,PTGDS,ABLIM1,NKAIN3,COL5A3,GPC5,SFXN5,TRPS1,SOX5,MSI2,RFX4,FGFR3,ATP13A4,NCKAP5,ACSS1,NPAS3,ERBB4,AHCYL2,CTNND2,QKI,SLC1A2,PARD3B,NRXN1,PREX2,MAML2,GPM6A,LSAMP,ITPR2,PCDH9,MACF1,PTPRZ1,NFIA,ZNF98,PITPNC1,CDH20,TNIK,FBXL7,HIF3A,ZBTB20,DTNA,SLC1A3,ATP1A2,LRIG1,NTM,CADM1,RYR3,NHSL1,SLC4A4 |
9.659e-03 | -4.64 | cell surface receptor signaling pathway via STAT | biological process | GO:0097696 | 54 | 2 | 18204 | 50 |
ERBB4,FGFR3 |
9.736e-03 | -4.63 | LHX3 (LIM homeobox 3) | protein interactions | 8022 | 175 | 3 | 19454 | 49 |
TRPS1,SOX5,NFIA |
1.001e-02 | -4.60 | response to cocaine | biological process | GO:0042220 | 55 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.002e-02 | -4.60 | SNTB1 (syntrophin beta 1) | protein interactions | 6641 | 60 | 2 | 19454 | 49 |
DTNA,FGFR3 |
1.002e-02 | -4.60 | Znf_NHR/GATA | interpro domains | IPR013088 | 56 | 2 | 18521 | 50 |
RORA,TRPS1 |
1.004e-02 | -4.60 | Nme2 (NME/NM23 nucleoside diphosphate kinase 2) | protein interactions | 18103 | 4 | 1 | 19454 | 49 |
RORA |
1.004e-02 | -4.60 | Ctbp2 (C-terminal binding protein 2) | protein interactions | 13017 | 4 | 1 | 19454 | 49 |
TRPS1 |
1.004e-02 | -4.60 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 49 |
GPM6A |
1.004e-02 | -4.60 | GATA3 (GATA binding protein 3) | protein interactions | 2625 | 177 | 3 | 19454 | 49 |
TRPS1,QKI,NFIA |
1.016e-02 | -4.59 | EZR (ezrin) | protein interactions | 7430 | 526 | 5 | 19454 | 49 |
DTNA,AHCYL2,TNIK,ABLIM1,MACF1 |
1.022e-02 | -4.58 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 49 |
CTNNA2,DTNA,CDH20 |
1.022e-02 | -4.58 | collagen type V trimer | cellular component | GO:0005588 | 4 | 1 | 19108 | 49 |
COL5A3 |
1.030e-02 | -4.58 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 18 |
RYR3 |
1.030e-02 | -4.58 | PGNDSYNTHASE | prints domains | PR01254 | 3 | 1 | 5227 | 18 |
PTGDS |
1.030e-02 | -4.58 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 18 |
GPM6A |
1.030e-02 | -4.58 | RORNUCRECPTR | prints domains | PR01293 | 3 | 1 | 5227 | 18 |
RORA |
1.030e-02 | -4.58 | INSP3RECEPTR | prints domains | PR00779 | 3 | 1 | 5227 | 18 |
ITPR2 |
1.030e-02 | -4.58 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 42 |
GPM6A |
1.030e-02 | -4.58 | ADOHCYASE_2 | prosite domains | PS00739 | 3 | 1 | 12186 | 42 |
AHCYL2 |
1.030e-02 | -4.58 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 42 |
CTNNA2 |
1.030e-02 | -4.58 | ADOHCYASE_1 | prosite domains | PS00738 | 3 | 1 | 12186 | 42 |
AHCYL2 |
1.030e-02 | -4.58 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 42 |
GPM6A |
1.035e-02 | -4.57 | propionate-CoA ligase activity | molecular function | GO:0050218 | 4 | 1 | 18094 | 47 |
ACSS1 |
1.035e-02 | -4.57 | tricarboxylic acid transmembrane transporter activity | molecular function | GO:0015142 | 4 | 1 | 18094 | 47 |
SFXN5 |
1.035e-02 | -4.57 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 47 |
RYR3 |
1.035e-02 | -4.57 | citrate transmembrane transporter activity | molecular function | GO:0015137 | 4 | 1 | 18094 | 47 |
SFXN5 |
1.035e-02 | -4.57 | short-chain fatty acid-CoA ligase activity | molecular function | GO:0031955 | 4 | 1 | 18094 | 47 |
ACSS1 |
1.035e-02 | -4.57 | acetate-CoA ligase activity | molecular function | GO:0003987 | 4 | 1 | 18094 | 47 |
ACSS1 |
1.036e-02 | -4.57 | release of sequestered calcium ion into cytosol | biological process | GO:0051209 | 56 | 2 | 18204 | 50 |
ITPR2,RYR3 |
1.036e-02 | -4.57 | asymmetric synapse | cellular component | GO:0032279 | 333 | 4 | 19108 | 49 |
CADM1,ERBB4,TNIK,CTNND2 |
1.049e-02 | -4.56 | monocarboxylic acid biosynthetic process | biological process | GO:0072330 | 165 | 3 | 18204 | 50 |
QKI,ACSS1,PTGDS |
1.049e-02 | -4.56 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 50 |
ATP1A2,SLC1A3,SLC1A2 |
1.049e-02 | -4.56 | homophilic cell adhesion via plasma membrane adhesion molecules | biological process | GO:0007156 | 165 | 3 | 18204 | 50 |
CDH20,CADM1,PCDH9 |
1.051e-02 | -4.56 | MYOD1 (myogenic differentiation 1) | protein interactions | 4654 | 180 | 3 | 19454 | 49 |
TRPS1,NFIA,RORA |
1.051e-02 | -4.56 | EPHA4 (EPH receptor A4) | protein interactions | 2043 | 180 | 3 | 19454 | 49 |
FGFR3,CTNNA2,AHCYL2 |
1.072e-02 | -4.54 | visual behavior | biological process | GO:0007632 | 57 | 2 | 18204 | 50 |
ATP1A2,SLC1A2 |
1.072e-02 | -4.54 | negative regulation of sequestering of calcium ion | biological process | GO:0051283 | 57 | 2 | 18204 | 50 |
ITPR2,RYR3 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_N | interpro domains | IPR019548 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | PCN-like_spectrin-like_rpt | interpro domains | IPR049538 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | FGF_rcpt_fam | interpro domains | IPR016248 | 4 | 1 | 18521 | 50 |
FGFR3 |
1.076e-02 | -4.53 | ACAS_N | interpro domains | IPR032387 | 4 | 1 | 18521 | 50 |
ACSS1 |
1.076e-02 | -4.53 | P5B-type_ATPase | interpro domains | IPR047821 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd-dom | interpro domains | IPR020604 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | Desmoplakin_Spectrin-like | interpro domains | IPR041573 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | P5A-ATPase_N | interpro domains | IPR047819 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | CTF/NFI | interpro domains | IPR000647 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_CS | interpro domains | IPR019739 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | AbLIM_anchor | interpro domains | IPR032402 | 4 | 1 | 18521 | 50 |
ABLIM1 |
1.076e-02 | -4.53 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 50 |
NKAIN3 |
1.076e-02 | -4.53 | NHS-like | interpro domains | IPR024845 | 4 | 1 | 18521 | 50 |
NHSL1 |
1.076e-02 | -4.53 | Tyr_kinase_EGF/ERB/XmrK_rcpt | interpro domains | IPR016245 | 4 | 1 | 18521 | 50 |
ERBB4 |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA2 |
1.082e-02 | -4.53 | DNA-binding transcription factor activity | molecular function | GO:0003700 | 1441 | 9 | 18094 | 47 |
HIF3A,TRPS1,RFX4,NPAS3,NFIA,ZBTB20,ZNF98,RORA,SOX5 |
1.094e-02 | -4.52 | negative regulation of male germ cell proliferation | biological process | GO:2000255 | 4 | 1 | 18204 | 50 |
PTGDS |
1.094e-02 | -4.52 | short-chain fatty acid biosynthetic process | biological process | GO:0051790 | 4 | 1 | 18204 | 50 |
ACSS1 |
1.094e-02 | -4.52 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 50 |
SOX5 |
1.094e-02 | -4.52 | regulation of collagen catabolic process | biological process | GO:0010710 | 4 | 1 | 18204 | 50 |
CST3 |
1.094e-02 | -4.52 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | negative regulation of germ cell proliferation | biological process | GO:1905937 | 4 | 1 | 18204 | 50 |
PTGDS |
1.094e-02 | -4.52 | cardiac muscle tissue regeneration | biological process | GO:0061026 | 4 | 1 | 18204 | 50 |
ERBB4 |
1.094e-02 | -4.52 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.098e-02 | -4.51 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 49 | 16828 | 49 |
PARD3B,NRXN1,ERBB4,NPAS3,SLC1A2,QKI,AHCYL2,CTNND2,MAML2,PREX2,ATP13A4,FGFR3,NCKAP5,MSI2,CST3,RFX4,ACSS1,TRPS1,SOX5,PTGDS,ABLIM1,RORA,GPC5,SFXN5,NKAIN3,COL5A3,CADM1,RYR3,SLC4A4,NHSL1,LRIG1,NTM,ZBTB20,ATP1A2,DTNA,SLC1A3,CDH20,NFIA,PTPRZ1,PITPNC1,ZNF98,FBXL7,HIF3A,TNIK,PCDH9,MACF1,ITPR2,LSAMP,GPM6A |
1.101e-02 | -4.51 | cadherin binding | molecular function | GO:0045296 | 335 | 4 | 18094 | 47 |
MACF1,CTNNA2,CTNND2,CDH20 |
1.103e-02 | -4.51 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 7 | 16828 | 49 |
NFIA,ERBB4,PCDH9,PREX2,ACSS1,LRIG1,HIF3A |
1.110e-02 | -4.50 | cellular homeostasis | biological process | GO:0019725 | 689 | 6 | 18204 | 50 |
RYR3,SLC1A3,ATP13A4,SLC4A4,ATP1A2,ZBTB20 |
1.111e-02 | -4.50 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 12 | 19108 | 49 |
AHCYL2,CTNNA2,ABLIM1,ATP1A2,CADM1,SLC1A3,MACF1,PCDH9,SLC1A2,CTNND2,GPM6A,DTNA |
1.118e-02 | -4.49 | parathyroid-carcinoma | COSMIC cancer mutations | parathyroid-carcinoma | 300 | 4 | 16828 | 49 |
MACF1,RYR3,GPC5,TRPS1 |
1.118e-02 | -4.49 | parietal_lobe | COSMIC cancer mutations | parietal_lobe | 55 | 2 | 16828 | 49 |
QKI,FGFR3 |
1.119e-02 | -4.49 | P5-ATPase | pfam domains | PF12409 | 4 | 1 | 17795 | 50 |
ATP13A4 |
1.119e-02 | -4.49 | Spectrin_3 | pfam domains | PF21019 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | NHS | pfam domains | PF15273 | 4 | 1 | 17795 | 50 |
NHSL1 |
1.119e-02 | -4.49 | CTF_NFI | pfam domains | PF00859 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | Spectrin_4 | pfam domains | PF21020 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | Spectrin_2 | pfam domains | PF18373 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | AbLIM_anchor | pfam domains | PF16182 | 4 | 1 | 17795 | 50 |
ABLIM1 |
1.119e-02 | -4.49 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 50 |
NKAIN3 |
1.119e-02 | -4.49 | NfI_DNAbd_pre-N | pfam domains | PF10524 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | ACAS_N | pfam domains | PF16177 | 4 | 1 | 17795 | 50 |
ACSS1 |
1.131e-02 | -4.48 | transmembrane receptor protein tyrosine kinase activity | molecular function | GO:0004714 | 62 | 2 | 18094 | 47 |
FGFR3,ERBB4 |
1.134e-02 | -4.48 | VSX1 (visual system homeobox 1) | protein interactions | 30813 | 64 | 2 | 19454 | 49 |
TRPS1,NFIA |
1.134e-02 | -4.48 | SYNC (syncoilin, intermediate filament protein) | protein interactions | 81493 | 64 | 2 | 19454 | 49 |
DTNA,MAML2 |
1.138e-02 | -4.48 | MamL-1 | smart domains | SM01275 | 3 | 1 | 9717 | 37 |
MAML2 |
1.138e-02 | -4.48 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 37 |
GPM6A |
1.138e-02 | -4.48 | AdoHcyase | smart domains | SM00996 | 3 | 1 | 9717 | 37 |
AHCYL2 |
1.138e-02 | -4.48 | AdoHcyase_NAD | smart domains | SM00997 | 3 | 1 | 9717 | 37 |
AHCYL2 |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.145e-02 | -4.47 | protein localization to synapse | biological process | GO:0035418 | 59 | 2 | 18204 | 50 |
ERBB4,NRXN1 |
1.160e-02 | -4.46 | skin-benign_melanocytic_nevus-junctional | COSMIC cancer mutations | skin-benign_melanocytic_nevus-junctional | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | urinary_tract-bladder-other-normal | COSMIC cancer mutations | urinary_tract-bladder-other-normal | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | urinary_tract-bladder-papilloma-inverted | COSMIC cancer mutations | urinary_tract-bladder-papilloma-inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-face-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-face-malignant_melanoma-superficial_spreading | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | skin-lower_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-nodular | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | inverted | COSMIC cancer mutations | inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.169e-02 | -4.45 | postsynaptic specialization | cellular component | GO:0099572 | 345 | 4 | 19108 | 49 |
ERBB4,CADM1,TNIK,CTNND2 |
1.181e-02 | -4.44 | HNF1B (HNF1 homeobox B) | protein interactions | 6928 | 188 | 3 | 19454 | 49 |
NFIA,SOX5,TRPS1 |
1.182e-02 | -4.44 | export across plasma membrane | biological process | GO:0140115 | 60 | 2 | 18204 | 50 |
SLC4A4,ATP1A2 |
1.184e-02 | -4.44 | - | gene3d domains | 1.20.58.1060 | 4 | 1 | 14470 | 43 |
MACF1 |
1.192e-02 | -4.43 | chemical homeostasis | biological process | GO:0048878 | 914 | 7 | 18204 | 50 |
SLC1A3,ATP1A2,ZBTB20,RYR3,ATP13A4,SLC4A4,RORA |
1.192e-02 | -4.43 | cartilage development | biological process | GO:0051216 | 173 | 3 | 18204 | 50 |
FGFR3,SOX5,NFIA |
1.200e-02 | -4.42 | Erythroid Transcription Factor GATA-1, subunit A | gene3d domains | 3.30.50.10 | 56 | 2 | 14470 | 43 |
RORA,TRPS1 |
1.203e-02 | -4.42 | MAML1 (mastermind like transcriptional coactivator 1) | protein interactions | 9794 | 66 | 2 | 19454 | 49 |
NFIA,MAML2 |
1.216e-02 | -4.41 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 5 | 16828 | 49 |
GPM6A,TRPS1,GPC5,RYR3,MACF1 |
1.223e-02 | -4.40 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 5 | 18204 | 50 |
ATP1A2,RYR3,SLC1A3,ATP13A4,SLC4A4 |
1.229e-02 | -4.40 | Ion transport by P-type ATPases | REACTOME pathways | R-HSA-936837 | 58 | 2 | 10285 | 30 |
ATP13A4,ATP1A2 |
1.244e-02 | -4.39 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 3 | 18094 | 47 |
SLC1A2,SLC1A3,SFXN5 |
1.253e-02 | -4.38 | SYT13 (synaptotagmin 13) | protein interactions | 57586 | 5 | 1 | 19454 | 49 |
NRXN1 |
1.253e-02 | -4.38 | ARSI (arylsulfatase family member I) | protein interactions | 340075 | 5 | 1 | 19454 | 49 |
AHCYL2 |
1.253e-02 | -4.38 | NRG2 (neuregulin 2) | protein interactions | 9542 | 5 | 1 | 19454 | 49 |
ERBB4 |
1.253e-02 | -4.38 | PTGER2 (prostaglandin E receptor 2) | protein interactions | 5732 | 5 | 1 | 19454 | 49 |
PTGDS |
1.253e-02 | -4.38 | RFX4 (regulatory factor X4) | protein interactions | 5992 | 5 | 1 | 19454 | 49 |
RFX4 |
1.253e-02 | -4.38 | Hk3 (hexokinase 3) | protein interactions | 25060 | 5 | 1 | 19454 | 49 |
PTGDS |
1.259e-02 | -4.38 | regulation of carbohydrate catabolic process | biological process | GO:0043470 | 62 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.262e-02 | -4.37 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 3 | 18094 | 47 |
SLC1A2,SFXN5,SLC1A3 |
1.262e-02 | -4.37 | bone-pelvis-chondrosarcoma | COSMIC cancer mutations | bone-pelvis-chondrosarcoma | 311 | 4 | 16828 | 49 |
LSAMP,PARD3B,COL5A3,ERBB4 |
1.262e-02 | -4.37 | Ig-like_fold | interpro domains | IPR013783 | 721 | 6 | 18521 | 50 |
NTM,LRIG1,LSAMP,PTPRZ1,CADM1,FGFR3 |
1.275e-02 | -4.36 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
1.292e-02 | -4.35 | neuroligin family protein binding | molecular function | GO:0097109 | 5 | 1 | 18094 | 47 |
NRXN1 |
1.292e-02 | -4.35 | fibroblast growth factor receptor activity | molecular function | GO:0005007 | 5 | 1 | 18094 | 47 |
FGFR3 |
1.302e-02 | -4.34 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 48 | 16828 | 49 |
TRPS1,SOX5,RORA,ABLIM1,PTGDS,COL5A3,NKAIN3,SFXN5,GPC5,CTNND2,QKI,AHCYL2,SLC1A2,NPAS3,ERBB4,PARD3B,NRXN1,PREX2,MAML2,RFX4,CST3,MSI2,NCKAP5,FGFR3,ATP13A4,ACSS1,ZNF98,PITPNC1,PTPRZ1,NFIA,CDH20,TNIK,HIF3A,FBXL7,GPM6A,ITPR2,LSAMP,PCDH9,MACF1,CADM1,SLC4A4,NHSL1,RYR3,ATP1A2,SLC1A3,ZBTB20,NTM,LRIG1 |
1.310e-02 | -4.34 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | 485 | 5 | 16828 | 49 |
ATP13A4,RYR3,LSAMP,PCDH9,SLC4A4 |
1.310e-02 | -4.34 | medullomyoblastoma | COSMIC cancer mutations | medullomyoblastoma | 485 | 5 | 16828 | 49 |
RYR3,ATP13A4,SLC4A4,PCDH9,LSAMP |
1.311e-02 | -4.33 | Signaling by BRAF and RAF fusions | REACTOME pathways | R-HSA-6802952 | 60 | 2 | 10285 | 30 |
MACF1,QKI |
1.314e-02 | -4.33 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 6 | 18204 | 50 |
SLC1A3,ATP1A2,GPM6A,RYR3,SLC4A4,ITPR2 |
1.321e-02 | -4.33 | non_small_cell_carcinoma | COSMIC cancer mutations | non_small_cell_carcinoma | 5198 | 23 | 16828 | 49 |
RORA,LSAMP,ITPR2,ABLIM1,COL5A3,PTPRZ1,TRPS1,PITPNC1,TNIK,FBXL7,HIF3A,SOX5,MSI2,FGFR3,ATP13A4,SLC1A3,LRIG1,NPAS3,ERBB4,QKI,CTNND2,PREX2,MAML2 |
1.321e-02 | -4.33 | lung-carcinoma-non_small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-non_small_cell_carcinoma | 5198 | 23 | 16828 | 49 |
CTNND2,QKI,NPAS3,ERBB4,PREX2,MAML2,MSI2,FGFR3,ATP13A4,SLC1A3,LRIG1,PITPNC1,PTPRZ1,TRPS1,TNIK,SOX5,HIF3A,FBXL7,RORA,ITPR2,LSAMP,ABLIM1,COL5A3 |
1.322e-02 | -4.33 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 5 | 18204 | 50 |
ATP1A2,SLC4A4,SLC1A3,ATP13A4,RYR3 |
1.332e-02 | -4.32 | human chr13q21.32 | chromosome location | human chr13q21.32 | 7 | 1 | 26134 | 50 |
PCDH9 |
1.332e-02 | -4.32 | human chr8q13.2 | chromosome location | human chr8q13.2 | 7 | 1 | 26134 | 50 |
PREX2 |
1.343e-02 | -4.31 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 50 |
SLC4A4 |
1.343e-02 | -4.31 | Protocadherin | interpro domains | IPR013585 | 5 | 1 | 18521 | 50 |
PCDH9 |
1.343e-02 | -4.31 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 50 |
PITPNC1 |
1.343e-02 | -4.31 | BBP-like | interpro domains | IPR045071 | 5 | 1 | 18521 | 50 |
QKI |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA2 |
1.343e-02 | -4.31 | Mtc | interpro domains | IPR004686 | 5 | 1 | 18521 | 50 |
SFXN5 |
1.343e-02 | -4.31 | P-type_TPase_V | interpro domains | IPR006544 | 5 | 1 | 18521 | 50 |
ATP13A4 |
1.357e-02 | -4.30 | NFIX (nuclear factor I X) | protein interactions | 4784 | 198 | 3 | 19454 | 49 |
TRPS1,SOX5,NFIA |
1.366e-02 | -4.29 | stem cell differentiation | biological process | GO:0048863 | 182 | 3 | 18204 | 50 |
ERBB4,MSI2,GPM6A |
1.366e-02 | -4.29 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 50 |
ATP1A2 |
1.366e-02 | -4.29 | propionate metabolic process | biological process | GO:0019541 | 5 | 1 | 18204 | 50 |
ACSS1 |
1.366e-02 | -4.29 | gephyrin clustering involved in postsynaptic density assembly | biological process | GO:0097116 | 5 | 1 | 18204 | 50 |
NRXN1 |
1.366e-02 | -4.29 | ERBB2-ERBB4 signaling pathway | biological process | GO:0038135 | 5 | 1 | 18204 | 50 |
ERBB4 |
1.366e-02 | -4.29 | otolith morphogenesis | biological process | GO:0032474 | 5 | 1 | 18204 | 50 |
LRIG1 |
1.366e-02 | -4.29 | tricarboxylic acid transport | biological process | GO:0006842 | 5 | 1 | 18204 | 50 |
SFXN5 |
1.366e-02 | -4.29 | citrate transport | biological process | GO:0015746 | 5 | 1 | 18204 | 50 |
SFXN5 |
1.367e-02 | -4.29 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 48 | 16828 | 49 |
RYR3,NHSL1,SLC4A4,CADM1,ZBTB20,DTNA,ATP1A2,SLC1A3,LRIG1,NTM,TNIK,FBXL7,HIF3A,PTPRZ1,NFIA,ZNF98,CDH20,GPM6A,LSAMP,ITPR2,MACF1,PCDH9,PREX2,MAML2,ERBB4,NPAS3,QKI,AHCYL2,CTNND2,SLC1A2,NRXN1,PARD3B,ACSS1,CST3,MSI2,RFX4,FGFR3,ATP13A4,NCKAP5,SOX5,TRPS1,NKAIN3,COL5A3,GPC5,SFXN5,RORA,PTGDS,ABLIM1 |
1.371e-02 | -4.29 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 18 |
CTNNA2 |
1.372e-02 | -4.29 | CTF_NFI_2 | prosite domains | PS51080 | 4 | 1 | 12186 | 42 |
NFIA |
1.372e-02 | -4.29 | CTF_NFI_1 | prosite domains | PS00349 | 4 | 1 | 12186 | 42 |
NFIA |
1.375e-02 | -4.29 | skin-upper_back-malignant_melanoma | COSMIC cancer mutations | skin-upper_back-malignant_melanoma | 319 | 4 | 16828 | 49 |
ERBB4,MACF1,GPC5,PARD3B |
1.383e-02 | -4.28 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 49 |
TNIK,GPM6A |
1.383e-02 | -4.28 | UNKL (unk like zinc finger) | protein interactions | 64718 | 71 | 2 | 19454 | 49 |
AHCYL2,QKI |
1.386e-02 | -4.28 | regulation of carbohydrate metabolic process | biological process | GO:0006109 | 183 | 3 | 18204 | 50 |
RORA,SLC4A4,ZBTB20 |
1.397e-02 | -4.27 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 50 |
PITPNC1 |
1.397e-02 | -4.27 | SFXNs | pfam domains | PF03820 | 5 | 1 | 17795 | 50 |
SFXN5 |
1.397e-02 | -4.27 | Protocadherin | pfam domains | PF08374 | 5 | 1 | 17795 | 50 |
PCDH9 |
1.397e-02 | -4.27 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 50 |
CTNNA2 |
1.412e-02 | -4.26 | neuron to neuron synapse | cellular component | GO:0098984 | 365 | 4 | 19108 | 49 |
CADM1,ERBB4,TNIK,CTNND2 |
1.413e-02 | -4.26 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 3 | 19454 | 49 |
RYR3,DTNA,ATP1A2 |
1.413e-02 | -4.26 | lower_leg | COSMIC cancer mutations | lower_leg | 174 | 3 | 16828 | 49 |
ERBB4,PREX2,FGFR3 |
1.418e-02 | -4.26 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
RYR3,SLC4A4,NHSL1,CADM1,LRIG1,NTM,ZBTB20,ATP1A2,SLC1A3,DTNA,FBXL7,HIF3A,TNIK,CDH20,PTPRZ1,NFIA,ZNF98,PITPNC1,LSAMP,ITPR2,PCDH9,MACF1,GPM6A,MAML2,PREX2,NRXN1,PARD3B,ERBB4,NPAS3,AHCYL2,QKI,CTNND2,SLC1A2,ACSS1,FGFR3,ATP13A4,NCKAP5,CST3,RFX4,SOX5,TRPS1,GPC5,SFXN5,NKAIN3,COL5A3,PTGDS,ABLIM1,RORA |
1.418e-02 | -4.26 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
CST3,RFX4,ATP13A4,FGFR3,NCKAP5,ACSS1,ERBB4,NPAS3,SLC1A2,CTNND2,AHCYL2,QKI,NRXN1,PARD3B,PREX2,MAML2,RORA,PTGDS,ABLIM1,NKAIN3,COL5A3,GPC5,SFXN5,TRPS1,SOX5,ZBTB20,DTNA,SLC1A3,ATP1A2,LRIG1,NTM,CADM1,RYR3,SLC4A4,NHSL1,GPM6A,PCDH9,MACF1,LSAMP,ITPR2,NFIA,PTPRZ1,PITPNC1,ZNF98,CDH20,TNIK,FBXL7,HIF3A |
1.418e-02 | -4.26 | positive regulation of tyrosine phosphorylation of STAT protein | biological process | GO:0042531 | 66 | 2 | 18204 | 50 |
FGFR3,ERBB4 |
1.418e-02 | -4.26 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
1.420e-02 | -4.25 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 49 |
TNIK,GPM6A |
1.432e-02 | -4.25 | FEV (FEV transcription factor, ETS family member) | protein interactions | 54738 | 202 | 3 | 19454 | 49 |
NFIA,TRPS1,SOX5 |
1.448e-02 | -4.24 | skin-lower_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-superficial_spreading | 5 | 1 | 16828 | 49 |
PREX2 |
1.448e-02 | -4.24 | skin-lower_back-other-nevus_sebaceous | COSMIC cancer mutations | skin-lower_back-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-nevus_sebaceous | COSMIC cancer mutations | skin-face-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-nevus_sebaceous | COSMIC cancer mutations | skin-shoulder-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hand-other-lichenoid_keratosis | COSMIC cancer mutations | skin-hand-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-other-lichenoid_keratosis | COSMIC cancer mutations | skin-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-lichenoid_keratosis | COSMIC cancer mutations | skin-breast-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-adnexal_tumour-syringocystadenoma_papilliferum | COSMIC cancer mutations | skin-adnexal_tumour-syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-lichenoid_keratosis | COSMIC cancer mutations | skin-neck-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-flank-other-lichenoid_keratosis | COSMIC cancer mutations | skin-flank-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-scalp-other-nevus_sebaceous | COSMIC cancer mutations | skin-scalp-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-nevus_sebaceous | COSMIC cancer mutations | skin-breast-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-arm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-arm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hip-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-hip-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-nevus_sebaceous | COSMIC cancer mutations | skin-neck-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | syringocystadenoma_papilliferum | COSMIC cancer mutations | syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_arm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_arm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-lichenoid_keratosis | COSMIC cancer mutations | skin-face-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-forearm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-forearm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-ear-other-nevus_sebaceous | COSMIC cancer mutations | skin-ear-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-chest-other-lichenoid_keratosis | COSMIC cancer mutations | skin-chest-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-lichenoid_keratosis | COSMIC cancer mutations | skin-shoulder-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | lichenoid_keratosis | COSMIC cancer mutations | lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.449e-02 | -4.23 | large_intestine-colon-carcinoma | COSMIC cancer mutations | large_intestine-colon-carcinoma | 2612 | 14 | 16828 | 49 |
AHCYL2,PTPRZ1,TRPS1,NRXN1,PREX2,RORA,ITPR2,MACF1,PCDH9,COL5A3,SLC1A3,GPC5,ACSS1,LRIG1 |
1.470e-02 | -4.22 | NFIC (nuclear factor I C) | protein interactions | 4782 | 204 | 3 | 19454 | 49 |
TRPS1,SOX5,NFIA |
1.493e-02 | -4.20 | presynapse | cellular component | GO:0098793 | 569 | 5 | 19108 | 49 |
TNIK,GPM6A,SLC1A2,ERBB4,NRXN1 |
1.496e-02 | -4.20 | TEC (tec protein tyrosine kinase) | protein interactions | 7006 | 74 | 2 | 19454 | 49 |
ERBB4,MSI2 |
1.502e-02 | -4.20 | SYTL3 (synaptotagmin like 3) | protein interactions | 94120 | 6 | 1 | 19454 | 49 |
NRXN1 |
1.502e-02 | -4.20 | FGF23 (fibroblast growth factor 23) | protein interactions | 8074 | 6 | 1 | 19454 | 49 |
FGFR3 |
1.502e-02 | -4.20 | SOX11 (SRY-box transcription factor 11) | protein interactions | 6664 | 6 | 1 | 19454 | 49 |
SOX5 |
1.502e-02 | -4.20 | FGF6 (fibroblast growth factor 6) | protein interactions | 2251 | 6 | 1 | 19454 | 49 |
FGFR3 |
1.502e-02 | -4.20 | SOX1 (SRY-box transcription factor 1) | protein interactions | 6656 | 6 | 1 | 19454 | 49 |
SOX5 |
1.502e-02 | -4.20 | FGF18 (fibroblast growth factor 18) | protein interactions | 8817 | 6 | 1 | 19454 | 49 |
FGFR3 |
1.502e-02 | -4.20 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 49 |
GPM6A |
1.502e-02 | -4.20 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 49 |
DTNA |
1.502e-02 | -4.20 | PBP2 (Pbp2p) | protein interactions | 852533 | 6 | 1 | 19454 | 49 |
QKI |
1.502e-02 | -4.20 | DAZ4 (deleted in azoospermia 4) | protein interactions | 57135 | 6 | 1 | 19454 | 49 |
QKI |
1.502e-02 | -4.20 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 49 |
DTNA |
1.502e-02 | -4.20 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 49 |
GPM6A |
1.502e-02 | -4.20 | NRG4 (neuregulin 4) | protein interactions | 145957 | 6 | 1 | 19454 | 49 |
ERBB4 |
1.511e-02 | -4.19 | Calcium signaling pathway | KEGG pathways | hsa04020 | 181 | 3 | 7161 | 21 |
ITPR2,RYR3,ERBB4 |
1.511e-02 | -4.19 | Calcium signaling pathway | KEGG pathways | ko04020 | 181 | 3 | 7161 | 21 |
RYR3,ITPR2,ERBB4 |
1.527e-02 | -4.18 | Constitutive Signaling by Aberrant PI3K in Cancer | REACTOME pathways | R-HSA-2219530 | 65 | 2 | 10285 | 30 |
FGFR3,ERBB4 |
1.547e-02 | -4.17 | cell-cell contact zone | cellular component | GO:0044291 | 74 | 2 | 19108 | 49 |
ATP1A2,PCDH9 |
1.549e-02 | -4.17 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 47 |
ATP1A2 |
1.549e-02 | -4.17 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 47 |
RYR3 |
1.549e-02 | -4.17 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 47 |
SLC4A4 |
1.553e-02 | -4.16 | IG_LIKE | prosite domains | PS50835 | 430 | 5 | 12186 | 42 |
FGFR3,CADM1,NTM,LSAMP,LRIG1 |
1.573e-02 | -4.15 | MIR200A (microRNA 200a) | protein interactions | 406983 | 76 | 2 | 19454 | 49 |
QKI,MSI2 |
1.583e-02 | -4.15 | MARCKS (myristoylated alanine rich protein kinase C substrate) | protein interactions | 4082 | 588 | 5 | 19454 | 49 |
MACF1,ABLIM1,SLC1A3,AHCYL2,DTNA |
1.597e-02 | -4.14 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 20 |
SLC1A3,ATP1A2 |
1.600e-02 | -4.14 | IG | smart domains | SM00409 | 394 | 5 | 9717 | 37 |
FGFR3,LRIG1,LSAMP,CADM1,NTM |
1.600e-02 | -4.13 | other | COSMIC cancer mutations | other | 14843 | 48 | 16828 | 49 |
SLC1A3,ATP1A2,DTNA,ZBTB20,NTM,LRIG1,SLC4A4,NHSL1,RYR3,CADM1,GPM6A,PCDH9,MACF1,ITPR2,LSAMP,TNIK,HIF3A,FBXL7,ZNF98,NFIA,PTPRZ1,CDH20,ACSS1,RFX4,CST3,MSI2,NCKAP5,ATP13A4,FGFR3,PREX2,MAML2,SLC1A2,QKI,CTNND2,AHCYL2,ERBB4,NPAS3,PARD3B,NRXN1,COL5A3,NKAIN3,SFXN5,GPC5,RORA,ABLIM1,PTGDS,SOX5,TRPS1 |
1.609e-02 | -4.13 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 50 |
ATP1A2 |
1.609e-02 | -4.13 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | GAR_dom_sf | interpro domains | IPR036534 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | Syndecan/Neurexin_dom | interpro domains | IPR027789 | 6 | 1 | 18521 | 50 |
NRXN1 |
1.609e-02 | -4.13 | GF_recep_IV | interpro domains | IPR032778 | 6 | 1 | 18521 | 50 |
ERBB4 |
1.609e-02 | -4.13 | GAR_dom | interpro domains | IPR003108 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Desmoplakin_SH3 | interpro domains | IPR041615 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 50 |
GPC5 |
1.627e-02 | -4.12 | sarcoplasmic reticulum | cellular component | GO:0016529 | 76 | 2 | 19108 | 49 |
ITPR2,RYR3 |
1.637e-02 | -4.11 | ERBB4-ERBB4 signaling pathway | biological process | GO:0038138 | 6 | 1 | 18204 | 50 |
ERBB4 |
1.637e-02 | -4.11 | negative regulation of extracellular matrix disassembly | biological process | GO:0010716 | 6 | 1 | 18204 | 50 |
CST3 |
1.637e-02 | -4.11 | asymmetric neuroblast division | biological process | GO:0055059 | 6 | 1 | 18204 | 50 |
SOX5 |
1.637e-02 | -4.11 | vocal learning | biological process | GO:0042297 | 6 | 1 | 18204 | 50 |
NRXN1 |
1.637e-02 | -4.11 | imitative learning | biological process | GO:0098596 | 6 | 1 | 18204 | 50 |
NRXN1 |
1.637e-02 | -4.11 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 50 |
SLC1A3 |
1.637e-02 | -4.11 | postsynaptic density protein 95 clustering | biological process | GO:0097119 | 6 | 1 | 18204 | 50 |
NRXN1 |
1.652e-02 | -4.10 | ANKRD40 (ankyrin repeat domain 40) | protein interactions | 91369 | 78 | 2 | 19454 | 49 |
MSI2,SOX5 |
1.652e-02 | -4.10 | MIR34C (microRNA 34c) | protein interactions | 407042 | 78 | 2 | 19454 | 49 |
QKI,MSI2 |
1.672e-02 | -4.09 | regulation of ATP metabolic process | biological process | GO:1903578 | 72 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.674e-02 | -4.09 | SH3_10 | pfam domains | PF17902 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | Syndecan | pfam domains | PF01034 | 6 | 1 | 17795 | 50 |
NRXN1 |
1.674e-02 | -4.09 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 50 |
DTNA |
1.674e-02 | -4.09 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 50 |
GPC5 |
1.674e-02 | -4.09 | Plectin | pfam domains | PF00681 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 50 |
DTNA |
1.674e-02 | -4.09 | GF_recep_IV | pfam domains | PF14843 | 6 | 1 | 17795 | 50 |
ERBB4 |
1.674e-02 | -4.09 | GAS2 | pfam domains | PF02187 | 6 | 1 | 17795 | 50 |
MACF1 |
1.693e-02 | -4.08 | FBXO45 (F-box protein 45) | protein interactions | 200933 | 79 | 2 | 19454 | 49 |
CTNNA2,NCKAP5 |
1.693e-02 | -4.08 | PRDM1 (PR/SET domain 1) | protein interactions | 639 | 79 | 2 | 19454 | 49 |
TRPS1,NFIA |
1.705e-02 | -4.07 | HAD_sf | interpro domains | IPR023214 | 74 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.709e-02 | -4.07 | skin-extremity-malignant_melanoma | COSMIC cancer mutations | skin-extremity-malignant_melanoma | 1875 | 11 | 16828 | 49 |
ACSS1,RYR3,FBXL7,COL5A3,PREX2,PCDH9,ATP13A4,CDH20,PITPNC1,ERBB4,PTPRZ1 |
1.709e-02 | -4.07 | human chr2q21.2 | chromosome location | human chr2q21.2 | 9 | 1 | 26134 | 50 |
NCKAP5 |
1.711e-02 | -4.07 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 18 |
SLC4A4 |
1.711e-02 | -4.07 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 18 |
PITPNC1 |
1.716e-02 | -4.07 | regulation of cartilage development | biological process | GO:0061035 | 73 | 2 | 18204 | 50 |
TRPS1,SOX5 |
1.731e-02 | -4.06 | GFAP (glial fibrillary acidic protein) | protein interactions | 2670 | 217 | 3 | 19454 | 49 |
NKAIN3,ABLIM1,RORA |
1.735e-02 | -4.05 | skin-forearm-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-forearm-malignant_melanoma-superficial_spreading | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-adnexal_tumour-trichoblastoma | COSMIC cancer mutations | skin-adnexal_tumour-trichoblastoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-upper_leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-upper_leg-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-lower_back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | kidney-carcinoma-collecting_duct_carcinoma | COSMIC cancer mutations | kidney-carcinoma-collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-malignant_melanoma | COSMIC cancer mutations | skin-head_neck-malignant_melanoma | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-abdomen-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-abdomen-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-flank-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-flank-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | autonomic_ganglia-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-paraganglioma-benign | 6 | 1 | 16828 | 49 |
NHSL1 |
1.735e-02 | -4.05 | skin-trunk-epidermal_nevus | COSMIC cancer mutations | skin-trunk-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-epidermal_nevus | COSMIC cancer mutations | skin-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-epidermal_nevus | COSMIC cancer mutations | skin-head_neck-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-face-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-face-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | collecting_duct_carcinoma | COSMIC cancer mutations | collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_leg-epidermal_nevus | COSMIC cancer mutations | skin-lower_leg-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-actinic_keratosis | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-actinic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-Bowen_disease | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-Bowen_disease | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-arm-epidermal_nevus | COSMIC cancer mutations | skin-arm-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-benign_melanocytic_nevus-lentiginous_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus-lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | lentiginous_nevus | COSMIC cancer mutations | lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.740e-02 | -4.05 | actin filament binding | molecular function | GO:0051015 | 211 | 3 | 18094 | 47 |
ABLIM1,CTNNA2,MACF1 |
1.750e-02 | -4.05 | Pum2 (pumilio RNA-binding family member 2) | protein interactions | 80913 | 7 | 1 | 19454 | 49 |
QKI |
1.750e-02 | -4.05 | FGF5 (fibroblast growth factor 5) | protein interactions | 2250 | 7 | 1 | 19454 | 49 |
FGFR3 |
1.750e-02 | -4.05 | SLC16A5 (solute carrier family 16 member 5) | protein interactions | 9121 | 7 | 1 | 19454 | 49 |
PTPRZ1 |
1.750e-02 | -4.05 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 49 |
NPAS3 |
1.750e-02 | -4.05 | Ahcyl1 (S-adenosylhomocysteine hydrolase-like 1) | protein interactions | 229709 | 7 | 1 | 19454 | 49 |
AHCYL2 |
1.750e-02 | -4.05 | ZBTB45 (zinc finger and BTB domain containing 45) | protein interactions | 84878 | 7 | 1 | 19454 | 49 |
ZBTB20 |
1.761e-02 | -4.04 | positive regulation of gliogenesis | biological process | GO:0014015 | 74 | 2 | 18204 | 50 |
QKI,PTPRZ1 |
1.768e-02 | -4.04 | ovary-carcinoma | COSMIC cancer mutations | ovary-carcinoma | 933 | 7 | 16828 | 49 |
ATP1A2,PREX2,TNIK,ITPR2,MACF1,FGFR3,ERBB4 |
1.770e-02 | -4.03 | Plakin repeat | gene3d domains | 3.90.1290.10 | 6 | 1 | 14470 | 43 |
MACF1 |
1.770e-02 | -4.03 | Gas2-like domain | gene3d domains | 3.30.920.20 | 6 | 1 | 14470 | 43 |
MACF1 |
1.774e-02 | -4.03 | SOX17 (SRY-box transcription factor 17) | protein interactions | 64321 | 81 | 2 | 19454 | 49 |
NFIA,TRPS1 |
1.802e-02 | -4.02 | Bile secretion | KEGG pathways | ko04976 | 71 | 2 | 7161 | 21 |
SLC4A4,ATP1A2 |
1.802e-02 | -4.02 | Bile secretion | KEGG pathways | hsa04976 | 71 | 2 | 7161 | 21 |
ATP1A2,SLC4A4 |
1.803e-02 | -4.02 | SOX2 (SRY-box transcription factor 2) | protein interactions | 6657 | 1342 | 8 | 19454 | 49 |
SOX5,QKI,MACF1,TRPS1,ITPR2,LSAMP,MSI2,NFIA |
1.804e-02 | -4.01 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 47 |
PITPNC1 |
1.804e-02 | -4.01 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 47 |
ATP1A2 |
1.804e-02 | -4.01 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 47 |
ATP1A2 |
1.847e-02 | -3.99 | FBXO2 (F-box protein 2) | protein interactions | 26232 | 403 | 4 | 19454 | 49 |
PCDH9,LRIG1,NTM,FGFR3 |
1.852e-02 | -3.99 | regulation of tyrosine phosphorylation of STAT protein | biological process | GO:0042509 | 76 | 2 | 18204 | 50 |
FGFR3,ERBB4 |
1.858e-02 | -3.99 | SYT1 (synaptotagmin 1) | protein interactions | 6857 | 83 | 2 | 19454 | 49 |
NRXN1,GPM6A |
1.858e-02 | -3.99 | PAX2 (paired box 2) | protein interactions | 5076 | 83 | 2 | 19454 | 49 |
NFIA,TRPS1 |
1.858e-02 | -3.99 | DNM3 (dynamin 3) | protein interactions | 26052 | 83 | 2 | 19454 | 49 |
FGFR3,GPM6A |
1.872e-02 | -3.98 | calcium ion transmembrane transport | biological process | GO:0070588 | 205 | 3 | 18204 | 50 |
RYR3,ITPR2,GPM6A |
1.875e-02 | -3.98 | Rcpt_L-dom | interpro domains | IPR000494 | 7 | 1 | 18521 | 50 |
ERBB4 |
1.875e-02 | -3.98 | Plectin_repeat | interpro domains | IPR001101 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Rcpt_L-dom_sf | interpro domains | IPR036941 | 7 | 1 | 18521 | 50 |
ERBB4 |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA2 |
1.875e-02 | -3.98 | Furin-like_Cys-rich_dom | interpro domains | IPR006211 | 7 | 1 | 18521 | 50 |
ERBB4 |
1.875e-02 | -3.98 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 50 |
CTNND2 |
1.875e-02 | -3.98 | Plakin_repeat_sf | interpro domains | IPR035915 | 7 | 1 | 18521 | 50 |
MACF1 |
1.878e-02 | -3.97 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 2 | 18094 | 47 |
ERBB4,FGFR3 |
1.882e-02 | -3.97 | HAD-like_sf | interpro domains | IPR036412 | 78 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.889e-02 | -3.97 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 47 | 16828 | 49 |
TRPS1,SOX5,RORA,ABLIM1,COL5A3,NKAIN3,SFXN5,GPC5,QKI,CTNND2,AHCYL2,SLC1A2,ERBB4,NPAS3,NRXN1,PARD3B,PREX2,MAML2,RFX4,MSI2,NCKAP5,FGFR3,ATP13A4,ACSS1,ZNF98,PITPNC1,PTPRZ1,NFIA,CDH20,TNIK,HIF3A,FBXL7,GPM6A,LSAMP,ITPR2,MACF1,PCDH9,CADM1,SLC4A4,NHSL1,RYR3,ATP1A2,SLC1A3,DTNA,ZBTB20,NTM,LRIG1 |
1.891e-02 | -3.97 | system process | biological process | GO:0003008 | 2015 | 11 | 18204 | 50 |
SLC1A2,SLC1A3,ABLIM1,NRXN1,PTPRZ1,ATP1A2,CTNNA2,RYR3,SLC4A4,LRIG1,DTNA |
1.896e-02 | -3.97 | Immunoglobulins | gene3d domains | 2.60.40.10 | 721 | 6 | 14470 | 43 |
LSAMP,NTM,LRIG1,PTPRZ1,FGFR3,CADM1 |
1.897e-02 | -3.96 | human chr12p11.23 | chromosome location | human chr12p11.23 | 10 | 1 | 26134 | 50 |
ITPR2 |
1.898e-02 | -3.96 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 2 | 18204 | 50 |
ATP1A2,NRXN1 |
1.902e-02 | -3.96 | testis | COSMIC cancer mutations | testis | 733 | 6 | 16828 | 49 |
TRPS1,TNIK,PREX2,ERBB4,MACF1,FGFR3 |
1.904e-02 | -3.96 | KLF3 (KLF transcription factor 3) | protein interactions | 51274 | 225 | 3 | 19454 | 49 |
SOX5,TRPS1,NFIA |
1.907e-02 | -3.96 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 50 |
RYR3 |
1.907e-02 | -3.96 | regulation of 3'-UTR-mediated mRNA stabilization | biological process | GO:1905868 | 7 | 1 | 18204 | 50 |
QKI |
1.907e-02 | -3.96 | regulation of oligodendrocyte progenitor proliferation | biological process | GO:0070445 | 7 | 1 | 18204 | 50 |
PTPRZ1 |
1.907e-02 | -3.96 | positive regulation of transcription of Notch receptor target | biological process | GO:0007221 | 7 | 1 | 18204 | 50 |
MAML2 |
1.907e-02 | -3.96 | glial cell fate specification | biological process | GO:0021780 | 7 | 1 | 18204 | 50 |
NFIA |
1.907e-02 | -3.96 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 50 |
CTNNA2 |
1.907e-02 | -3.96 | S-adenosylmethionine cycle | biological process | GO:0033353 | 7 | 1 | 18204 | 50 |
AHCYL2 |
1.907e-02 | -3.96 | observational learning | biological process | GO:0098597 | 7 | 1 | 18204 | 50 |
NRXN1 |
1.907e-02 | -3.96 | regulation of male germ cell proliferation | biological process | GO:2000254 | 7 | 1 | 18204 | 50 |
PTGDS |
1.911e-02 | -3.96 | synaptic membrane | cellular component | GO:0097060 | 400 | 4 | 19108 | 49 |
GPM6A,SLC1A2,ERBB4,NRXN1 |
1.914e-02 | -3.96 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | 73 | 2 | 16828 | 49 |
FGFR3,MACF1 |
1.943e-02 | -3.94 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
SLC1A2,NCKAP5,MACF1,ITPR2,ATP13A4,PREX2,GPC5 |
1.943e-02 | -3.94 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
PREX2,GPC5,SLC1A2,ATP13A4,NCKAP5,MACF1,ITPR2 |
1.944e-02 | -3.94 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
1.944e-02 | -3.94 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
1.949e-02 | -3.94 | Thyroid hormone synthesis | KEGG pathways | hsa04918 | 74 | 2 | 7161 | 21 |
ITPR2,ATP1A2 |
1.949e-02 | -3.94 | Thyroid hormone synthesis | KEGG pathways | ko04918 | 74 | 2 | 7161 | 21 |
ATP1A2,ITPR2 |
1.951e-02 | -3.94 | Oncogenic MAPK signaling | REACTOME pathways | R-HSA-6802957 | 74 | 2 | 10285 | 30 |
MACF1,QKI |
1.951e-02 | -3.94 | Recep_L_domain | pfam domains | PF01030 | 7 | 1 | 17795 | 50 |
ERBB4 |
1.951e-02 | -3.94 | Furin-like | pfam domains | PF00757 | 7 | 1 | 17795 | 50 |
ERBB4 |
1.964e-02 | -3.93 | oligodendroglioma_Grade_II | COSMIC cancer mutations | oligodendroglioma_Grade_II | 74 | 2 | 16828 | 49 |
MACF1,FGFR3 |
1.974e-02 | -3.93 | Tyr_kinase_cat_dom | interpro domains | IPR020635 | 80 | 2 | 18521 | 50 |
FGFR3,ERBB4 |
1.986e-02 | -3.92 | EGLN1 (egl-9 family hypoxia inducible factor 1) | protein interactions | 54583 | 86 | 2 | 19454 | 49 |
HIF3A,FGFR3 |
1.991e-02 | -3.92 | regulation of glial cell differentiation | biological process | GO:0045685 | 79 | 2 | 18204 | 50 |
QKI,PTPRZ1 |
1.998e-02 | -3.91 | PTGER1 (prostaglandin E receptor 1) | protein interactions | 5731 | 8 | 1 | 19454 | 49 |
PTGDS |
1.998e-02 | -3.91 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 1 | 19454 | 49 |
NTM |
1.998e-02 | -3.91 | DEPP1 (DEPP autophagy regulator 1) | protein interactions | 11067 | 8 | 1 | 19454 | 49 |
QKI |
1.999e-02 | -3.91 | Gastric acid secretion | KEGG pathways | hsa04971 | 75 | 2 | 7161 | 21 |
ITPR2,ATP1A2 |
1.999e-02 | -3.91 | Gastric acid secretion | KEGG pathways | ko04971 | 75 | 2 | 7161 | 21 |
ITPR2,ATP1A2 |
2.004e-02 | -3.91 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 6 | 19108 | 49 |
GPM6A,ATP1A2,CTNND2,SLC1A3,NRXN1,CADM1 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-intradermal | COSMIC cancer mutations | skin-benign_melanocytic_nevus-intradermal | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-adnexal_tumour-trichilemmoma | COSMIC cancer mutations | skin-adnexal_tumour-trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-shoulder-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-shoulder-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | nevus_sebaceous | COSMIC cancer mutations | nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-malignant_melanoma-nodular | COSMIC cancer mutations | skin-face-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-other-nevus_sebaceous | COSMIC cancer mutations | skin-other-nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-compound | COSMIC cancer mutations | skin-benign_melanocytic_nevus-compound | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | trichilemmoma | COSMIC cancer mutations | trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-chest-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-chest-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-adnexal_tumour-malignant_adnexal_tumour | COSMIC cancer mutations | skin-face-adnexal_tumour-malignant_adnexal_tumour | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | urinary_tract-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma-transitional_cell_carcinoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-upper_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-neck-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-neck-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.025e-02 | -3.90 | FGFR3b ligand binding and activation | REACTOME pathways | R-HSA-190371 | 7 | 1 | 10285 | 30 |
FGFR3 |
2.025e-02 | -3.90 | Nectin/Necl trans heterodimerization | REACTOME pathways | R-HSA-420597 | 7 | 1 | 10285 | 30 |
CADM1 |
2.029e-02 | -3.90 | ZNF608 (zinc finger protein 608) | protein interactions | 57507 | 87 | 2 | 19454 | 49 |
NFIA,SOX5 |
2.029e-02 | -3.90 | MIR141 (microRNA 141) | protein interactions | 406933 | 87 | 2 | 19454 | 49 |
QKI,MSI2 |
2.029e-02 | -3.90 | Kctd5 (potassium channel tetramerisation domain containing 5) | protein interactions | 69259 | 87 | 2 | 19454 | 49 |
SLC1A3,TRPS1 |
2.029e-02 | -3.90 | NHLH1 (nescient helix-loop-helix 1) | protein interactions | 4807 | 87 | 2 | 19454 | 49 |
TRPS1,NFIA |
2.035e-02 | -3.89 | HAD superfamily/HAD-like | gene3d domains | 3.40.50.1000 | 74 | 2 | 14470 | 43 |
ATP1A2,ATP13A4 |
2.043e-02 | -3.89 | acral_lentiginous | COSMIC cancer mutations | acral_lentiginous | 745 | 6 | 16828 | 49 |
MACF1,FGFR3,CDH20,ATP13A4,ERBB4,PREX2 |
2.044e-02 | -3.89 | Signaling by EGFR | REACTOME pathways | R-HSA-177929 | 364 | 4 | 10285 | 30 |
ITPR2,LRIG1,FGFR3,ERBB4 |
2.044e-02 | -3.89 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 25 | 16828 | 49 |
SOX5,PTPRZ1,COL5A3,NKAIN3,ABLIM1,MACF1,ITPR2,RORA,SLC4A4,MAML2,RYR3,PREX2,CADM1,CTNND2,NPAS3,ERBB4,LRIG1,SLC1A3,DTNA,ATP1A2,ZBTB20,NCKAP5,ATP13A4,FGFR3,CST3 |
2.051e-02 | -3.89 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 42 |
GPC5 |
2.051e-02 | -3.89 | GAR | prosite domains | PS51460 | 6 | 1 | 12186 | 42 |
MACF1 |
2.060e-02 | -3.88 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 47 |
ATP1A2 |
2.060e-02 | -3.88 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 47 |
SLC1A3 |
2.060e-02 | -3.88 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 47 |
ATP1A2 |
2.062e-02 | -3.88 | Receptor L-domain | gene3d domains | 3.80.20.20 | 7 | 1 | 14470 | 43 |
ERBB4 |
2.087e-02 | -3.87 | adult locomotory behavior | biological process | GO:0008344 | 81 | 2 | 18204 | 50 |
PREX2,ATP1A2 |
2.102e-02 | -3.86 | PDZ domain binding | molecular function | GO:0030165 | 86 | 2 | 18094 | 47 |
DTNA,CADM1 |
2.105e-02 | -3.86 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 4 | 19108 | 49 |
TNIK,SLC1A2,GPM6A,ERBB4 |
2.106e-02 | -3.86 | eye-uveal_tract-malignant_melanoma-spindle | COSMIC cancer mutations | eye-uveal_tract-malignant_melanoma-spindle | 363 | 4 | 16828 | 49 |
PREX2,CTNND2,MACF1,PCDH9 |
2.106e-02 | -3.86 | Muscle contraction | REACTOME pathways | R-HSA-397014 | 204 | 3 | 10285 | 30 |
ATP1A2,ITPR2,RYR3 |
2.109e-02 | -3.86 | HMG20A (high mobility group 20A) | protein interactions | 10363 | 234 | 3 | 19454 | 49 |
NFIA,DTNA,SOX5 |
2.117e-02 | -3.85 | SOX10 (SRY-box transcription factor 10) | protein interactions | 6663 | 89 | 2 | 19454 | 49 |
TRPS1,NFIA |
2.117e-02 | -3.85 | PLEKHA2 (pleckstrin homology domain containing A2) | protein interactions | 59339 | 89 | 2 | 19454 | 49 |
AHCYL2,DTNA |
2.118e-02 | -3.85 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 26 | 16828 | 49 |
ATP13A4,FGFR3,ABLIM1,NCKAP5,MACF1,ITPR2,RORA,RFX4,LRIG1,GPC5,NTM,ZBTB20,ATP1A2,NRXN1,CADM1,NFIA,PTPRZ1,ERBB4,PITPNC1,CTNND2,MAML2,RYR3,SLC4A4,SOX5,TNIK,PREX2 |
2.118e-02 | -3.85 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 26 | 16828 | 49 |
LRIG1,NTM,ZBTB20,ATP1A2,ATP13A4,FGFR3,NCKAP5,RFX4,MAML2,RYR3,SLC4A4,PREX2,NRXN1,CADM1,ERBB4,CTNND2,GPC5,ABLIM1,MACF1,ITPR2,RORA,SOX5,TNIK,NFIA,PTPRZ1,PITPNC1 |
2.123e-02 | -3.85 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 49 |
SLC1A3,DTNA,ATP1A2,ZBTB20,LRIG1,CADM1,SLC4A4,NHSL1,RYR3,GPM6A,MACF1,PCDH9,ITPR2,LSAMP,PITPNC1,ZNF98,NFIA,PTPRZ1,CDH20,TNIK,HIF3A,FBXL7,MSI2,NCKAP5,ATP13A4,FGFR3,ACSS1,SLC1A2,QKI,AHCYL2,CTNND2,NPAS3,ERBB4,NRXN1,PARD3B,PREX2,MAML2,RORA,ABLIM1,PTGDS,COL5A3,NKAIN3,SFXN5,GPC5,TRPS1,SOX5 |
2.123e-02 | -3.85 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 49 |
COL5A3,NKAIN3,SFXN5,GPC5,RORA,ABLIM1,PTGDS,SOX5,TRPS1,ACSS1,MSI2,NCKAP5,ATP13A4,FGFR3,PREX2,MAML2,SLC1A2,AHCYL2,QKI,CTNND2,ERBB4,NPAS3,PARD3B,NRXN1,GPM6A,MACF1,PCDH9,LSAMP,ITPR2,TNIK,HIF3A,FBXL7,PITPNC1,ZNF98,NFIA,PTPRZ1,CDH20,DTNA,SLC1A3,ATP1A2,ZBTB20,LRIG1,SLC4A4,NHSL1,RYR3,CADM1 |
2.127e-02 | -3.85 | ConA-like_dom_sf | interpro domains | IPR013320 | 219 | 3 | 18521 | 50 |
RYR3,NRXN1,COL5A3 |
2.140e-02 | -3.84 | RFX-like | interpro domains | IPR039779 | 8 | 1 | 18521 | 50 |
RFX4 |
2.140e-02 | -3.84 | Villin_headpiece_dom_sf | interpro domains | IPR036886 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | Plakin | interpro domains | IPR043197 | 8 | 1 | 18521 | 50 |
MACF1 |
2.140e-02 | -3.84 | Villin_headpiece | interpro domains | IPR003128 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.162e-02 | -3.83 | CTDSPL (CTD small phosphatase like) | protein interactions | 10217 | 90 | 2 | 19454 | 49 |
CADM1,DTNA |
2.177e-02 | -3.83 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 50 |
CTNNA2 |
2.177e-02 | -3.83 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 50 |
SLC1A3 |
2.177e-02 | -3.83 | cell proliferation in hindbrain | biological process | GO:0021534 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | regulation of germ cell proliferation | biological process | GO:1905936 | 8 | 1 | 18204 | 50 |
PTGDS |
2.177e-02 | -3.83 | cell proliferation in external granule layer | biological process | GO:0021924 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 50 |
ATP1A2 |
2.177e-02 | -3.83 | cerebellar granule cell precursor proliferation | biological process | GO:0021930 | 8 | 1 | 18204 | 50 |
RORA |
2.177e-02 | -3.83 | ERBB4 signaling pathway | biological process | GO:0038130 | 8 | 1 | 18204 | 50 |
ERBB4 |
2.180e-02 | -3.83 | CAMK2A (calcium/calmodulin dependent protein kinase II alpha) | protein interactions | 815 | 237 | 3 | 19454 | 49 |
GPM6A,ITPR2,SOX5 |
2.185e-02 | -3.82 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 9 | 16828 | 49 |
TNIK,GPC5,RYR3,SLC4A4,TRPS1,CTNND2,NRXN1,LSAMP,NCKAP5 |
2.186e-02 | -3.82 | skin-upper_arm-malignant_melanoma | COSMIC cancer mutations | skin-upper_arm-malignant_melanoma | 553 | 5 | 16828 | 49 |
PREX2,ERBB4,PARD3B,ITPR2,SLC4A4 |
2.207e-02 | -3.81 | FOXI1 (forkhead box I1) | protein interactions | 2299 | 91 | 2 | 19454 | 49 |
NFIA,TRPS1 |
2.207e-02 | -3.81 | PTPN21 (protein tyrosine phosphatase non-receptor type 21) | protein interactions | 11099 | 91 | 2 | 19454 | 49 |
ERBB4,AHCYL2 |
2.207e-02 | -3.81 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 49 |
NTM,GPM6A |
2.219e-02 | -3.81 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-T_cell_large_granular_lymphocytic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-T_cell_large_granular_lymphocytic_leukaemia | 79 | 2 | 16828 | 49 |
MAML2,CADM1 |
2.224e-02 | -3.81 | glial cell differentiation | biological process | GO:0010001 | 219 | 3 | 18204 | 50 |
NFIA,QKI,PTPRZ1 |
2.226e-02 | -3.80 | VHP | pfam domains | PF02209 | 8 | 1 | 17795 | 50 |
ABLIM1 |
2.233e-02 | -3.80 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 2 | 18204 | 50 |
ATP1A2,NKAIN3 |
2.233e-02 | -3.80 | stem cell development | biological process | GO:0048864 | 84 | 2 | 18204 | 50 |
ERBB4,MSI2 |
2.233e-02 | -3.80 | L-amino acid transport | biological process | GO:0015807 | 84 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
2.244e-02 | -3.80 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 3 | 10285 | 30 |
RYR3,ATP13A4,ATP1A2 |
2.245e-02 | -3.80 | Ywhag (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide) | protein interactions | 22628 | 9 | 1 | 19454 | 49 |
QKI |
2.245e-02 | -3.80 | NRXN2 (neurexin 2) | protein interactions | 9379 | 9 | 1 | 19454 | 49 |
MACF1 |
2.245e-02 | -3.80 | MUC4 (mucin 4, cell surface associated) | protein interactions | 4585 | 9 | 1 | 19454 | 49 |
ERBB4 |
2.245e-02 | -3.80 | KLB (klotho beta) | protein interactions | 152831 | 9 | 1 | 19454 | 49 |
FGFR3 |
2.245e-02 | -3.80 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 49 |
CTNNA2 |
2.245e-02 | -3.80 | GUSBP1 (GUSB pseudogene 1) | protein interactions | 728411 | 9 | 1 | 19454 | 49 |
FGFR3 |
2.250e-02 | -3.79 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 3 | 18204 | 50 |
ATP1A2,NRXN1,SLC1A3 |
2.253e-02 | -3.79 | SOX9 (SRY-box transcription factor 9) | protein interactions | 6662 | 92 | 2 | 19454 | 49 |
TRPS1,NFIA |
2.253e-02 | -3.79 | FNTA (farnesyltransferase, CAAX box, subunit alpha) | protein interactions | 2339 | 92 | 2 | 19454 | 49 |
FGFR3,TNIK |
2.253e-02 | -3.79 | POTEI (POTE ankyrin domain family member I) | protein interactions | 653269 | 92 | 2 | 19454 | 49 |
FGFR3,DTNA |
2.262e-02 | -3.79 | thyroid | COSMIC cancer mutations | thyroid | 9867 | 36 | 16828 | 49 |
NHSL1,SLC4A4,RYR3,MAML2,PREX2,CADM1,PARD3B,NRXN1,SLC1A2,CTNND2,ERBB4,ACSS1,LRIG1,DTNA,ATP1A2,NCKAP5,ATP13A4,FGFR3,CST3,SOX5,HIF3A,TNIK,CDH20,ZNF98,NFIA,TRPS1,PTPRZ1,GPC5,COL5A3,PCDH9,MACF1,ABLIM1,ITPR2,LSAMP,PTGDS,RORA |
2.264e-02 | -3.79 | GAS2 | smart domains | SM00243 | 6 | 1 | 9717 | 37 |
MACF1 |
2.272e-02 | -3.78 | human chr6q26 | chromosome location | human chr6q26 | 12 | 1 | 26134 | 50 |
QKI |
2.283e-02 | -3.78 | chondrocyte differentiation | biological process | GO:0002062 | 85 | 2 | 18204 | 50 |
FGFR3,SOX5 |
2.285e-02 | -3.78 | platelet dense tubular network membrane | cellular component | GO:0031095 | 9 | 1 | 19108 | 49 |
ITPR2 |
2.299e-02 | -3.77 | ODR4 (odr-4 GPCR localization factor homolog) | protein interactions | 54953 | 93 | 2 | 19454 | 49 |
LRIG1,GPM6A |
2.299e-02 | -3.77 | MIR19B2 (microRNA 19b-2) | protein interactions | 406981 | 93 | 2 | 19454 | 49 |
MSI2,QKI |
2.299e-02 | -3.77 | RBM23 (RNA binding motif protein 23) | protein interactions | 55147 | 93 | 2 | 19454 | 49 |
AHCYL2,QKI |
2.299e-02 | -3.77 | DMRTB1 (DMRT like family B with proline rich C-terminal 1) | protein interactions | 63948 | 93 | 2 | 19454 | 49 |
MSI2,QKI |
2.299e-02 | -3.77 | TEX11 (testis expressed 11) | protein interactions | 56159 | 93 | 2 | 19454 | 49 |
QKI,SOX5 |
2.300e-02 | -3.77 | - | gene3d domains | 2.80.10.50 | 79 | 2 | 14470 | 43 |
ITPR2,RYR3 |
2.306e-02 | -3.77 | central_nervous_system-chiasm-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-chiasm-glioma-astrocytoma_Grade_I | 8 | 1 | 16828 | 49 |
QKI |
2.306e-02 | -3.77 | skin-chest-malignant_melanoma-nodular | COSMIC cancer mutations | skin-chest-malignant_melanoma-nodular | 8 | 1 | 16828 | 49 |
PREX2 |
2.306e-02 | -3.77 | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | junctional | COSMIC cancer mutations | junctional | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | trichoblastoma | COSMIC cancer mutations | trichoblastoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | actinic_keratosis | COSMIC cancer mutations | actinic_keratosis | 8 | 1 | 16828 | 49 |
FGFR3 |
2.309e-02 | -3.77 | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | 561 | 5 | 16828 | 49 |
ERBB4,TNIK,RYR3,MAML2,FGFR3 |
2.311e-02 | -3.77 | Downregulation of ERBB4 signaling | REACTOME pathways | R-HSA-1253288 | 8 | 1 | 10285 | 30 |
ERBB4 |
2.311e-02 | -3.77 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 30 |
GPC5 |
2.323e-02 | -3.76 | lipid binding | molecular function | GO:0008289 | 861 | 6 | 18094 | 47 |
ITPR2,PITPNC1,ATP1A2,RORA,PARD3B,PTGDS |
2.325e-02 | -3.76 | T_cell_large_granular_lymphocytic_leukaemia | COSMIC cancer mutations | T_cell_large_granular_lymphocytic_leukaemia | 81 | 2 | 16828 | 49 |
CADM1,MAML2 |
2.334e-02 | -3.76 | protein localization to cell junction | biological process | GO:1902414 | 86 | 2 | 18204 | 50 |
NRXN1,ERBB4 |
2.345e-02 | -3.75 | WWC1 (WW and C2 domain containing 1) | protein interactions | 23286 | 94 | 2 | 19454 | 49 |
TNIK,ABLIM1 |
2.345e-02 | -3.75 | QSER1 (glutamine and serine rich 1) | protein interactions | 79832 | 94 | 2 | 19454 | 49 |
SOX5,NFIA |
2.345e-02 | -3.75 | FOXP4 (forkhead box P4) | protein interactions | 116113 | 94 | 2 | 19454 | 49 |
SOX5,NFIA |
2.352e-02 | -3.75 | organic anion transport | biological process | GO:0015711 | 398 | 4 | 18204 | 50 |
SLC4A4,SLC1A2,SLC1A3,SFXN5 |
2.353e-02 | -3.75 | Villin headpiece domain | gene3d domains | 1.10.950.10 | 8 | 1 | 14470 | 43 |
ABLIM1 |
2.404e-02 | -3.73 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 50 |
SLC4A4 |
2.404e-02 | -3.73 | DNA-bd_RFX | interpro domains | IPR003150 | 9 | 1 | 18521 | 50 |
RFX4 |
2.404e-02 | -3.73 | Prot_inh_cystat_CS | interpro domains | IPR018073 | 9 | 1 | 18521 | 50 |
CST3 |
2.405e-02 | -3.73 | atypical_teratoid-rhabdoid_tumour | COSMIC cancer mutations | atypical_teratoid-rhabdoid_tumour | 213 | 3 | 16828 | 49 |
FGFR3,NCKAP5,PCDH9 |
2.405e-02 | -3.73 | central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour | COSMIC cancer mutations | central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour | 213 | 3 | 16828 | 49 |
PCDH9,NCKAP5,FGFR3 |
2.433e-02 | -3.72 | Endochondral Ossification | WikiPathways | WP474 | 65 | 2 | 5310 | 20 |
FGFR3,SOX5 |
2.437e-02 | -3.71 | kidney-carcinoma-renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma | 4535 | 20 | 16828 | 49 |
FGFR3,ITPR2,MACF1,PCDH9,MSI2,RORA,LRIG1,NRXN1,PTPRZ1,ERBB4,TRPS1,QKI,CTNND2,PITPNC1,FBXL7,MAML2,SOX5,HIF3A,TNIK,PREX2 |
2.437e-02 | -3.71 | renal_cell_carcinoma | COSMIC cancer mutations | renal_cell_carcinoma | 4535 | 20 | 16828 | 49 |
PREX2,TNIK,SOX5,HIF3A,MAML2,FBXL7,PITPNC1,QKI,CTNND2,TRPS1,PTPRZ1,ERBB4,NRXN1,LRIG1,MSI2,RORA,PCDH9,MACF1,ITPR2,FGFR3 |
2.446e-02 | -3.71 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 50 |
RYR3 |
2.446e-02 | -3.71 | activated T cell proliferation | biological process | GO:0050798 | 9 | 1 | 18204 | 50 |
CADM1 |
2.446e-02 | -3.71 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 50 |
CTNNA2 |
2.446e-02 | -3.71 | positive regulation of synapse maturation | biological process | GO:0090129 | 9 | 1 | 18204 | 50 |
NRXN1 |
2.446e-02 | -3.71 | polyamine transmembrane transport | biological process | GO:1902047 | 9 | 1 | 18204 | 50 |
ATP13A4 |
2.446e-02 | -3.71 | cyclooxygenase pathway | biological process | GO:0019371 | 9 | 1 | 18204 | 50 |
PTGDS |
2.446e-02 | -3.71 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 50 |
CTNNA2 |
2.446e-02 | -3.71 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 50 |
ATP1A2 |
2.452e-02 | -3.71 | NCOR2 (nuclear receptor corepressor 2) | protein interactions | 9612 | 248 | 3 | 19454 | 49 |
SOX5,NFIA,TNIK |
2.456e-02 | -3.71 | membrane | cellular component | GO:0016020 | 9220 | 31 | 19108 | 49 |
SLC1A2,NTM,FGFR3,PCDH9,HIF3A,NRXN1,GPM6A,DTNA,CTNND2,LSAMP,RYR3,CTNNA2,PTPRZ1,ITPR2,PTGDS,ATP13A4,PARD3B,LRIG1,CST3,MACF1,TNIK,SLC1A3,SFXN5,ERBB4,GPC5,CADM1,NKAIN3,SLC4A4,PREX2,ATP1A2,CDH20 |
2.459e-02 | -3.71 | human chr5p15.1 | chromosome location | human chr5p15.1 | 13 | 1 | 26134 | 50 |
FBXL7 |
2.469e-02 | -3.70 | neck | COSMIC cancer mutations | neck | 1231 | 8 | 16828 | 49 |
CTNND2,ERBB4,FGFR3,ATP13A4,COL5A3,ATP1A2,PREX2,GPC5 |
2.486e-02 | -3.69 | SOCS3 (suppressor of cytokine signaling 3) | protein interactions | 9021 | 97 | 2 | 19454 | 49 |
ERBB4,FGFR3 |
2.487e-02 | -3.69 | transcription regulator activity | molecular function | GO:0140110 | 1937 | 10 | 18094 | 47 |
TRPS1,HIF3A,ZBTB20,ZNF98,NPAS3,NFIA,RFX4,SOX5,MAML2,RORA |
2.491e-02 | -3.69 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 49 |
PITPNC1 |
2.491e-02 | -3.69 | Vbp1 (von Hippel-Lindau binding protein 1) | protein interactions | 22327 | 10 | 1 | 19454 | 49 |
ABLIM1 |
2.491e-02 | -3.69 | Hsp90aa1 (heat shock protein 90, alpha (cytosolic), class A member 1) | protein interactions | 15519 | 10 | 1 | 19454 | 49 |
QKI |
2.491e-02 | -3.69 | BANK1 (B cell scaffold protein with ankyrin repeats 1) | protein interactions | 55024 | 10 | 1 | 19454 | 49 |
ITPR2 |
2.491e-02 | -3.69 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 49 |
GPM6A |
2.491e-02 | -3.69 | Mrpl13 (mitochondrial ribosomal protein L13) | protein interactions | 68537 | 10 | 1 | 19454 | 49 |
QKI |
2.491e-02 | -3.69 | P2rx7 (purinergic receptor P2X 7) | protein interactions | 29665 | 10 | 1 | 19454 | 49 |
PTPRZ1 |
2.491e-02 | -3.69 | EREG (epiregulin) | protein interactions | 2069 | 10 | 1 | 19454 | 49 |
ERBB4 |
2.491e-02 | -3.69 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 49 |
GPM6A |
2.491e-02 | -3.69 | PTPRT (protein tyrosine phosphatase receptor type T) | protein interactions | 11122 | 10 | 1 | 19454 | 49 |
ERBB4 |
2.495e-02 | -3.69 | axon | cellular component | GO:0030424 | 650 | 5 | 19108 | 49 |
CTNNA2,PCDH9,GPM6A,DTNA,SLC1A2 |
2.501e-02 | -3.69 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 50 |
SLC4A4 |
2.501e-02 | -3.69 | RFX_DNA_binding | pfam domains | PF02257 | 9 | 1 | 17795 | 50 |
RFX4 |
2.504e-02 | -3.69 | salivary_gland-carcinoma | COSMIC cancer mutations | salivary_gland-carcinoma | 383 | 4 | 16828 | 49 |
ERBB4,TNIK,FGFR3,MAML2 |
2.504e-02 | -3.69 | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 49 |
MAML2,FGFR3,ERBB4,TNIK |
2.504e-02 | -3.69 | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 49 |
ERBB4,TNIK,FGFR3,MAML2 |
2.504e-02 | -3.69 | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 49 |
MAML2,FGFR3,TNIK,ERBB4 |
2.504e-02 | -3.69 | upper_aerodigestive_tract-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-carcinoma | 383 | 4 | 16828 | 49 |
FGFR3,MAML2,ERBB4,TNIK |
2.521e-02 | -3.68 | sarcoplasm | cellular component | GO:0016528 | 96 | 2 | 19108 | 49 |
ITPR2,RYR3 |
2.534e-02 | -3.68 | MED27 (mediator complex subunit 27) | protein interactions | 9442 | 98 | 2 | 19454 | 49 |
QKI,SOX5 |
2.534e-02 | -3.68 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 2 | 19454 | 49 |
LSAMP,GPM6A |
2.534e-02 | -3.68 | VAV2 (vav guanine nucleotide exchange factor 2) | protein interactions | 7410 | 98 | 2 | 19454 | 49 |
ERBB4,NCKAP5 |
2.536e-02 | -3.67 | perineuronal net | cellular component | GO:0072534 | 10 | 1 | 19108 | 49 |
PTPRZ1 |
2.539e-02 | -3.67 | regulation of purine nucleotide metabolic process | biological process | GO:1900542 | 90 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
2.555e-02 | -3.67 | CRX (cone-rod homeobox) | protein interactions | 1406 | 252 | 3 | 19454 | 49 |
TRPS1,SOX5,NFIA |
2.555e-02 | -3.67 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 3 | 19454 | 49 |
NHSL1,ERBB4,TNIK |
2.566e-02 | -3.66 | adrenal_cortical_carcinoma | COSMIC cancer mutations | adrenal_cortical_carcinoma | 2256 | 12 | 16828 | 49 |
NCKAP5,PCDH9,PTPRZ1,SLC1A2,RFX4,CTNND2,LRIG1,MAML2,NHSL1,SOX5,ZBTB20,ATP1A2 |
2.568e-02 | -3.66 | polyamine transmembrane transporter activity | molecular function | GO:0015203 | 10 | 1 | 18094 | 47 |
ATP13A4 |
2.568e-02 | -3.66 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 47 |
PITPNC1 |
2.580e-02 | -3.66 | ATPase-coupled transmembrane transporter activity | molecular function | GO:0042626 | 96 | 2 | 18094 | 47 |
ATP1A2,ATP13A4 |
2.581e-02 | -3.66 | connective tissue development | biological process | GO:0061448 | 232 | 3 | 18204 | 50 |
NFIA,SOX5,FGFR3 |
2.582e-02 | -3.66 | ZFHX3 (zinc finger homeobox 3) | protein interactions | 463 | 99 | 2 | 19454 | 49 |
TRPS1,SOX5 |
2.582e-02 | -3.66 | TNKS (tankyrase) | protein interactions | 8658 | 99 | 2 | 19454 | 49 |
TNIK,PCDH9 |
2.586e-02 | -3.66 | parotid | COSMIC cancer mutations | parotid | 578 | 5 | 16828 | 49 |
ERBB4,TNIK,FGFR3,RYR3,MAML2 |
2.589e-02 | -3.65 | shoulder | COSMIC cancer mutations | shoulder | 387 | 4 | 16828 | 49 |
PREX2,ERBB4,MACF1,FGFR3 |
2.591e-02 | -3.65 | Bowen_disease | COSMIC cancer mutations | Bowen_disease | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-chest-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-chest-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | skin-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-other-seborrhoeic_keratosis | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | in_situ_epithelial_neoplasm | COSMIC cancer mutations | in_situ_epithelial_neoplasm | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | compound | COSMIC cancer mutations | compound | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | epidermal_nevus | COSMIC cancer mutations | epidermal_nevus | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | COSMIC cancer mutations | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-benign_melanocytic_nevus-congenital | COSMIC cancer mutations | skin-benign_melanocytic_nevus-congenital | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-upper_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.592e-02 | -3.65 | regulation of nucleotide metabolic process | biological process | GO:0006140 | 91 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
2.621e-02 | -3.64 | oesophagus-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-carcinoma-adenocarcinoma | 13112 | 44 | 16828 | 49 |
ATP1A2,SLC1A3,ZBTB20,NTM,LRIG1,CADM1,NHSL1,SLC4A4,RYR3,GPM6A,ITPR2,LSAMP,PCDH9,MACF1,ZNF98,PTPRZ1,CDH20,TNIK,HIF3A,FBXL7,RFX4,CST3,NCKAP5,FGFR3,ATP13A4,ACSS1,CTNND2,QKI,AHCYL2,SLC1A2,NPAS3,ERBB4,PARD3B,NRXN1,PREX2,MAML2,RORA,PTGDS,COL5A3,NKAIN3,SFXN5,GPC5,TRPS1,SOX5 |
2.630e-02 | -3.64 | SFN (stratifin) | protein interactions | 2810 | 671 | 5 | 19454 | 49 |
ABLIM1,MACF1,NFIA,TNIK,PARD3B |
2.630e-02 | -3.64 | APBA1 (amyloid beta precursor protein binding family A member 1) | protein interactions | 320 | 100 | 2 | 19454 | 49 |
ABLIM1,NRXN1 |
2.630e-02 | -3.64 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 49 |
GPM6A,ATP1A2 |
2.634e-02 | -3.64 | DYNLL2 (dynein light chain LC8-type 2) | protein interactions | 140735 | 255 | 3 | 19454 | 49 |
NHSL1,TRPS1,NFIA |
2.636e-02 | -3.64 | PLEC | smart domains | SM00250 | 7 | 1 | 9717 | 37 |
MACF1 |
2.637e-02 | -3.64 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 6 | 18204 | 50 |
ITPR2,TNIK,RYR3,ATP1A2,FGFR3,PREX2 |
2.639e-02 | -3.63 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | REACTOME pathways | R-HSA-6811558 | 87 | 2 | 10285 | 30 |
FGFR3,ERBB4 |
2.646e-02 | -3.63 | human chr2p13.2 | chromosome location | human chr2p13.2 | 14 | 1 | 26134 | 50 |
SFXN5 |
2.646e-02 | -3.63 | human chr2p16.3 | chromosome location | human chr2p16.3 | 14 | 1 | 26134 | 50 |
NRXN1 |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.668e-02 | -3.62 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.679e-02 | -3.62 | CLEC4A (C-type lectin domain family 4 member A) | protein interactions | 50856 | 101 | 2 | 19454 | 49 |
CTNNA2,FGFR3 |
2.679e-02 | -3.62 | ILKAP (ILK associated serine/threonine phosphatase) | protein interactions | 80895 | 101 | 2 | 19454 | 49 |
FGFR3,ERBB4 |
2.690e-02 | -3.62 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 4 | 18204 | 50 |
NRXN1,SLC1A2,SLC1A3,DTNA |
2.690e-02 | -3.62 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 4 | 18204 | 50 |
SLC1A2,SLC1A3,NRXN1,DTNA |
2.697e-02 | -3.61 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 4 | 19454 | 49 |
SOX5,MACF1,ABLIM1,DTNA |
2.714e-02 | -3.61 | postsynaptic density assembly | biological process | GO:0097107 | 10 | 1 | 18204 | 50 |
NRXN1 |
2.714e-02 | -3.61 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 50 |
RYR3 |
2.714e-02 | -3.61 | establishment of centrosome localization | biological process | GO:0051660 | 10 | 1 | 18204 | 50 |
PARD3B |
2.714e-02 | -3.61 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 50 |
SOX5 |
2.714e-02 | -3.61 | otolith development | biological process | GO:0048840 | 10 | 1 | 18204 | 50 |
LRIG1 |
2.714e-02 | -3.61 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 1 | 18204 | 50 |
ATP1A2 |
2.714e-02 | -3.61 | postsynaptic membrane assembly | biological process | GO:0097104 | 10 | 1 | 18204 | 50 |
NRXN1 |
2.714e-02 | -3.61 | learned vocalization behavior or vocal learning | biological process | GO:0098598 | 10 | 1 | 18204 | 50 |
NRXN1 |
2.714e-02 | -3.61 | mitochondrial fragmentation involved in apoptotic process | biological process | GO:0043653 | 10 | 1 | 18204 | 50 |
ERBB4 |
2.714e-02 | -3.61 | action potential propagation | biological process | GO:0098870 | 10 | 1 | 18204 | 50 |
ATP1A2 |
2.719e-02 | -3.60 | Tyr_kinase_AS | interpro domains | IPR008266 | 95 | 2 | 18521 | 50 |
ERBB4,FGFR3 |
2.724e-02 | -3.60 | GATAZNFINGER | prints domains | PR00619 | 8 | 1 | 5227 | 18 |
TRPS1 |
2.724e-02 | -3.60 | LIPOCALIN | prints domains | PR00179 | 8 | 1 | 5227 | 18 |
PTGDS |
2.725e-02 | -3.60 | GATA_ZN_FINGER_1 | prosite domains | PS00344 | 8 | 1 | 12186 | 42 |
TRPS1 |
2.725e-02 | -3.60 | HP | prosite domains | PS51089 | 8 | 1 | 12186 | 42 |
ABLIM1 |
2.728e-02 | -3.60 | MIR7-1 (microRNA 7-1) | protein interactions | 407043 | 102 | 2 | 19454 | 49 |
MSI2,QKI |
2.735e-02 | -3.60 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 4 | 19454 | 49 |
MACF1,CTNND2,ERBB4,DTNA |
2.737e-02 | -3.60 | Cobll1 (Cobl-like 1) | protein interactions | 319876 | 11 | 1 | 19454 | 49 |
ABLIM1 |
2.737e-02 | -3.60 | GAL3ST1 (galactose-3-O-sulfotransferase 1) | protein interactions | 9514 | 11 | 1 | 19454 | 49 |
LRIG1 |
2.737e-02 | -3.60 | Batf3 (basic leucine zipper transcription factor, ATF-like 3) | protein interactions | 381319 | 11 | 1 | 19454 | 49 |
MACF1 |
2.737e-02 | -3.60 | IL7 (interleukin 7) | protein interactions | 3574 | 11 | 1 | 19454 | 49 |
QKI |
2.737e-02 | -3.60 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 49 |
NHSL1 |
2.737e-02 | -3.60 | DAZ1 (deleted in azoospermia 1) | protein interactions | 1617 | 11 | 1 | 19454 | 49 |
QKI |
2.737e-02 | -3.60 | SYTL1 (synaptotagmin like 1) | protein interactions | 84958 | 11 | 1 | 19454 | 49 |
NRXN1 |
2.737e-02 | -3.60 | IRAG1 (inositol 1,4,5-triphosphate receptor associated 1) | protein interactions | 10335 | 11 | 1 | 19454 | 49 |
ITPR2 |
2.737e-02 | -3.60 | Wipi2 (WD repeat domain, phosphoinositide interacting 2) | protein interactions | 74781 | 11 | 1 | 19454 | 49 |
MACF1 |
2.737e-02 | -3.60 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 49 |
GPM6A |
2.737e-02 | -3.60 | CCDC17 (coiled-coil domain containing 17) | protein interactions | 149483 | 11 | 1 | 19454 | 49 |
FGFR3 |
2.737e-02 | -3.60 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 49 |
ATP1A2 |
2.737e-02 | -3.60 | PTGDR (prostaglandin D2 receptor) | protein interactions | 5729 | 11 | 1 | 19454 | 49 |
PTGDS |
2.741e-02 | -3.60 | uveal_tract | COSMIC cancer mutations | uveal_tract | 587 | 5 | 16828 | 49 |
FGFR3,MACF1,PCDH9,PREX2,CTNND2 |
2.752e-02 | -3.59 | Protein digestion and absorption | KEGG pathways | ko04974 | 89 | 2 | 7161 | 21 |
ATP1A2,COL5A3 |
2.752e-02 | -3.59 | Protein digestion and absorption | KEGG pathways | hsa04974 | 89 | 2 | 7161 | 21 |
ATP1A2,COL5A3 |
2.756e-02 | -3.59 | muscle contraction | biological process | GO:0006936 | 238 | 3 | 18204 | 50 |
DTNA,ATP1A2,RYR3 |
2.756e-02 | -3.59 | protein localization to cell periphery | biological process | GO:1990778 | 238 | 3 | 18204 | 50 |
TNIK,MACF1,ERBB4 |
2.775e-02 | -3.58 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 50 |
NPAS3 |
2.775e-02 | -3.58 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 50 |
SLC4A4 |
2.782e-02 | -3.58 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
2.786e-02 | -3.58 | platelet dense tubular network | cellular component | GO:0031094 | 11 | 1 | 19108 | 49 |
ITPR2 |
2.786e-02 | -3.58 | perisynaptic extracellular matrix | cellular component | GO:0098966 | 11 | 1 | 19108 | 49 |
PTPRZ1 |
2.800e-02 | -3.58 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 6 | 19454 | 49 |
PARD3B,CTNNA2,PTPRZ1,NHSL1,DTNA,CTNND2 |
2.807e-02 | -3.57 | calcium ion transmembrane import into cytosol | biological process | GO:0097553 | 95 | 2 | 18204 | 50 |
RYR3,ITPR2 |
2.811e-02 | -3.57 | PI3K/AKT Signaling in Cancer | REACTOME pathways | R-HSA-2219528 | 90 | 2 | 10285 | 30 |
ERBB4,FGFR3 |
2.814e-02 | -3.57 | basolateral plasma membrane | cellular component | GO:0016323 | 257 | 3 | 19108 | 49 |
CADM1,SLC4A4,ERBB4 |
2.821e-02 | -3.57 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 47 |
SLC1A2 |
2.821e-02 | -3.57 | acetylcholine receptor binding | molecular function | GO:0033130 | 11 | 1 | 18094 | 47 |
NRXN1 |
2.832e-02 | -3.56 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 50 |
NKAIN3 |
2.842e-02 | -3.56 | Signaling by the B Cell Receptor (BCR) | REACTOME pathways | R-HSA-983705 | 229 | 3 | 10285 | 30 |
FGFR3,ERBB4,ITPR2 |
2.849e-02 | -3.56 | protein binding | molecular function | GO:0005515 | 13983 | 42 | 18094 | 47 |
DTNA,MSI2,SLC1A2,TNIK,SLC1A3,QKI,CDH20,RYR3,ABLIM1,GPC5,GPM6A,PTGDS,MAML2,AHCYL2,ERBB4,FGFR3,CADM1,CST3,ACSS1,RFX4,PITPNC1,SOX5,NTM,ATP1A2,RORA,CTNND2,LRIG1,FBXL7,HIF3A,COL5A3,PTPRZ1,NPAS3,NFIA,ITPR2,SLC4A4,LSAMP,PARD3B,SFXN5,TRPS1,MACF1,CTNNA2,NRXN1 |
2.865e-02 | -3.55 | urinary_tract-bladder-carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma | 14050 | 46 | 16828 | 49 |
MAML2,PREX2,PARD3B,NRXN1,ERBB4,NPAS3,SLC1A2,CTNND2,QKI,AHCYL2,ACSS1,ATP13A4,FGFR3,NCKAP5,MSI2,RFX4,SOX5,TRPS1,GPC5,SFXN5,COL5A3,PTGDS,ABLIM1,RORA,RYR3,SLC4A4,CADM1,LRIG1,NTM,ZBTB20,ATP1A2,DTNA,SLC1A3,FBXL7,HIF3A,TNIK,CDH20,NFIA,PTPRZ1,PITPNC1,ZNF98,MACF1,PCDH9,LSAMP,ITPR2,GPM6A |
2.865e-02 | -3.55 | soft_tissue-striated_muscle-rhabdomyosarcoma | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma | 594 | 5 | 16828 | 49 |
MACF1,COL5A3,CTNND2,PREX2,TRPS1 |
2.875e-02 | -3.55 | lung-carcinoma-pleomorphic_carcinoma | COSMIC cancer mutations | lung-carcinoma-pleomorphic_carcinoma | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | skin-back-malignant_melanoma-nodular | COSMIC cancer mutations | skin-back-malignant_melanoma-nodular | 10 | 1 | 16828 | 49 |
PREX2 |
2.875e-02 | -3.55 | chiasm | COSMIC cancer mutations | chiasm | 10 | 1 | 16828 | 49 |
QKI |
2.875e-02 | -3.55 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | renal_cell_carcinoma_unclassified | COSMIC cancer mutations | renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | intradermal | COSMIC cancer mutations | intradermal | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | kidney-carcinoma-renal_cell_carcinoma_unclassified | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.878e-02 | -3.55 | BEND3 (BEN domain containing 3) | protein interactions | 57673 | 105 | 2 | 19454 | 49 |
TNIK,TRPS1 |
2.878e-02 | -3.55 | IRF2BP2 (interferon regulatory factor 2 binding protein 2) | protein interactions | 359948 | 105 | 2 | 19454 | 49 |
NFIA,ERBB4 |
2.880e-02 | -3.55 | PI3K events in ERBB4 signaling | REACTOME pathways | R-HSA-1250342 | 10 | 1 | 10285 | 30 |
ERBB4 |
2.880e-02 | -3.55 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 30 |
FGFR3 |
2.896e-02 | -3.54 | Methionine degradation | KEGG pathways | M00035 | 10 | 1 | 7161 | 21 |
AHCYL2 |
2.896e-02 | -3.54 | Methionine degradation | KEGG pathways | hsa_M00035 | 10 | 1 | 7161 | 21 |
AHCYL2 |
2.917e-02 | -3.53 | nerve development | biological process | GO:0021675 | 97 | 2 | 18204 | 50 |
SLC1A3,LRIG1 |
2.917e-02 | -3.53 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
2.927e-02 | -3.53 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 30 |
NTM,LSAMP |
2.929e-02 | -3.53 | USP30 (ubiquitin specific peptidase 30) | protein interactions | 84749 | 106 | 2 | 19454 | 49 |
FGFR3,QKI |
2.931e-02 | -3.53 | Fib_collagen_C | interpro domains | IPR000885 | 11 | 1 | 18521 | 50 |
COL5A3 |
2.933e-02 | -3.53 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 43 |
SLC4A4 |
2.972e-02 | -3.52 | kidney-carcinoma | COSMIC cancer mutations | kidney-carcinoma | 3720 | 17 | 16828 | 49 |
RORA,MSI2,ITPR2,FGFR3,LRIG1,CTNND2,QKI,PITPNC1,PTPRZ1,ERBB4,TRPS1,TNIK,PREX2,SOX5,HIF3A,FBXL7,MAML2 |
2.981e-02 | -3.51 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | intracellular mRNA localization | biological process | GO:0008298 | 11 | 1 | 18204 | 50 |
QKI |
2.981e-02 | -3.51 | polyamine transport | biological process | GO:0015846 | 11 | 1 | 18204 | 50 |
ATP13A4 |
2.981e-02 | -3.51 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 50 |
RYR3 |
2.982e-02 | -3.51 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 49 |
SLC4A4 |
2.982e-02 | -3.51 | IL15 (interleukin 15) | protein interactions | 3600 | 12 | 1 | 19454 | 49 |
LRIG1 |
2.982e-02 | -3.51 | PTPN20 (protein tyrosine phosphatase non-receptor type 20) | protein interactions | 26095 | 12 | 1 | 19454 | 49 |
ERBB4 |
2.982e-02 | -3.51 | SMIM20 (small integral membrane protein 20) | protein interactions | 389203 | 12 | 1 | 19454 | 49 |
ERBB4 |
2.982e-02 | -3.51 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 49 |
TNIK |
2.982e-02 | -3.51 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 49 |
GPM6A |
2.999e-02 | -3.51 | regulation of synapse organization | biological process | GO:0050807 | 246 | 3 | 18204 | 50 |
GPM6A,CTNNA2,NRXN1 |
2.999e-02 | -3.51 | positive regulation of neurogenesis | biological process | GO:0050769 | 246 | 3 | 18204 | 50 |
QKI,MACF1,PTPRZ1 |
3.007e-02 | -3.50 | VHP | smart domains | SM00153 | 8 | 1 | 9717 | 37 |
ABLIM1 |
3.012e-02 | -3.50 | ATXN1 (ataxin 1) | protein interactions | 6310 | 469 | 4 | 19454 | 49 |
QKI,NFIA,CST3,PTGDS |
3.031e-02 | -3.50 | PAX8 (paired box 8) | protein interactions | 7849 | 108 | 2 | 19454 | 49 |
TRPS1,NFIA |
3.031e-02 | -3.50 | CAMKV (CaM kinase like vesicle associated) | protein interactions | 79012 | 108 | 2 | 19454 | 49 |
AHCYL2,GPM6A |
3.034e-02 | -3.50 | response to wounding | biological process | GO:0009611 | 431 | 4 | 18204 | 50 |
NFIA,MACF1,SLC1A3,SLC1A2 |
3.034e-02 | -3.50 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 4 | 18204 | 50 |
NRXN1,SLC1A2,SLC1A3,DTNA |
3.034e-02 | -3.50 | g-Secretase Mediated ErbB4 Signalling Pathway | SMPDB pathways | SMP0089975 | 7 | 1 | 1369 | 6 |
ERBB4 |
3.034e-02 | -3.50 | Ethanol Degradation | SMPDB pathways | SMP0000449 | 7 | 1 | 1369 | 6 |
ACSS1 |
3.035e-02 | -3.49 | synapse-associated extracellular matrix | cellular component | GO:0099535 | 12 | 1 | 19108 | 49 |
PTPRZ1 |
3.035e-02 | -3.49 | fibrillar collagen trimer | cellular component | GO:0005583 | 12 | 1 | 19108 | 49 |
COL5A3 |
3.035e-02 | -3.49 | banded collagen fibril | cellular component | GO:0098643 | 12 | 1 | 19108 | 49 |
COL5A3 |
3.035e-02 | -3.49 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 49 |
ATP1A2 |
3.046e-02 | -3.49 | Negative regulation of the PI3K/AKT network | REACTOME pathways | R-HSA-199418 | 94 | 2 | 10285 | 30 |
FGFR3,ERBB4 |
3.049e-02 | -3.49 | COLFI | pfam domains | PF01410 | 11 | 1 | 17795 | 50 |
COL5A3 |
3.049e-02 | -3.49 | PAS_11 | pfam domains | PF14598 | 11 | 1 | 17795 | 50 |
HIF3A |
3.049e-02 | -3.49 | LRRCT | pfam domains | PF01463 | 11 | 1 | 17795 | 50 |
LRIG1 |
3.060e-02 | -3.49 | CYSTATIN | prosite domains | PS00287 | 9 | 1 | 12186 | 42 |
CST3 |
3.060e-02 | -3.49 | RFX_DBD | prosite domains | PS51526 | 9 | 1 | 12186 | 42 |
RFX4 |
3.063e-02 | -3.49 | spleen | COSMIC cancer mutations | spleen | 408 | 4 | 16828 | 49 |
TNIK,PTPRZ1,PARD3B,NTM |
3.074e-02 | -3.48 | inositol 1,4,5 trisphosphate binding | molecular function | GO:0070679 | 12 | 1 | 18094 | 47 |
ITPR2 |
3.079e-02 | -3.48 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 4 | 18204 | 50 |
ATP13A4,SLC1A3,RYR3,ATP1A2 |
3.083e-02 | -3.48 | MIR34B (microRNA 34b) | protein interactions | 407041 | 109 | 2 | 19454 | 49 |
MSI2,QKI |
3.087e-02 | -3.48 | eye | COSMIC cancer mutations | eye | 606 | 5 | 16828 | 49 |
PREX2,CTNND2,FGFR3,PCDH9,MACF1 |
3.106e-02 | -3.47 | RDX (radixin) | protein interactions | 5962 | 272 | 3 | 19454 | 49 |
MACF1,FGFR3,ABLIM1 |
3.139e-02 | -3.46 | calcium ion binding | molecular function | GO:0005509 | 683 | 5 | 18094 | 47 |
PCDH9,ITPR2,MACF1,RYR3,NRXN1 |
3.149e-02 | -3.46 | RNA polymerase II cis-regulatory region sequence-specific DNA binding | molecular function | GO:0000978 | 1180 | 7 | 18094 | 47 |
RORA,SOX5,HIF3A,ZBTB20,ZNF98,NFIA,RFX4 |
3.151e-02 | -3.46 | steroid binding | molecular function | GO:0005496 | 107 | 2 | 18094 | 47 |
RORA,ATP1A2 |
3.157e-02 | -3.46 | calcium ion transport | biological process | GO:0006816 | 251 | 3 | 18204 | 50 |
ITPR2,GPM6A,RYR3 |
3.158e-02 | -3.46 | skin-scalp-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-neck-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-neck-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-back-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-back-malignant_melanoma-superficial_spreading | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | prostate-hyperplasia | COSMIC cancer mutations | prostate-hyperplasia | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | kidney-other-oncocytoma | COSMIC cancer mutations | kidney-other-oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | seborrhoeic_keratosis | COSMIC cancer mutations | seborrhoeic_keratosis | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | congenital | COSMIC cancer mutations | congenital | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | oncocytoma | COSMIC cancer mutations | oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | pleomorphic_carcinoma | COSMIC cancer mutations | pleomorphic_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-hand-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-hand-malignant_melanoma-acral_lentiginous | 11 | 1 | 16828 | 49 |
PREX2 |
3.189e-02 | -3.45 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 3 | 18204 | 50 |
GPM6A,CTNNA2,NRXN1 |
3.193e-02 | -3.44 | Lipocalin | interpro domains | IPR002345 | 12 | 1 | 18521 | 50 |
PTGDS |
3.193e-02 | -3.44 | Lipocalin_CS | interpro domains | IPR022272 | 12 | 1 | 18521 | 50 |
PTGDS |
3.193e-02 | -3.44 | MAD_homology1_Dwarfin-type | interpro domains | IPR003619 | 12 | 1 | 18521 | 50 |
NFIA |
3.226e-02 | -3.43 | Rbm47 (RNA binding motif protein 47) | protein interactions | 245945 | 13 | 1 | 19454 | 49 |
QKI |
3.226e-02 | -3.43 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 49 |
NTM |
3.226e-02 | -3.43 | PCDHA2 (protocadherin alpha 2) | protein interactions | 56146 | 13 | 1 | 19454 | 49 |
NFIA |
3.226e-02 | -3.43 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 49 |
GPM6A |
3.226e-02 | -3.43 | MYO16 (myosin XVI) | protein interactions | 23026 | 13 | 1 | 19454 | 49 |
NRXN1 |
3.233e-02 | -3.43 | ACTB (actin beta) | protein interactions | 60 | 958 | 6 | 19454 | 49 |
SFXN5,AHCYL2,DTNA,NHSL1,MACF1,ABLIM1 |
3.240e-02 | -3.43 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 3 | 18521 | 50 |
RYR3,DTNA,MACF1 |
3.241e-02 | -3.43 | CEP170P1 (centrosomal protein 170 pseudogene 1) | protein interactions | 645455 | 112 | 2 | 19454 | 49 |
MACF1,TRPS1 |
3.241e-02 | -3.43 | EDA (ectodysplasin A) | protein interactions | 1896 | 112 | 2 | 19454 | 49 |
ERBB4,GPM6A |
3.248e-02 | -3.43 | microglia differentiation | biological process | GO:0014004 | 12 | 1 | 18204 | 50 |
QKI |
3.248e-02 | -3.43 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 50 |
SLC1A2 |
3.248e-02 | -3.43 | regulation of blood vessel remodeling | biological process | GO:0060312 | 12 | 1 | 18204 | 50 |
CST3 |
3.248e-02 | -3.43 | negative regulation of collagen metabolic process | biological process | GO:0010713 | 12 | 1 | 18204 | 50 |
CST3 |
3.302e-02 | -3.41 | endoplasmic reticulum | cellular component | GO:0005783 | 2051 | 10 | 19108 | 49 |
NRXN1,ITPR2,CST3,FGFR3,AHCYL2,RYR3,ATP13A4,COL5A3,ATP1A2,PTGDS |
3.310e-02 | -3.41 | bladder | COSMIC cancer mutations | bladder | 14112 | 46 | 16828 | 49 |
CDH20,ZNF98,PITPNC1,PTPRZ1,NFIA,HIF3A,FBXL7,TNIK,LSAMP,ITPR2,PCDH9,MACF1,GPM6A,CADM1,SLC4A4,RYR3,NTM,LRIG1,SLC1A3,ATP1A2,DTNA,ZBTB20,TRPS1,SOX5,ABLIM1,PTGDS,RORA,SFXN5,GPC5,COL5A3,NRXN1,PARD3B,AHCYL2,CTNND2,QKI,SLC1A2,NPAS3,ERBB4,MAML2,PREX2,NCKAP5,FGFR3,ATP13A4,RFX4,MSI2,ACSS1 |
3.310e-02 | -3.41 | urinary_tract | COSMIC cancer mutations | urinary_tract | 14112 | 46 | 16828 | 49 |
NTM,LRIG1,SLC1A3,DTNA,ATP1A2,ZBTB20,SLC4A4,RYR3,CADM1,MACF1,PCDH9,LSAMP,ITPR2,GPM6A,HIF3A,FBXL7,TNIK,CDH20,PITPNC1,ZNF98,NFIA,PTPRZ1,ACSS1,NCKAP5,ATP13A4,FGFR3,RFX4,MSI2,MAML2,PREX2,PARD3B,NRXN1,SLC1A2,CTNND2,AHCYL2,QKI,NPAS3,ERBB4,SFXN5,GPC5,COL5A3,ABLIM1,PTGDS,RORA,SOX5,TRPS1 |
3.321e-02 | -3.40 | MH1 | pfam domains | PF03165 | 12 | 1 | 17795 | 50 |
NFIA |
3.326e-02 | -3.40 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 47 |
SLC4A4 |
3.326e-02 | -3.40 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 47 |
ATP1A2 |
3.334e-02 | -3.40 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 6 | 19454 | 49 |
PARD3B,FGFR3,NHSL1,MACF1,PITPNC1,ABLIM1 |
3.342e-02 | -3.40 | EV release from cardiac cells and their functional effects | WikiPathways | WP3297 | 9 | 1 | 5310 | 20 |
ERBB4 |
3.351e-02 | -3.40 | cell fate commitment | biological process | GO:0045165 | 257 | 3 | 18204 | 50 |
ERBB4,SOX5,NFIA |
3.389e-02 | -3.38 | human chr7q31.32 | chromosome location | human chr7q31.32 | 18 | 1 | 26134 | 50 |
PTPRZ1 |
3.389e-02 | -3.38 | human chr18q21.33 | chromosome location | human chr18q21.33 | 18 | 1 | 26134 | 50 |
CDH20 |
3.394e-02 | -3.38 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 18 |
SLC4A4 |
3.401e-02 | -3.38 | CAV1 (caveolin 1) | protein interactions | 857 | 719 | 5 | 19454 | 49 |
MACF1,SLC1A3,AHCYL2,DTNA,TNIK |
3.401e-02 | -3.38 | TBXT (T-box transcription factor T) | protein interactions | 6862 | 115 | 2 | 19454 | 49 |
NFIA,TRPS1 |
3.418e-02 | -3.38 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 11 | 16828 | 49 |
ATP1A2,DTNA,PREX2,TNIK,SLC4A4,SOX5,TRPS1,NFIA,PTPRZ1,ERBB4,FGFR3 |
3.427e-02 | -3.37 | adrenal_gland | COSMIC cancer mutations | adrenal_gland | 2628 | 13 | 16828 | 49 |
MAML2,SOX5,NHSL1,PTPRZ1,CTNND2,SLC1A2,ZBTB20,ATP1A2,LRIG1,RFX4,FGFR3,PCDH9,NCKAP5 |
3.440e-02 | -3.37 | skin-benign_melanocytic_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-abdomen-malignant_melanoma-nodular | COSMIC cancer mutations | skin-abdomen-malignant_melanoma-nodular | 12 | 1 | 16828 | 49 |
PREX2 |
3.440e-02 | -3.37 | central_nervous_system-fourth_ventricle-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-fourth_ventricle-glioma-astrocytoma_Grade_I | 12 | 1 | 16828 | 49 |
QKI |
3.440e-02 | -3.37 | skin-face-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-basal_cell_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | cervix-carcinoma-mixed_adenosquamous_carcinoma | COSMIC cancer mutations | cervix-carcinoma-mixed_adenosquamous_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.446e-02 | -3.37 | Signaling by activated point mutants of FGFR3 | REACTOME pathways | R-HSA-1839130 | 12 | 1 | 10285 | 30 |
FGFR3 |
3.446e-02 | -3.37 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 30 |
GPC5 |
3.446e-02 | -3.37 | Regulation of gene expression by Hypoxia-inducible Factor | REACTOME pathways | R-HSA-1234158 | 12 | 1 | 10285 | 30 |
HIF3A |
3.446e-02 | -3.37 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 30 |
GPC5 |
3.446e-02 | -3.37 | Ethanol oxidation | REACTOME pathways | R-HSA-71384 | 12 | 1 | 10285 | 30 |
ACSS1 |
3.446e-02 | -3.37 | FGFR3 mutant receptor activation | REACTOME pathways | R-HSA-2033514 | 12 | 1 | 10285 | 30 |
FGFR3 |
3.448e-02 | -3.37 | cis-regulatory region sequence-specific DNA binding | molecular function | GO:0000987 | 1203 | 7 | 18094 | 47 |
SOX5,RORA,HIF3A,ZNF98,ZBTB20,NFIA,RFX4 |
3.462e-02 | -3.36 | Bile Acid Indirect Signalling Pathway | SMPDB pathways | SMP0086851 | 8 | 1 | 1369 | 6 |
FGFR3 |
3.470e-02 | -3.36 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 49 |
SLC1A2 |
3.470e-02 | -3.36 | DACT2 (dishevelled binding antagonist of beta catenin 2) | protein interactions | 168002 | 14 | 1 | 19454 | 49 |
ZBTB20 |
3.470e-02 | -3.36 | SYT5 (synaptotagmin 5) | protein interactions | 6861 | 14 | 1 | 19454 | 49 |
NRXN1 |
3.470e-02 | -3.36 | FGF7 (fibroblast growth factor 7) | protein interactions | 2252 | 14 | 1 | 19454 | 49 |
FGFR3 |
3.470e-02 | -3.36 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 1 | 19454 | 49 |
GPM6A |
3.470e-02 | -3.36 | Asap1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain1) | protein interactions | 13196 | 14 | 1 | 19454 | 49 |
MACF1 |
3.470e-02 | -3.36 | MB (myoglobin) | protein interactions | 4151 | 14 | 1 | 19454 | 49 |
MAML2 |
3.470e-02 | -3.36 | CTSO (cathepsin O) | protein interactions | 1519 | 14 | 1 | 19454 | 49 |
CST3 |
3.470e-02 | -3.36 | VSX2 (visual system homeobox 2) | protein interactions | 338917 | 14 | 1 | 19454 | 49 |
AHCYL2 |
3.479e-02 | -3.36 | phosphatidylinositol binding | molecular function | GO:0035091 | 276 | 3 | 18094 | 47 |
ITPR2,PITPNC1,PARD3B |
3.481e-02 | -3.36 | Disease | REACTOME pathways | R-HSA-1643685 | 858 | 6 | 10285 | 30 |
QKI,MACF1,FGFR3,ERBB4,GPC5,MAML2 |
3.484e-02 | -3.36 | cell-cell adhesion via plasma-membrane adhesion molecules | biological process | GO:0098742 | 261 | 3 | 18204 | 50 |
CADM1,CDH20,PCDH9 |
3.500e-02 | -3.35 | Cadherin_CS | interpro domains | IPR020894 | 109 | 2 | 18521 | 50 |
PCDH9,CDH20 |
3.500e-02 | -3.35 | Ion_trans_dom | interpro domains | IPR005821 | 109 | 2 | 18521 | 50 |
RYR3,ITPR2 |
3.510e-02 | -3.35 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 43 |
CTNNA2 |
3.510e-02 | -3.35 | SYT6 (synaptotagmin 6) | protein interactions | 148281 | 117 | 2 | 19454 | 49 |
AHCYL2,NRXN1 |
3.510e-02 | -3.35 | ELK3 (ETS transcription factor ELK3) | protein interactions | 2004 | 117 | 2 | 19454 | 49 |
NFIA,TRPS1 |
3.514e-02 | -3.35 | cerebellar Purkinje cell differentiation | biological process | GO:0021702 | 13 | 1 | 18204 | 50 |
RORA |
3.514e-02 | -3.35 | postsynaptic specialization assembly | biological process | GO:0098698 | 13 | 1 | 18204 | 50 |
NRXN1 |
3.514e-02 | -3.35 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 50 |
ATP1A2 |
3.514e-02 | -3.35 | T-helper 17 cell differentiation | biological process | GO:0072539 | 13 | 1 | 18204 | 50 |
RORA |
3.514e-02 | -3.35 | olfactory bulb interneuron differentiation | biological process | GO:0021889 | 13 | 1 | 18204 | 50 |
ERBB4 |
3.514e-02 | -3.35 | glial cell fate commitment | biological process | GO:0021781 | 13 | 1 | 18204 | 50 |
NFIA |
3.514e-02 | -3.35 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 50 |
ATP1A2 |
3.514e-02 | -3.35 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 50 |
CTNNA2 |
3.545e-02 | -3.34 | NEDD4 (NEDD4 E3 ubiquitin protein ligase) | protein interactions | 4734 | 494 | 4 | 19454 | 49 |
TNIK,FGFR3,MAML2,ERBB4 |
3.553e-02 | -3.34 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 48 | 16828 | 49 |
RORA,PTGDS,ABLIM1,NKAIN3,COL5A3,GPC5,SFXN5,TRPS1,SOX5,MSI2,RFX4,ATP13A4,FGFR3,NCKAP5,ACSS1,ERBB4,NPAS3,SLC1A2,CTNND2,QKI,AHCYL2,NRXN1,PARD3B,PREX2,MAML2,GPM6A,PCDH9,MACF1,ITPR2,LSAMP,NFIA,PTPRZ1,PITPNC1,ZNF98,CDH20,TNIK,FBXL7,HIF3A,ZBTB20,DTNA,ATP1A2,SLC1A3,LRIG1,NTM,CADM1,RYR3,NHSL1,SLC4A4 |
3.565e-02 | -3.33 | PLCD3 (phospholipase C delta 3) | protein interactions | 113026 | 118 | 2 | 19454 | 49 |
TNIK,AHCYL2 |
3.567e-02 | -3.33 | OCLN (occludin) | protein interactions | 100506658 | 495 | 4 | 19454 | 49 |
ABLIM1,MACF1,DTNA,TNIK |
3.574e-02 | -3.33 | human chr6q24.1 | chromosome location | human chr6q24.1 | 19 | 1 | 26134 | 50 |
NHSL1 |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.574e-02 | -3.33 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 50 |
CTNND2 |
3.577e-02 | -3.33 | microtubule minus-end binding | molecular function | GO:0051011 | 14 | 1 | 18094 | 47 |
MACF1 |
3.581e-02 | -3.33 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | 249 | 3 | 16828 | 49 |
MACF1,FGFR3,PTPRZ1 |
3.612e-02 | -3.32 | long-chain fatty acid metabolic process | biological process | GO:0001676 | 109 | 2 | 18204 | 50 |
QKI,PTGDS |
3.612e-02 | -3.32 | postsynapse organization | biological process | GO:0099173 | 109 | 2 | 18204 | 50 |
NRXN1,CTNND2 |
3.617e-02 | -3.32 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 3 | 16828 | 49 |
TNIK,MACF1,FGFR3 |
3.621e-02 | -3.32 | regulation of nervous system development | biological process | GO:0051960 | 456 | 4 | 18204 | 50 |
MACF1,QKI,NRXN1,PTPRZ1 |
3.646e-02 | -3.31 | skin-scalp-malignant_melanoma | COSMIC cancer mutations | skin-scalp-malignant_melanoma | 634 | 5 | 16828 | 49 |
ERBB4,PREX2,PTPRZ1,NFIA,NTM |
3.676e-02 | -3.30 | HOXB9 (homeobox B9) | protein interactions | 3219 | 120 | 2 | 19454 | 49 |
NFIA,AHCYL2 |
3.678e-02 | -3.30 | HLH_DNA-bd_sf | interpro domains | IPR036638 | 112 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.678e-02 | -3.30 | bHLH_dom | interpro domains | IPR011598 | 112 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.695e-02 | -3.30 | small molecule biosynthetic process | biological process | GO:0044283 | 459 | 4 | 18204 | 50 |
SLC1A3,QKI,ACSS1,PTGDS |
3.695e-02 | -3.30 | synaptic signaling | biological process | GO:0099536 | 459 | 4 | 18204 | 50 |
DTNA,SLC1A2,SLC1A3,NRXN1 |
3.702e-02 | -3.30 | TyrKc | smart domains | SM00219 | 80 | 2 | 9717 | 37 |
ERBB4,FGFR3 |
3.714e-02 | -3.29 | FGF9 (fibroblast growth factor 9) | protein interactions | 2254 | 15 | 1 | 19454 | 49 |
FGFR3 |
3.714e-02 | -3.29 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 1 | 19454 | 49 |
TNIK |
3.714e-02 | -3.29 | TESPA1 (thymocyte expressed, positive selection associated 1) | protein interactions | 9840 | 15 | 1 | 19454 | 49 |
ITPR2 |
3.715e-02 | -3.29 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 14 | 18204 | 50 |
MACF1,SFXN5,NRXN1,ATP1A2,ZBTB20,PTPRZ1,CST3,ERBB4,RORA,CADM1,TRPS1,PTGDS,SOX5,QKI |
3.721e-02 | -3.29 | skin-shoulder-malignant_melanoma-nodular | COSMIC cancer mutations | skin-shoulder-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | Brenner_tumour | COSMIC cancer mutations | Brenner_tumour | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | endometrium-ovary-endometriosis | COSMIC cancer mutations | endometrium-ovary-endometriosis | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_I | 13 | 1 | 16828 | 49 |
QKI |
3.721e-02 | -3.29 | skin-scalp-malignant_melanoma-nodular | COSMIC cancer mutations | skin-scalp-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | cervix-carcinoma-adenocarcinoma | COSMIC cancer mutations | cervix-carcinoma-adenocarcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-back-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-back-carcinoma-basal_cell_carcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.728e-02 | -3.29 | LIPOCALIN | prosite domains | PS00213 | 11 | 1 | 12186 | 42 |
PTGDS |
3.728e-02 | -3.29 | NC1_FIB | prosite domains | PS51461 | 11 | 1 | 12186 | 42 |
COL5A3 |
3.728e-02 | -3.29 | GATA_ZN_FINGER_2 | prosite domains | PS50114 | 11 | 1 | 12186 | 42 |
TRPS1 |
3.728e-02 | -3.29 | Phospholipase C-mediated cascade; FGFR3 | REACTOME pathways | R-HSA-5654227 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.728e-02 | -3.29 | CLEC7A (Dectin-1) induces NFAT activation | REACTOME pathways | R-HSA-5607763 | 13 | 1 | 10285 | 30 |
ITPR2 |
3.728e-02 | -3.29 | NOTCH2 intracellular domain regulates transcription | REACTOME pathways | R-HSA-2197563 | 13 | 1 | 10285 | 30 |
MAML2 |
3.728e-02 | -3.29 | ERBB2 Activates PTK6 Signaling | REACTOME pathways | R-HSA-8847993 | 13 | 1 | 10285 | 30 |
ERBB4 |
3.728e-02 | -3.29 | Notch-HLH transcription pathway | REACTOME pathways | R-HSA-350054 | 13 | 1 | 10285 | 30 |
MAML2 |
3.728e-02 | -3.29 | FGFR3c ligand binding and activation | REACTOME pathways | R-HSA-190372 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.728e-02 | -3.29 | FGFR3 ligand binding and activation | REACTOME pathways | R-HSA-190239 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.732e-02 | -3.29 | MED15 (mediator complex subunit 15) | protein interactions | 51586 | 121 | 2 | 19454 | 49 |
QKI,NFIA |
3.750e-02 | -3.28 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 2 | 16828 | 49 |
GPC5,QKI |
3.764e-02 | -3.28 | Ion_trans | pfam domains | PF00520 | 109 | 2 | 17795 | 50 |
RYR3,ITPR2 |
3.771e-02 | -3.28 | protein localization to membrane | biological process | GO:0072657 | 462 | 4 | 18204 | 50 |
TNIK,ERBB4,MACF1,NRXN1 |
3.779e-02 | -3.28 | neurotransmitter receptor localization to postsynaptic specialization membrane | biological process | GO:0099645 | 14 | 1 | 18204 | 50 |
ERBB4 |
3.779e-02 | -3.28 | protein localization to postsynaptic specialization membrane | biological process | GO:0099633 | 14 | 1 | 18204 | 50 |
ERBB4 |
3.779e-02 | -3.28 | acetyl-CoA biosynthetic process | biological process | GO:0006085 | 14 | 1 | 18204 | 50 |
ACSS1 |
3.779e-02 | -3.28 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 50 |
ATP1A2 |
3.779e-02 | -3.28 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 50 |
SLC1A2 |
3.779e-02 | -3.28 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 50 |
RYR3 |
3.779e-02 | -3.28 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 50 |
ATP1A2 |
3.779e-02 | -3.28 | cellular response to ethanol | biological process | GO:0071361 | 14 | 1 | 18204 | 50 |
ITPR2 |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
SLC1A2 |
3.788e-02 | -3.27 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 49 |
NHSL1,DTNA |
3.794e-02 | -3.27 | regulation of gliogenesis | biological process | GO:0014013 | 112 | 2 | 18204 | 50 |
PTPRZ1,QKI |
3.798e-02 | -3.27 | Cadherin-like_dom | interpro domains | IPR002126 | 114 | 2 | 18521 | 50 |
CDH20,PCDH9 |
3.828e-02 | -3.26 | AMP binding | molecular function | GO:0016208 | 15 | 1 | 18094 | 47 |
ACSS1 |
3.828e-02 | -3.26 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 47 |
PITPNC1 |
3.844e-02 | -3.26 | SPSB4 (splA/ryanodine receptor domain and SOCS box containing 4) | protein interactions | 92369 | 123 | 2 | 19454 | 49 |
PCDH9,LRIG1 |
3.844e-02 | -3.26 | PAX7 (paired box 7) | protein interactions | 5081 | 123 | 2 | 19454 | 49 |
NFIA,TRPS1 |
3.848e-02 | -3.26 | VEGFR2 mediated cell proliferation | REACTOME pathways | R-HSA-5218921 | 258 | 3 | 10285 | 30 |
ERBB4,FGFR3,ITPR2 |
3.864e-02 | -3.25 | GATA | pfam domains | PF00320 | 14 | 1 | 17795 | 50 |
TRPS1 |
3.881e-02 | -3.25 | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 107 | 2 | 16828 | 49 |
PARD3B,HIF3A |
3.900e-02 | -3.24 | germ_cell_tumour | COSMIC cancer mutations | germ_cell_tumour | 867 | 6 | 16828 | 49 |
TRPS1,TNIK,PREX2,ERBB4,MACF1,FGFR3 |
3.904e-02 | -3.24 | secondary active transmembrane transporter activity | molecular function | GO:0015291 | 289 | 3 | 18094 | 47 |
SLC1A2,SLC4A4,SLC1A3 |
3.914e-02 | -3.24 | skin-leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-leg-malignant_melanoma-nodular | 258 | 3 | 16828 | 49 |
PTPRZ1,SLC4A4,ATP13A4 |
3.918e-02 | -3.24 | regulation of circadian rhythm | biological process | GO:0042752 | 114 | 2 | 18204 | 50 |
PTGDS,RORA |
3.920e-02 | -3.24 | Cadherin-like_sf | interpro domains | IPR015919 | 116 | 2 | 18521 | 50 |
CDH20,PCDH9 |
3.943e-02 | -3.23 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 50 |
GPC5 |
3.947e-02 | -3.23 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 5 | 16828 | 49 |
FGFR3,PREX2,TNIK,ERBB4,TRPS1 |
3.954e-02 | -3.23 | Cadherin | pfam domains | PF00028 | 112 | 2 | 17795 | 50 |
PCDH9,CDH20 |
3.956e-02 | -3.23 | SYTL2 (synaptotagmin like 2) | protein interactions | 54843 | 16 | 1 | 19454 | 49 |
NRXN1 |
3.956e-02 | -3.23 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 49 |
CTNNA2 |
3.956e-02 | -3.23 | Sumo3 (small ubiquitin-like modifier 3) | protein interactions | 20610 | 16 | 1 | 19454 | 49 |
ITPR2 |
3.956e-02 | -3.23 | CTSK (cathepsin K) | protein interactions | 1513 | 16 | 1 | 19454 | 49 |
FGFR3 |
3.956e-02 | -3.23 | SYT4 (synaptotagmin 4) | protein interactions | 6860 | 16 | 1 | 19454 | 49 |
NRXN1 |
3.956e-02 | -3.23 | NBL1 (NBL1, DAN family BMP antagonist) | protein interactions | 4681 | 16 | 1 | 19454 | 49 |
LRIG1 |
3.956e-02 | -3.23 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 49 |
CTNNA2 |
3.956e-02 | -3.23 | SYT9 (synaptotagmin 9) | protein interactions | 143425 | 16 | 1 | 19454 | 49 |
NRXN1 |
3.956e-02 | -3.23 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 1 | 19454 | 49 |
MACF1 |
3.956e-02 | -3.23 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 49 |
ZBTB20 |
3.956e-02 | -3.23 | TMEM134 (transmembrane protein 134) | protein interactions | 80194 | 16 | 1 | 19454 | 49 |
ERBB4 |
3.956e-02 | -3.23 | AMMECR1L (AMMECR1 like) | protein interactions | 83607 | 16 | 1 | 19454 | 49 |
MACF1 |
3.956e-02 | -3.23 | HLA-H (major histocompatibility complex, class I, H (pseudogene)) | protein interactions | 3136 | 16 | 1 | 19454 | 49 |
FGFR3 |
3.956e-02 | -3.23 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 49 |
TNIK |
3.967e-02 | -3.23 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 46 | 16828 | 49 |
DTNA,ATP1A2,SLC1A3,ZBTB20,NTM,LRIG1,SLC4A4,NHSL1,RYR3,CADM1,GPM6A,ITPR2,LSAMP,PCDH9,MACF1,TNIK,HIF3A,FBXL7,ZNF98,PITPNC1,PTPRZ1,NFIA,CDH20,ACSS1,RFX4,NCKAP5,FGFR3,ATP13A4,PREX2,MAML2,QKI,AHCYL2,CTNND2,SLC1A2,NPAS3,ERBB4,NRXN1,PARD3B,COL5A3,NKAIN3,SFXN5,GPC5,RORA,ABLIM1,SOX5,TRPS1 |
3.971e-02 | -3.23 | gliogenesis | biological process | GO:0042063 | 275 | 3 | 18204 | 50 |
PTPRZ1,QKI,NFIA |
3.975e-02 | -3.23 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 50 |
ATP1A2 |
3.975e-02 | -3.23 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 50 |
TNIK |
3.975e-02 | -3.23 | Znf_GATA | interpro domains | IPR000679 | 15 | 1 | 18521 | 50 |
TRPS1 |
4.002e-02 | -3.22 | soft_tissue-small_round_cell_tumour | COSMIC cancer mutations | soft_tissue-small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | in_situ_neoplasm | COSMIC cancer mutations | in_situ_neoplasm | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | small_round_cell_tumour | COSMIC cancer mutations | small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | endometriosis | COSMIC cancer mutations | endometriosis | 14 | 1 | 16828 | 49 |
FGFR3 |
4.008e-02 | -3.22 | learning or memory | biological process | GO:0007611 | 276 | 3 | 18204 | 50 |
NRXN1,PTPRZ1,ATP1A2 |
4.010e-02 | -3.22 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 30 |
ABLIM1 |
4.010e-02 | -3.22 | SHC1 events in ERBB4 signaling | REACTOME pathways | R-HSA-1250347 | 14 | 1 | 10285 | 30 |
ERBB4 |
4.016e-02 | -3.21 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 49 |
PITPNC1,GPM6A |
4.027e-02 | -3.21 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 1 | 19108 | 49 |
TNIK |
4.043e-02 | -3.21 | cerebellar Purkinje cell layer formation | biological process | GO:0021694 | 15 | 1 | 18204 | 50 |
RORA |
4.043e-02 | -3.21 | regulation of circadian sleep/wake cycle, sleep | biological process | GO:0045187 | 15 | 1 | 18204 | 50 |
PTGDS |
4.043e-02 | -3.21 | synapse maturation | biological process | GO:0060074 | 15 | 1 | 18204 | 50 |
NFIA |
4.043e-02 | -3.21 | neuroblast division | biological process | GO:0055057 | 15 | 1 | 18204 | 50 |
SOX5 |
4.043e-02 | -3.21 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 50 |
RYR3 |
4.043e-02 | -3.21 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 50 |
RYR3 |
4.043e-02 | -3.21 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 50 |
ATP1A2 |
4.043e-02 | -3.21 | chondrocyte proliferation | biological process | GO:0035988 | 15 | 1 | 18204 | 50 |
FGFR3 |
4.043e-02 | -3.21 | exit from mitosis | biological process | GO:0010458 | 15 | 1 | 18204 | 50 |
NFIA |
4.043e-02 | -3.21 | regulation of neuron projection arborization | biological process | GO:0150011 | 15 | 1 | 18204 | 50 |
MACF1 |
4.043e-02 | -3.21 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 50 |
SLC1A2 |
4.043e-02 | -3.21 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 50 |
ATP1A2 |
4.078e-02 | -3.20 | oxysterol binding | molecular function | GO:0008142 | 16 | 1 | 18094 | 47 |
RORA |
4.081e-02 | -3.20 | Circadian rythm related genes | WikiPathways | WP3594 | 207 | 3 | 5310 | 20 |
PTGDS,CST3,RORA |
4.083e-02 | -3.20 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 12 | 16828 | 49 |
NHSL1,RYR3,PREX2,CDH20,PARD3B,NFIA,TRPS1,NPAS3,SLC1A3,MACF1,NCKAP5,FGFR3 |
4.083e-02 | -3.20 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 12 | 16828 | 49 |
SLC1A3,MACF1,NCKAP5,FGFR3,NHSL1,RYR3,PREX2,PARD3B,CDH20,NPAS3,TRPS1,NFIA |
4.103e-02 | -3.19 | CDH1 (cadherin 1) | protein interactions | 999 | 757 | 5 | 19454 | 49 |
NHSL1,CTNNA2,MACF1,ABLIM1,CTNND2 |
4.112e-02 | -3.19 | COLFI | smart domains | SM00038 | 11 | 1 | 9717 | 37 |
COL5A3 |
4.132e-02 | -3.19 | SYT2 (synaptotagmin 2) | protein interactions | 127833 | 128 | 2 | 19454 | 49 |
NRXN1,AHCYL2 |
4.132e-02 | -3.19 | TEAD2 (TEA domain transcription factor 2) | protein interactions | 8463 | 128 | 2 | 19454 | 49 |
TRPS1,ZBTB20 |
4.132e-02 | -3.19 | MYB (MYB proto-oncogene, transcription factor) | protein interactions | 4602 | 128 | 2 | 19454 | 49 |
TRPS1,NFIA |
4.134e-02 | -3.19 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 50 |
TNIK |
4.134e-02 | -3.19 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 50 |
ATP1A2 |
4.152e-02 | -3.18 | PROTEIN_KINASE_TYR | prosite domains | PS00109 | 94 | 2 | 12186 | 42 |
ERBB4,FGFR3 |
4.168e-02 | -3.18 | positive regulation of phosphorus metabolic process | biological process | GO:0010562 | 697 | 5 | 18204 | 50 |
ERBB4,SLC4A4,FGFR3,TNIK,ZBTB20 |
4.168e-02 | -3.18 | positive regulation of phosphate metabolic process | biological process | GO:0045937 | 697 | 5 | 18204 | 50 |
FGFR3,TNIK,ZBTB20,ERBB4,SLC4A4 |
4.190e-02 | -3.17 | CHD7 (chromodomain helicase DNA binding protein 7) | protein interactions | 55636 | 129 | 2 | 19454 | 49 |
SOX5,ZBTB20 |
4.198e-02 | -3.17 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 49 |
DTNA |
4.198e-02 | -3.17 | Pef1 (penta-EF hand domain containing 1) | protein interactions | 67898 | 17 | 1 | 19454 | 49 |
QKI |
4.198e-02 | -3.17 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 49 |
GPC5 |
4.198e-02 | -3.17 | NOTCH4 (notch receptor 4) | protein interactions | 4855 | 17 | 1 | 19454 | 49 |
MAML2 |
4.198e-02 | -3.17 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 49 |
NTM |
4.198e-02 | -3.17 | SEPSECS (Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) | protein interactions | 51091 | 17 | 1 | 19454 | 49 |
ABLIM1 |
4.198e-02 | -3.17 | MSANTD2 (Myb/SANT DNA binding domain containing 2) | protein interactions | 79684 | 17 | 1 | 19454 | 49 |
SOX5 |
4.198e-02 | -3.17 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 49 |
GPM6A |
4.198e-02 | -3.17 | SHD (Src homology 2 domain containing transforming protein D) | protein interactions | 56961 | 17 | 1 | 19454 | 49 |
ERBB4 |
4.223e-02 | -3.16 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 3 | 16828 | 49 |
SOX5,RYR3,CDH20 |
4.265e-02 | -3.15 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 3 | 18204 | 50 |
CTNND2,MACF1,TNIK |
4.274e-02 | -3.15 | adenoid_cystic_carcinoma | COSMIC cancer mutations | adenoid_cystic_carcinoma | 1123 | 7 | 16828 | 49 |
TNIK,RYR3,MAML2,RORA,ERBB4,CTNND2,FGFR3 |
4.277e-02 | -3.15 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 3 | 19454 | 49 |
DTNA,MACF1,NRXN1 |
4.282e-02 | -3.15 | hypothalamus | COSMIC cancer mutations | hypothalamus | 15 | 1 | 16828 | 49 |
QKI |
4.282e-02 | -3.15 | ureter | COSMIC cancer mutations | ureter | 15 | 1 | 16828 | 49 |
FGFR3 |
4.290e-02 | -3.15 | ERBB2 Regulates Cell Motility | REACTOME pathways | R-HSA-6785631 | 15 | 1 | 10285 | 30 |
ERBB4 |
4.290e-02 | -3.15 | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | REACTOME pathways | R-HSA-2162123 | 15 | 1 | 10285 | 30 |
PTGDS |
4.294e-02 | -3.15 | Helix-loop-helix DNA-binding domain | gene3d domains | 4.10.280.10 | 111 | 2 | 14470 | 43 |
NPAS3,HIF3A |
4.307e-02 | -3.14 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | S-adenosylmethionine metabolic process | biological process | GO:0046500 | 16 | 1 | 18204 | 50 |
AHCYL2 |
4.307e-02 | -3.14 | neuron cell-cell adhesion | biological process | GO:0007158 | 16 | 1 | 18204 | 50 |
NRXN1 |
4.307e-02 | -3.14 | short-chain fatty acid metabolic process | biological process | GO:0046459 | 16 | 1 | 18204 | 50 |
ACSS1 |
4.307e-02 | -3.14 | asymmetric cell division | biological process | GO:0008356 | 16 | 1 | 18204 | 50 |
SOX5 |
4.307e-02 | -3.14 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 50 |
SLC1A3 |
4.307e-02 | -3.14 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 50 |
SLC1A2 |
4.308e-02 | -3.14 | TRPS1 (transcriptional repressor GATA binding 1) | protein interactions | 7227 | 131 | 2 | 19454 | 49 |
NFIA,SOX5 |
4.308e-02 | -3.14 | NCOA2 (nuclear receptor coactivator 2) | protein interactions | 10499 | 131 | 2 | 19454 | 49 |
RORA,NFIA |
4.308e-02 | -3.14 | ZNF609 (zinc finger protein 609) | protein interactions | 23060 | 131 | 2 | 19454 | 49 |
NFIA,SOX5 |
4.311e-02 | -3.14 | human chr2q34 | chromosome location | human chr2q34 | 23 | 1 | 26134 | 50 |
ERBB4 |
4.327e-02 | -3.14 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 1 | 18094 | 47 |
PTPRZ1 |
4.327e-02 | -3.14 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 1 | 18094 | 47 |
PTPRZ1 |
4.352e-02 | -3.13 | skin-chest-malignant_melanoma | COSMIC cancer mutations | skin-chest-malignant_melanoma | 114 | 2 | 16828 | 49 |
PREX2,ERBB4 |
4.379e-02 | -3.13 | export from cell | biological process | GO:0140352 | 485 | 4 | 18204 | 50 |
SLC4A4,NRXN1,ATP1A2,PTGDS |
4.381e-02 | -3.13 | TYRKINASE | prints domains | PR00109 | 98 | 2 | 5227 | 18 |
ERBB4,FGFR3 |
4.410e-02 | -3.12 | prostate-adenoma | COSMIC cancer mutations | prostate-adenoma | 1634 | 9 | 16828 | 49 |
MACF1,NPAS3,PTPRZ1,ERBB4,GPC5,HIF3A,SOX5,ZBTB20,COL5A3 |
4.432e-02 | -3.12 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 20 |
RYR3 |
4.440e-02 | -3.11 | Cnot2 (CCR4-NOT transcription complex, subunit 2) | protein interactions | 72068 | 18 | 1 | 19454 | 49 |
MACF1 |
4.440e-02 | -3.11 | PTGFR (prostaglandin F receptor) | protein interactions | 5737 | 18 | 1 | 19454 | 49 |
PTGDS |
4.440e-02 | -3.11 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 49 |
NTM |
4.440e-02 | -3.11 | TTC29 (tetratricopeptide repeat domain 29) | protein interactions | 83894 | 18 | 1 | 19454 | 49 |
MACF1 |
4.440e-02 | -3.11 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 1 | 19454 | 49 |
FGFR3 |
4.477e-02 | -3.11 | DWA | smart domains | SM00523 | 12 | 1 | 9717 | 37 |
NFIA |
4.477e-02 | -3.11 | ZnF_GATA | smart domains | SM00401 | 12 | 1 | 9717 | 37 |
TRPS1 |
4.487e-02 | -3.10 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 2 | 19454 | 49 |
NTM,GPM6A |
4.493e-02 | -3.10 | CA_dom | interpro domains | IPR001148 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | PAC | interpro domains | IPR001610 | 17 | 1 | 18521 | 50 |
HIF3A |
4.493e-02 | -3.10 | Cystatin_dom | interpro domains | IPR000010 | 17 | 1 | 18521 | 50 |
CST3 |
4.493e-02 | -3.10 | CA_dom_sf | interpro domains | IPR036398 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | AMP-bd_C | interpro domains | IPR025110 | 17 | 1 | 18521 | 50 |
ACSS1 |
4.506e-02 | -3.10 | Cadherins | gene3d domains | 2.60.40.60 | 114 | 2 | 14470 | 43 |
PCDH9,CDH20 |
4.507e-02 | -3.10 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 49 | 16828 | 49 |
SFXN5,GPC5,COL5A3,NKAIN3,ABLIM1,PTGDS,RORA,SOX5,TRPS1,ACSS1,NCKAP5,ATP13A4,FGFR3,RFX4,CST3,MSI2,MAML2,PREX2,PARD3B,NRXN1,SLC1A2,QKI,AHCYL2,CTNND2,NPAS3,ERBB4,PCDH9,MACF1,ITPR2,LSAMP,GPM6A,HIF3A,FBXL7,TNIK,CDH20,PITPNC1,ZNF98,NFIA,PTPRZ1,NTM,LRIG1,ATP1A2,SLC1A3,DTNA,ZBTB20,SLC4A4,NHSL1,RYR3,CADM1 |
4.547e-02 | -3.09 | SOX15 (SRY-box transcription factor 15) | protein interactions | 6665 | 135 | 2 | 19454 | 49 |
TRPS1,NFIA |
4.547e-02 | -3.09 | FOXP1 (forkhead box P1) | protein interactions | 27086 | 135 | 2 | 19454 | 49 |
NFIA,SOX5 |
4.557e-02 | -3.09 | salivary_gland | COSMIC cancer mutations | salivary_gland | 1139 | 7 | 16828 | 49 |
TNIK,RYR3,MAML2,CTNND2,ERBB4,RORA,FGFR3 |
4.561e-02 | -3.09 | renal_pelvis | COSMIC cancer mutations | renal_pelvis | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | urinary_tract-carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | flank | COSMIC cancer mutations | flank | 16 | 1 | 16828 | 49 |
FGFR3 |
4.570e-02 | -3.09 | PI3K events in ERBB2 signaling | REACTOME pathways | R-HSA-1963642 | 16 | 1 | 10285 | 30 |
ERBB4 |
4.570e-02 | -3.09 | GRB2 events in ERBB2 signaling | REACTOME pathways | R-HSA-1963640 | 16 | 1 | 10285 | 30 |
ERBB4 |
4.570e-02 | -3.09 | mammary gland epithelial cell differentiation | biological process | GO:0060644 | 17 | 1 | 18204 | 50 |
ERBB4 |
4.570e-02 | -3.09 | ureter development | biological process | GO:0072189 | 17 | 1 | 18204 | 50 |
NFIA |
4.570e-02 | -3.09 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 50 |
SLC1A2 |
4.570e-02 | -3.09 | T-helper 17 type immune response | biological process | GO:0072538 | 17 | 1 | 18204 | 50 |
RORA |
4.570e-02 | -3.09 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 1 | 18204 | 50 |
ATP1A2 |
4.570e-02 | -3.09 | T cell mediated cytotoxicity | biological process | GO:0001913 | 17 | 1 | 18204 | 50 |
CADM1 |
4.570e-02 | -3.09 | cGMP metabolic process | biological process | GO:0046068 | 17 | 1 | 18204 | 50 |
RORA |
4.570e-02 | -3.09 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 50 |
ATP1A2 |
4.570e-02 | -3.09 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 50 |
RYR3 |
4.570e-02 | -3.09 | viral genome replication | biological process | GO:0019079 | 17 | 1 | 18204 | 50 |
NFIA |
4.570e-02 | -3.09 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 50 |
CTNNA2 |
4.570e-02 | -3.09 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 50 |
TNIK |
4.576e-02 | -3.08 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 47 |
PITPNC1 |
4.576e-02 | -3.08 | GABA receptor binding | molecular function | GO:0050811 | 18 | 1 | 18094 | 47 |
ERBB4 |
4.613e-02 | -3.08 | PDZ | pfam domains | PF00595 | 122 | 2 | 17795 | 50 |
PARD3B,PREX2 |
4.629e-02 | -3.07 | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | Pathway Interaction DB | hif1apathway | 15 | 1 | 2226 | 7 |
HIF3A |
4.631e-02 | -3.07 | cellular response to growth factor stimulus | biological process | GO:0071363 | 494 | 4 | 18204 | 50 |
FGFR3,NFIA,SOX5,ERBB4 |
4.669e-02 | -3.06 | TBL1X (transducin beta like 1 X-linked) | protein interactions | 6907 | 137 | 2 | 19454 | 49 |
SOX5,NFIA |
4.671e-02 | -3.06 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 3 | 14470 | 43 |
MACF1,RYR3,DTNA |
4.673e-02 | -3.06 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 50 |
DTNA |
4.673e-02 | -3.06 | Carb_anhydrase | pfam domains | PF00194 | 17 | 1 | 17795 | 50 |
PTPRZ1 |
4.673e-02 | -3.06 | AMP-binding_C | pfam domains | PF13193 | 17 | 1 | 17795 | 50 |
ACSS1 |
4.673e-02 | -3.06 | Cystatin | pfam domains | PF00031 | 17 | 1 | 17795 | 50 |
CST3 |
4.681e-02 | -3.06 | INKA1 (inka box actin regulator 1) | protein interactions | 389119 | 19 | 1 | 19454 | 49 |
ZBTB20 |
4.681e-02 | -3.06 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 49 |
ATP1A2 |
4.681e-02 | -3.06 | NLGN1 (neuroligin 1) | protein interactions | 22871 | 19 | 1 | 19454 | 49 |
NRXN1 |
4.681e-02 | -3.06 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 49 |
GPM6A |
4.681e-02 | -3.06 | HBEGF (heparin binding EGF like growth factor) | protein interactions | 1839 | 19 | 1 | 19454 | 49 |
ERBB4 |
4.681e-02 | -3.06 | CNTNAP4 (contactin associated protein family member 4) | protein interactions | 85445 | 19 | 1 | 19454 | 49 |
MACF1 |
4.681e-02 | -3.06 | TNR (tenascin R) | protein interactions | 7143 | 19 | 1 | 19454 | 49 |
PTPRZ1 |
4.681e-02 | -3.06 | ZNF532 (zinc finger protein 532) | protein interactions | 55205 | 19 | 1 | 19454 | 49 |
ERBB4 |
4.681e-02 | -3.06 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 49 |
DTNA |
4.681e-02 | -3.06 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 49 |
DTNA |
4.681e-02 | -3.06 | SYT7 (synaptotagmin 7) | protein interactions | 9066 | 19 | 1 | 19454 | 49 |
NRXN1 |
4.722e-02 | -3.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | 15813 | 49 | 16828 | 49 |
TRPS1,SOX5,ABLIM1,PTGDS,RORA,SFXN5,GPC5,COL5A3,NKAIN3,NRXN1,PARD3B,SLC1A2,QKI,CTNND2,AHCYL2,ERBB4,NPAS3,MAML2,PREX2,NCKAP5,ATP13A4,FGFR3,RFX4,CST3,MSI2,ACSS1,CDH20,PITPNC1,ZNF98,NFIA,PTPRZ1,HIF3A,FBXL7,TNIK,PCDH9,MACF1,LSAMP,ITPR2,GPM6A,CADM1,SLC4A4,NHSL1,RYR3,NTM,LRIG1,DTNA,SLC1A3,ATP1A2,ZBTB20 |
4.734e-02 | -3.05 | NAD+ Signalling and Aging | SMPDB pathways | SMP0084271 | 11 | 1 | 1369 | 6 |
RORA |
4.752e-02 | -3.05 | Furin_repeat | interpro domains | IPR006212 | 18 | 1 | 18521 | 50 |
ERBB4 |
4.752e-02 | -3.05 | Leu-rich_rpt_4 | interpro domains | IPR025875 | 18 | 1 | 18521 | 50 |
LRIG1 |
4.752e-02 | -3.05 | Leu-rich_rpt_Cys-con_subtyp | interpro domains | IPR006553 | 18 | 1 | 18521 | 50 |
FBXL7 |
4.764e-02 | -3.04 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 49 |
ATP1A2 |
4.764e-02 | -3.04 | astrocyte projection | cellular component | GO:0097449 | 19 | 1 | 19108 | 49 |
SLC1A2 |
4.764e-02 | -3.04 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 49 |
GPM6A |
4.764e-02 | -3.04 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 1 | 19108 | 49 |
TNIK |
4.792e-02 | -3.04 | DUSP22 (dual specificity phosphatase 22) | protein interactions | 56940 | 139 | 2 | 19454 | 49 |
QKI,CTNNA2 |
4.793e-02 | -3.04 | Cell-type Dependent Selectivity of CCK2R Signaling | WikiPathways | WP3679 | 13 | 1 | 5310 | 20 |
RYR3 |
4.802e-02 | -3.04 | ligand-gated monoatomic cation channel activity | molecular function | GO:0099094 | 135 | 2 | 18094 | 47 |
ITPR2,RYR3 |
4.804e-02 | -3.04 | carboxylic acid transport | biological process | GO:0046942 | 297 | 3 | 18204 | 50 |
SFXN5,SLC1A3,SLC1A2 |
4.804e-02 | -3.04 | muscle system process | biological process | GO:0003012 | 297 | 3 | 18204 | 50 |
RYR3,ATP1A2,DTNA |
4.804e-02 | -3.04 | skeletal system development | biological process | GO:0001501 | 500 | 4 | 18204 | 50 |
NFIA,SOX5,TRPS1,FGFR3 |
4.822e-02 | -3.03 | cell population proliferation | biological process | GO:0008283 | 726 | 5 | 18204 | 50 |
CADM1,FGFR3,SOX5,NFIA,RORA |
4.824e-02 | -3.03 | alkali metal ion binding | molecular function | GO:0031420 | 19 | 1 | 18094 | 47 |
ATP1A2 |
4.832e-02 | -3.03 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 50 |
CTNND2 |
4.832e-02 | -3.03 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 50 |
ATP1A2 |
4.832e-02 | -3.03 | regulation of extracellular matrix disassembly | biological process | GO:0010715 | 18 | 1 | 18204 | 50 |
CST3 |
4.832e-02 | -3.03 | positive regulation of circadian rhythm | biological process | GO:0042753 | 18 | 1 | 18204 | 50 |
RORA |
4.839e-02 | -3.03 | squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-non_chronically_sun_exposed_site-malignant_melanoma | COSMIC cancer mutations | skin-non_chronically_sun_exposed_site-malignant_melanoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | optic_nerve | COSMIC cancer mutations | optic_nerve | 17 | 1 | 16828 | 49 |
QKI |
4.839e-02 | -3.03 | skin-other-verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | skin-other-verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I | 17 | 1 | 16828 | 49 |
QKI |
4.839e-02 | -3.03 | non_chronically_sun_exposed_site | COSMIC cancer mutations | non_chronically_sun_exposed_site | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | breast-carcinoma-neuroendocrine_carcinoma | COSMIC cancer mutations | breast-carcinoma-neuroendocrine_carcinoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.843e-02 | -3.03 | organic acid transport | biological process | GO:0015849 | 298 | 3 | 18204 | 50 |
SLC1A2,SLC1A3,SFXN5 |
4.848e-02 | -3.03 | Elevation of cytosolic Ca2+ levels | REACTOME pathways | R-HSA-139853 | 17 | 1 | 10285 | 30 |
ITPR2 |
4.853e-02 | -3.03 | SATB2 (SATB homeobox 2) | protein interactions | 23314 | 140 | 2 | 19454 | 49 |
NFIA,SOX5 |
4.853e-02 | -3.03 | WDR48 (WD repeat domain 48) | protein interactions | 57599 | 140 | 2 | 19454 | 49 |
AHCYL2,FBXL7 |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.880e-02 | -3.02 | KLF8 (KLF transcription factor 8) | protein interactions | 11279 | 326 | 3 | 19454 | 49 |
TRPS1,SOX5,NFIA |
4.894e-02 | -3.02 | response to organophosphorus | biological process | GO:0046683 | 129 | 2 | 18204 | 50 |
ITPR2,RYR3 |
4.916e-02 | -3.01 | UPK2 (uroplakin 2) | protein interactions | 7379 | 141 | 2 | 19454 | 49 |
CTNNA2,PCDH9 |
4.921e-02 | -3.01 | FAM13C (family with sequence similarity 13 member C) | protein interactions | 220965 | 20 | 1 | 19454 | 49 |
AHCYL2 |
4.921e-02 | -3.01 | ANXA13 (annexin A13) | protein interactions | 312 | 20 | 1 | 19454 | 49 |
MSI2 |
4.921e-02 | -3.01 | MLC1 (modulator of VRAC current 1) | protein interactions | 23209 | 20 | 1 | 19454 | 49 |
DTNA |
4.921e-02 | -3.01 | CACFD1 (calcium channel flower domain containing 1) | protein interactions | 11094 | 20 | 1 | 19454 | 49 |
PITPNC1 |
4.921e-02 | -3.01 | ADRA1D (adrenoceptor alpha 1D) | protein interactions | 146 | 20 | 1 | 19454 | 49 |
DTNA |
4.921e-02 | -3.01 | CCKBR (cholecystokinin B receptor) | protein interactions | 887 | 20 | 1 | 19454 | 49 |
NTM |
4.921e-02 | -3.01 | RNF183 (ring finger protein 183) | protein interactions | 138065 | 20 | 1 | 19454 | 49 |
PTGDS |
4.921e-02 | -3.01 | PON1 (paraoxonase 1) | protein interactions | 5444 | 20 | 1 | 19454 | 49 |
SFXN5 |
4.921e-02 | -3.01 | Kif1c (kinesin family member 1C) | protein interactions | 16562 | 20 | 1 | 19454 | 49 |
ABLIM1 |
4.921e-02 | -3.01 | Sass6 (SAS-6 centriolar assembly protein) | protein interactions | 72776 | 20 | 1 | 19454 | 49 |
MACF1 |
4.921e-02 | -3.01 | NCAM2 (neural cell adhesion molecule 2) | protein interactions | 4685 | 20 | 1 | 19454 | 49 |
CTNND2 |
4.921e-02 | -3.01 | OXT (oxytocin/neurophysin I prepropeptide) | protein interactions | 5020 | 20 | 1 | 19454 | 49 |
FGFR3 |
4.921e-02 | -3.01 | ALX3 (ALX homeobox 3) | protein interactions | 257 | 20 | 1 | 19454 | 49 |
MACF1 |
4.921e-02 | -3.01 | SNX20 (sorting nexin 20) | protein interactions | 124460 | 20 | 1 | 19454 | 49 |
AHCYL2 |
4.936e-02 | -3.01 | - | gene3d domains | 2.60.120.1000 | 17 | 1 | 14470 | 43 |
COL5A3 |
4.936e-02 | -3.01 | Alpha carbonic anhydrase | gene3d domains | 3.10.200.10 | 17 | 1 | 14470 | 43 |
PTPRZ1 |
4.941e-02 | -3.01 | LRR_4 | pfam domains | PF12799 | 18 | 1 | 17795 | 50 |
LRIG1 |
4.951e-02 | -3.01 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 4 | 18204 | 50 |
ITPR2,RYR3,SLC1A3,SLC1A2 |
4.962e-02 | -3.00 | thalamus | COSMIC cancer mutations | thalamus | 284 | 3 | 16828 | 49 |
DTNA,QKI,FGFR3 |
4.991e-02 | -3.00 | NCOR1 (nuclear receptor corepressor 1) | protein interactions | 9611 | 329 | 3 | 19454 | 49 |
SOX5,ERBB4,NFIA |